

CITATION REPORT

List of articles citing

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

DOI: 10.1056/nejm200103153441101

New England Journal of Medicine, 2001, 344, 783-92.

Source: <https://exaly.com/paper-pdf/32313328/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2240	Adaptive immunity in cancer immunology and therapeutics. 2014 , 8, 441		26
2239	Sympathetic nervous system alterations with HER2+ antagonism: an early marker of cardiac dysfunction with breast cancer treatment?. 2014 , 8, 446		11
2238	Sun Tzu and the Art of BusinessSun Tzu and the Art of Business By McNeillyMark R., Oxford: Oxford University Press, 1996, 225 pages, hard, cover, \$25.00. 1997 , 11, 129-130		1
2237	Editorial. 1998 , 11, 1-1		
2236	A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. 2001 , 24, 903-20		142
2235	HER2/neu as a predictive factor in breast cancer. 2001 , 2, 129-35; discussion 136-7		53
2234	Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography. 2001 , 2, 229-34		33
2233	Novel Approaches in the Early Treatment of Breast Cancer. 2001 , 2, S5-S6		
2232	Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations. 2001 , 2 Suppl 1, S15-9		6
2231	Present state and future prospects: a review of cooperative groups' adjuvant and neoadjuvant trials in breast cancer. 2001 , 2 Suppl 1, S20-30		5
2230	Update on HER-2 as a target for cancer therapy: herceptin in the clinical setting. 2001 , 3, 380-4		25
2229	From the molecule to the clinic--inhibiting HER2 to treat breast cancer. <i>New England Journal of Medicine</i> , 2001 , 344, 841-2	59.2	55
2228	Translational research--traffic on the bridge. 2001 , 55, 565-71		9
2227	Metronomic scheduling: the future of chemotherapy?. 2001 , 2, 733-40		221
2226	Recent Data with Trastuzumab/Chemotherapy Combinations in HER2-Overexpressing Breast Cancer. 2001 , 2, 107-109		
2225	Commentary on Platinum Compounds in the Treatment of Advanced Breast Cancer 2001 , 2, 209		
2224	The therapeutic use of antibodies for malignancy. 2001 , 8, 255-9		5

2223	A "bureausceptic" view of cancer drug rationing. 2001 , 358, 1660	2
2222	Cáncer de mama. Clasificación y concepto. 2001 , 8, 3041-3049	
2221	Actualización en cáncer de mama: aspectos clínicos y terapéuticos. 2001 , 8, 597-605	
2220	Innovative cancer drug targets: genomics, transcriptomics and clinomics. 2001 , 2, 911-5	7
2219	Radioimmunotherapy versus traditional, nontargeted forms of systemic cancer treatment. 2001 , 1, 501-5	1
2218	Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. 2001 , 33, 451-5	82
2217	Blood stem cell transplantation for breast cancer: new approaches using pre- peri- post-transplant immunotherapy. 2001 , 1, 1029-48	6
2216	Targeted therapy in oncology: the agony and ecstasy of personalized medicine. 2001 , 1, 321-2	3
2215	Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. 2001 , 60, 290-301	99
2214	Palliative systemic antineoplastic therapy. 2001 , 399-420	
2213	Angiogenesis in cancer. 2001 , 19, 3299-301	7
2212	Effectiveness of Trastuzumab (Herceptin) in a patient with locally recurrent breast cancer after cardiac failure caused by severe cytotoxic pretreatment. 2001 , 61, 271-4	1
2211	Dose-intensity, dose-escalation, and dose-density in the adjuvant chemotherapy of primary, operable breast cancer. 2001 , 14, 81-9	1
2210	Early-stage Hodgkin's disease: to mantle or not to mantle?. 2001 , 19, 3298-9	
2209	Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab. 2001 , 19, 3297-8	42
2208	Discussing do-not-resuscitate status: furthering the discourse. 2001 , 19, 3301-2	0
2207	ERRATUM. 2001 , 19, 3302-3302	1
2206	Systemic therapy. 2001 , 13, 436-49	2

2205	Duration of therapy in metastatic breast cancer: management using Herceptin. 2001 , 12, 561-8	11
2204	Current status of HER2 testing: caught between a rock and a hard place. 2001 , 116, 806-10	63
2203	Systemic treatment of metastatic breast cancer. 2001 , 62, 289-95	8
2202	CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. 2001 , 98, 3383-9	354
2201	Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. 2001 , 19, 3117-25	64
2200	Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. 2001 , 19, 2722-30	327
2199	New combinations with Herceptin in metastatic breast cancer. 2001 , 61 Suppl 2, 50-7	42
2198	Phase III trial of chemotherapy ? HerceptinR in metastatic breast cancer. 2001 , 3, 1	
2197	Adjuvant anti-HER2 monoclonal antibody therapy [ready for breast cancer?]. 2001 , 10, 161-163	2
2196	Magic bullets finally find their mark. 2001 , 41, 383-91	
2195	The use of anthracyclines and taxanes for adjuvant therapy of breast cancer. 2001 , 10, 90-95	1
2194	Genomic circuits and the integrative biology of cardiomyopathies. 2001 , 3, L3-L9	1
2193	Interaction between Herceptin and taxanes. 2001 , 61 Suppl 2, 43-9	19
2192	Farnesyl transferase inhibitors--a novel therapy for breast cancer. 2001 , 8, 227-35	24
2191	Das Mammakarzinom. 2001 , 34, 1065-1078	
2190	The role of adjuvant monoclonal antibody therapy for breast cancer: rationale and new studies. 2001 , 3, 516-22	13
2189	Antikörper, Immuntoxine, Radioimmunkonjugate. 2001 , 7, 1206-1219	1
2188	Compassionate use of humanized anti-HER2/neu protein, trastuzumab for metastatic breast cancer in Japan. 2001 , 8, 310-5	7

2187	Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 Monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab). 2001 , 8, 316-20	11
2186	Impact of new non-cytotoxics in the treatment of ovarian cancer. 2001 , 11 Suppl 1, 68-72	6
2185	Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. 2001 , 92, 2965-74	87
2184	Use of paclitaxel in patients with pre-existing cardiomyopathy: a review of our experience. 2001 , 93, 139-41	19
2183	New approaches to proteomic analysis of breast cancer. 2001 , 1, 1205-15	186
2182	Occult micrometastasis: enrichment, identification and characterization of single disseminated tumour cells. 2001 , 11, 327-37	61
2181	Breast cancer and the immune system: opportunities and pitfalls. 2001 , 6, 467-75	8
2180	Breast cancer in the clinic: treatments past, treatments future. 2001 , 6, 487-95	8
2179	Death receptor ligands, in particular TRAIL, to overcome drug resistance. 2001 , 20, 51-6	41
2178	Trastuzumab: designer drug or fashionable fad?. 2001 , 13, 427-33	1
2177	Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status. 2001 , 85, 1764-70	16
2176	Molecular targets for breast cancer therapy and prevention. 2001 , 7, 548-52	235
2175	The development of androgen-independent prostate cancer. 2001 , 1, 34-45	1848
2174	Putting tumours in context. 2001 , 1, 46-54	1686
2173	Improving the efficacy of antibody-based cancer therapies. 2001 , 1, 118-29	687
2172	Tumor targeting using anti-her2 immunoliposomes. 2001 , 74, 95-113	279
2171	Anthracyclines in breast cancer: therapy and issues of toxicity. 2001 , 10, 8-15	10
2170	Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. 2001 , 93, 1830-2	78

2169	Strategies of medical treatment for metastatic breast cancer (Review). 2001 , 19, 733-9	1
2168	Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). 2001 , 93, 1852-7	725
2167	A Systematic Overview of Chemotherapy Effects in Breast Cancer. 2001 , 40, 253-281	113
2166	Trastuzumab and breast cancer. <i>New England Journal of Medicine</i> , 2001 , 345, 995-6	59.2 117
2165	An isoform of the coactivator AIB1 that increases hormone and growth factor sensitivity is overexpressed in breast cancer. 2001 , 276, 39736-41	63
2164	Trastuzumab in the treatment of HER2 positive breast cancer. 2001 , 7, 9-25	1
2163	Chemotherapy and herceptin for HER2(+) metastatic breast cancer: the best drug?. 2001 , 6, 315-6	8
2162	A systematic overview of chemotherapy effects in breast cancer. 2001 , 40, 253-81	120
2161	Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. 2001 , 61 Suppl 2, 14-21	164
2160	Dose scheduling--Herceptin. 2001 , 61 Suppl 2, 31-6	36
2159	Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. 2001 , 61 Suppl 2, 58-66	123
2158	Breast cancer. 2001 , 6, 338-46	7
2157	Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. 2001 , 8, 175-82	105
2156	Mutant cell surface receptors as targets for individualized cancer diagnosis and therapy. 2001 , 1, 121-8	6
2155	First-line Herceptin monotherapy in metastatic breast cancer. 2001 , 61 Suppl 2, 37-42	164
2154	Testing for HER2 status. 2001 , 61 Suppl 2, 22-30	56
2153	Drugs targeted against protein kinases. 2001 , 6, 303-15	25
2152	Monogene and polygene therapy for the treatment of experimental prostate cancers by use of apoptotic genes bax and bad driven by the prostate-specific promoter ARR(2)PB. 2002 , 13, 2051-64	22

2151	Role of steroid hormones and growth factors in breast cancer. 2002 , 40, 969-74	4
2150	Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast. 2002 , 22, 583-92	13
2149	Medical management of breast cancer: today and tomorrow. 2002 , 17, 137-49	9
2148	The development and clinical use of trastuzumab (Herceptin). 2002 , 9, 75-85	129
2147	Molecular Cytogenetics. 2002 ,	2
2146	Immunology for Surgeons. 2002 ,	
2145	Questionable benefit of melatonin for antioxidant pharmacologic therapy. 2002 , 20, 4127-8; author reply 4128-9	9
2144	Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. 2002 , 277, 35862-8	81
2143	Intracellular domains of target antigens influence their capacity to trigger antibody-dependent cell-mediated cytotoxicity. 2002 , 168, 3275-82	22
2142	Identification of novel non-phosphorylated ligands, which bind selectively to the SH2 domain of Grb7. 2002 , 277, 11918-26	70
2141	Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. 2002 , 99, 8880-5	368
2140	Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. 2002 , 20, 2812-23	928
2139	Immunotherapy of colorectal cancer. 2002 , 64, 181-200	9
2138	A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. 2002 , 87, 15-20	56
2137	Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. 2002 , 2, 143-50	73
2136	Recent Advances in the Systemic Management of Metastatic Breast Cancer. 2002 , 15, 52-61	2
2135	Detection of anthracycline-induced cardiotoxicity: is there light at the end of the tunnel?. 2002 , 13, 647-9	13
2134	Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. 2002 , 13, 1717-29	45

2133	The impact of chip technology on cancer medicine. 2002 , 13 Suppl 4, 109-13	4
2132	Effect of fixation period on HER2/neu gene amplification detected by fluorescence in situ hybridization in invasive breast carcinoma. 2002 , 50, 1693-6	41
2131	Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. 2002 , 94, 855-7	323
2130	Radiation recall dermatitis may represent the Koebner phenomenon. 2002 , 20, 4130; author reply 4130	15
2129	Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. 2002 , 20, 1800-8	473
2128	Clinical effectiveness of trastuzumab: early experience. 2002 , 8, 19-25	
2127	Novel endpoints and design of early clinical trials. 2002 , 13 Suppl 4, 139-43	45
2126	HER2 in brain metastases: issues of concordance, survival, and treatment. 2002 , 20, 4130-3	49
2125	Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing. 2002 , 13, 8-9	28
2124	Treatment for anthracycline-pretreated metastatic breast cancer. 2002 , 7 Suppl 6, 4-12	45
2123	Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. 2002 , 20, 3106-13	115
2122	Do quality-of-life randomized clinical trials support clinicians in their decision-making?. 2002 , 20, 4126-7; author reply 4127	14
2121	Cardiac dysfunction in clinical trials of trastuzumab. 2002 , 20, 4119; author reply 4120	4
2120	What can we learn from Herceptin trials in metastatic breast cancer?. 2002 , 63 Suppl 1, 39-46	36
2119	Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. 2002 , 21, 1111-7	67
2118	Fetal ontogeny and tumor expression of the early thymic antigen UN1. 2002 , 20, 707	
2117	HER2/neu amplification in breast cancer: stratification by tumor type and grade. 2002 , 117, 916-21	85
2116	Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation. 2002 , 7, 34-45	61

2115	Analysis of anticancer drugs and their metabolites by mass spectrometry. 2002 , 3, 463-80	12
2114	Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. 2002 , 20, 3545-57	92
2113	The emergence of resistance to targeted cancer therapeutics. 2002 , 3, 603-23	21
2112	Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. 2002 , 13, 65-72	197
2111	[Growth factors in otorhinolaryngology]. 2002 , 81 Suppl 1, S39-60	1
2110	FISH detection of HER2 amplification in breast cancer. 2002 , 204, 353-67	1
2109	Overexpression of erb B2 remains a major risk factor in non-metastatic breast cancers treated with high-dose alkylating agents and autologous stem cell transplantation. 2002 , 29, 753-7	1
2108	The role of adjuvant therapy for pancreatic cancer. 2002 , 11, 87-107	7
2107	Integration of molecular diagnostics with therapeutics: implications for drug discovery and patient care. 2002 , 2, 531-41	12
2106	What's so special about ?trastuzumab?. 2002 , 40, 65-67	
2105	Tumours: Targeting of Monoclonal Antibodies for Imaging and Potential for Therapy. 2002 ,	1
2104	Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets. 2002 , 22, 303-13	72
2103	[Evidence-based recommendations on treating locoregional and distant metastases of carcinomas of the breast]. 2002 , 124, 284-92	3
2102	[Evidence-based recommendations on primary treatment of carcinomas of the breast]. 2002 , 124, 293-303	6
2101	Identification of novel targets for cancer therapy using expression proteomics. 2002 , 16, 478-85	65
2100	Application of recombinant antibodies in cancer patients. 2003 , 207, 27-53	
2099	New paradigms in oncological therapeutics: redefining combination chemotherapy. 2002 , 13, 1697-8	3
2098	Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. 2002 , 13, 1036-43	246

2097	Treatment options in hormone resistant prostate cancer. 2002 , 13 Suppl 4, 95-102	3
2096	Current status of HER2 testing. 2002 , 63 Suppl 1, 25-32	42
2095	New Techniques and Agents in the Adjuvant Therapy of Pancreatic Cancer. 2002 , 41, 582-595	33
2094	Breast Cancer. 2002 , 287-299	
2093	Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. 2002 , 7, 410-7	128
2092	Immunotherapy of ovarian cancer. 2002 , 2, 409-17	6
2091	Medical Oncology Analysis. 2002 , 1, 182-184	
2090	Chipping away at breast cancer: insights from microarray studies of human and mouse mammary cancer. 2002 , 9, 207-20	24
2089	"Build quality in"--HER2 testing in the real world. 2002 , 94, 788-9	8
2088	Epirubicin, Cisplatin, and protracted venous-infusion Fluorouracil in advanced esophagogastric cancer. 2002 , 20, 4124-5; author reply 4125-6	1
2087	Use and abuse of statistics in evidence-based medicine. 2002 , 20, 4122-3; author reply 4123-4	2
2086	Need for a quantitative meta-analysis of trials of adjuvant interferon in melanoma. 2002 , 20, 4120-1; author reply 4121-2	6
2085	Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. 2002 , 94, 852-4	399
2084	Prostate cancer risk groups and comparisons: fruitless or fruitful?. 2002 , 20, 4129; author reply 4129-30	4
2083	Cancer Guide Analysis. 2002 , 1, 205-208	
2082	Retrospective assessment of hypercoagulability in breast cancer prevention trial. 2002 , 20, 4133-4	9
2081	Perspectives on anti-HER monoclonal antibodies. 2002 , 63 Suppl 1, 17-24	57
2080	Interobserver interpretative reproducibility of GOLDFISH, a first generation gold-facilitated autometallographic bright field in situ hybridization assay for HER-2/neu amplification in invasive mammary carcinoma. 2002 , 26, 908-13	27

2079 Current World Literature. **2002**, 14, 81-101

2078 Pathological Evaluation of HER2 Overexpression: For the Treatment of Metastatic Breast Cancers by Humanized Anti-HER2 Monoclonal Antibody(Trastuzumab).. **2002**, 35, 77-81 3

2077 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. **2002**, 20, 719-26 1708

2076 Moving forward: Herceptin in the adjuvant setting. **2002**, 63 Suppl 1, 57-63 34

2075 Clinical endpoints in trials of drugs for cancer: time for a rethink?. **2002**, 324, 1389-91 8

2074 Cardiac dysfunction in the trastuzumab clinical trials experience. **2002**, 20, 1215-21 764

2073 Quantitation of erbB2 positivity for evaluation of high-risk patients. **2002**, 34, 544-53 2

2072 Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. **2002**, 105, 1551-4 237

2071 Critical review of current treatment strategies for advanced hormone insensitive breast cancer. **2002**, 20 Suppl 2, 1-14 11

2070 Overexpression of HER-2 in thick melanoma. **2002**, 12, 139-45 14

2069 HER2 Testing in Patients With Breast Cancer: Poor Correlation Between Weak Positivity by Immunohistochemistry and Gene Amplification by Fluorescence In Situ Hybridization. **2002**, 77, 148-154 135

2068 Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. **2002**, 8, 461-8 75

2067 Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. **2002**, 100, 2123-31 103

2066 Cytostatic drugs. **2002**, 533-552

2065 Future of monoclonal antibodies in the treatment of hematologic malignancies. **2002**, 9, 152-66 64

2064 New targets and drugs in cancer chemotherapy. **2002**, 11, 117-25 4

2063 17 Expression and gene copy number alterations of her-2/neu (ERBB2) gene in prostate cancer. **2002**, 2, 449-456

2062 HER-2/neu Gene Amplification and Protein Overexpression in Breast Carcinoma: Immunohistochemistry and Fluorescence in situ Hybridization. **2002**, 1, 259-265

- 2061 HER-2/neu Amplification Detected by Fluorescence in situ Hybridization in Cytological Samples from Breast Cancer. **2002**, 1, 267-278
- 2060 Role of Cadherins in Breast Cancer. **2002**, 343-349
- 2059 The origins of intracrine hormone action. **2002**, 323, 43-8 35
- 2058 HER-2/neu Status: Comparison of Quantitative Immunohistochemistry by Automated Cellular Imaging and Fluorescence In Situ Hybridization. **2002**, 7, 75-80
- 2057 HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. **2002**, 77, 148-54 156
- 2056 Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification. **2002**, 160, 1589-95 48
- 2055 In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines. **2002**, 13, 1743-8 59
- 2054 Molecular aspects of ovarian cancer. **2002**, 16, 483-97 32
- 2053 Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers. **2002**, 25, 301-11 57
- 2052 Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. **2002**, 41, 431-44 148
- 2051 Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. **2002**, 62, 209-43 187
- 2050 Anastrozole. **2002**, 62, 2493-2494 17
- 2049 The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. **2002**, 3, 125-35; discussion 136-7 65
- 2048 Peripheral blood c-erbB-2 expression by reverse transcriptase-polymerase chain reaction in breast cancer patients receiving chemotherapy. **2002**, 3, 201-5 13
- 2047 Resistance to trastuzumab: a necessary evil or a temporary challenge?. **2002**, 3, 247-57; discussion 258-9 54
- 2046 Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results. **2002**, 3 Suppl 1, 17-20 43
- 2045 Gemcitabine in breast cancer: future directions. **2002**, 3 Suppl 1, 45-8 6
- 2044 Ongoing US cooperative group trials using taxanes in the adjuvant setting. **2002**, 3 Suppl 2, S53-8 4

2043	HER2-positive breast cancer: update on Breast Cancer International Research Group trials. 2002 , 3 Suppl 2, S75-9	25
2042	Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. 2002 , 3, 1739-51	86
2041	The role of the ubiquitination-proteasome pathway in breast cancer: ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer. 2003 , 5, 8-15	42
2040	Liposome-based drug delivery in breast cancer treatment. 2002 , 4, 95-9	314
2039	Spotlight on Trastuzumab in Metastatic Breast Cancer Overexpressing HER2. 2002 , 1, 217-221	
2038	Chemotherapy in Metastatic Urothelial Cancer. 2002 , 1, 23-31	
2037	Strategies for improving quality of life in older patients with metastatic breast cancer. 2002 , 19, 605-22	13
2036	Efficacy and economics of hormonal therapies for advanced breast cancer. 2002 , 19, 453-63	17
2035	Estado actual en el tratamiento del c�ncer. 2002 , 9, 546-551	
2034	Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. 2002 , 115, 4251-62	154
2033	Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience. 2002 , 20, 1215-1221	930
2032	The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. 2002 , 80, 91-102	81
2031	Individualized cancer therapy: molecular approaches to the prediction of tumor response. 2002 , 2, 113-9	13
2030	Paclitaxel in cancer therapy. 2002 , 3, 755-66	237
2029	Biotechnology and drug discovery--the future is here: a guide for the practicing urologist. 2002 , 59, 643-51	
2028	New drugs for breast cancer. 2002 , 360, 790-2	23
2027	Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. 2002 , 160, 339-45	75
2026	New treatment modalities for hormone-resistant prostate cancer. 2002 , 1, 139-41	

2025	What is the role of HER-2/neu and trastuzumab (Herceptin) in lung cancer?. 2002 , 36, 263-4	8
2024	Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. 2002 , 37, 17-27	26
2023	Genogenic immunohistochemistry: a new era in diagnostic immunohistochemistry. 2002 , 8, 193-200	11
2022	From bench to bedside: a diagnostics framework for pharmacogenetics research. 2002 , 77, 57-60	5
2021	Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. 2002 , 9, 993-1004	118
2020	Trastuzumab: hopes and realities. 2002 , 3, 137-44	134
2019	Impact of the Human Genome Project on the clinical management of sporadic cancers. 2002 , 3, 349-56	11
2018	Receptor tyrosine kinases as targets for anticancer drugs. 2002 , 8, 17-23	196
2017	The ErbB receptor family: a therapeutic target for cancer. 2002 , 8, S19-26	145
2016	2001 Highlights from: San Antonio Breast Cancer Symposium, San Antonio, Texas, December 10-13, 2001, Focus on Novel Approaches in Breast Cancer. 2002 , 3, 21-25	3
2015	Resistance to Trastuzumab: Mechanistic Uncertainties. 2002 , 3, 258-259	7
2014	Smart drugs: tyrosine kinase inhibitors in cancer therapy. 2002 , 1, 117-23	423
2013	Focus on breast cancer. 2002 , 1, 319-22	76
2012	[Principal therapeutic uses of monoclonal antibodies in oncology]. 2002 , 6 Suppl 1, 24s-28s	3
2011	Rational therapeutic intervention in cancer: kinases as drug targets. 2002 , 12, 111-5	113
2010	Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report. 2002 , 38, 1730-8	15
2009	Improved survival in advanced breast cancer with docetaxel and capecitabine in combination: biological synergy or an artefact of trial design?. 2002 , 38, 1957-60	3
2008	Tumor M2 pyruvate kinase--determination in breast cancer patients receiving trastuzumab therapy. 2002 , 187, 223-8	13

2007	The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. 2002 , 20, 2310-8	669
2006	Exploiting molecular targets in pancreatic cancer. 2002 , 16, 139-57	10
2005	Clinical trial designs for targeted agents. 2002 , 16, 1287-305	12
2004	Serologic Concentrations of HER-2/neu in Breast Cancer Patients with Visceral Metastases Receiving Trastuzumab Therapy Predict the Clinical Course. 2002 , 48, 1360-1362	27
2003	Medical oncology. 2002 , 176, 25	
2002	Retargeting of natural killer cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. 2002 , 100, 1265-1273	192
2001	Native human blood dendritic cells as potent effectors in antibody-dependent cellular cytotoxicity. 2002 , 100, 1502-1504	42
2000	Combination Versus Sequential Single-Agent Therapy in Metastatic Breast Cancer. 2002 , 7, 13-19	146
1999	Mammaglobin A: A Promising Marker for Breast Cancer. 2002 , 48, 1362-1364	43
1998	HER-2 Inhibitors: Clinical Results. 2002 , 1, S3-S4	2
1997	Herceptin in Elderly Patients. 2002 , 88, S37-S38	
1996	Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes. 2002 , 20, 2217-9	64
1995	Emerging technologies for HER2 testing. 2002 , 63 Suppl 1, 33-8	32
1994	Molecular mechanisms in signal transduction: new targets for the therapy of gynecologic malignancies. 2002 , 25, 240-7	3
1993	Apoptosis and the treatment of breast cancer. 2002 , 15, 71-82	4
1992	ErbB receptor tyrosine kinase inhibitors as therapeutic agents. 2002 , 7, d1926	9
1991	Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. 2002 , 20, 3095-105	327
1990	Trastuzumab use in breast cancer: clinical issues. 2002 , 9, 499-507	27

1989	The future of targeted therapy: combining novel agents. 2002 , 63 Suppl 1, 47-56	21
1988	Molecular targets in cancer therapy and their impact on cancer management. 2002 , 63 Suppl 1, 1-5	8
1987	Limitations of combination anti-angiogenesis and chemotherapy. 2002 , 2, 804-804	0
1986	Continuing-education programs in pharmacogenomics for pharmacists. 2002 , 59, 722-5	19
1985	Targeted therapy using novel agents in the treatment of non-small-cell lung cancer. 2002 , 3 Suppl 1, S30-8	17
1984	Trastuzumab in the treatment of non-small cell lung cancer. 2002 , 29, 59-65	33
1983	c-erbB-2 in breast cancer: development of a clinically useful marker. 2002 , 29, 231-45	100
1982	Present and future treatment of advanced non-small cell lung cancer. 2002 , 29, 9-16	12
1981	Traditional Chinese medicine in the treatment of breast cancer. 2002 , 29, 563-74	75
1980	Molecular targets as therapeutic strategies in the management of breast cancer. 2002 , 12, 341-51	8
1979	Liposome-encapsulated doxorubicin is less cardiotoxic than conventional doxorubicin for metastatic breast cancer. 2002 , 3, 110-112	
1978	Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/ protein and vascular endothelial growth factor. 2002 , 29, 29-37	7
1977	Trastuzumab/chemotherapy combinations in metastatic breast cancer. 2002 , 29, 38-43	6
1976	Amplification and expression of genes from the 17q11 approximately q12 amplicon in breast cancer cells. 2002 , 136, 43-7	45
1975	Signaling revealed by mapping molecular interactions. 2002 , 2, 169-186	11
1974	Androgen-dependent mammary carcinogenesis in rats transgenic for the Neu proto-oncogene. 2002 , 2, 67-79	13
1973	Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. 2002 , 2, 127-37	729
1972	A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization. 2002 , 2, 93-5	43

1971	Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. 2002 , 2, 451-61	284
1970	HER2/neu in the management of invasive breast cancer. 2002 , 194, 488-501	33
1969	Integrating diagnostics and therapeutics: revolutionizing drug discovery and patient care. 2002 , 7, 859-64	27
1968	Protein tyrosine kinases: autoregulation and small-molecule inhibition. 2002 , 12, 735-41	70
1967	Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies. 2002 , 11, 13-23	14
1966	Novel therapies for lung cancer. 2002 , 11, 229-41	12
1965	Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer. 2002 , 98, 883-8	79
1964	Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. 2002 , 101, 567-75	117
1963	Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. 2002 , 94, 25-36	414
1962	HER-2 profiling and targeting in prostate carcinoma. 2002 , 94, 980-986	119
1961	ErbB2 expression is correlated with increased survival of patients with osteosarcoma. 2002 , 94, 1397-404	103
1960	HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. 2002 , 94, 2169-73	82
1959	HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial. 2002 , 94, 2584-9	50
1958	Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. 2002 , 95, 301-8	36
1957	Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?. 2002 , 95, 1009-15	115
1956	Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology. 2002 , 95, 1650-5	45
1955	Trastuzumab-associated cardiotoxicity. 2002 , 95, 1592-600	272
1954	Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast. 2002 , 94, 895-901	34

1953	Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones. 2002 , 34, 104-14	60
1952	Breast cancer and leukemia: the forest for the trees?. 2002 , 9, 717-8	1
1951	The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma. 2002 , 8, 252-6	17
1950	Localized and locally advanced bladder cancer. 2002 , 3, 413-28	4
1949	HER2 overexpressing metastatic breast cancer. 2002 , 3, 163-74	17
1948	Tyrosine kinase inhibitors: a clinical perspective. 2002 , 4, 9-19	36
1947	New molecular targets of breast cancer therapy. 2002 , 178, 123-33	17
1946	[Breast carcinoma. Biological principles, classification and prognostic factors]. 2002 , 43, 329-30, 333-9	1
1945	[New therapeutic approaches: stem cell assisted high dose chemotherapy and molecular techniques in breast carcinoma]. 2002 , 43, 364-72	
1944	Phage-displayed random peptide libraries in mice: toxicity after serial panning. 2002 , 50, 325-32	21
1943	Evidence for the use of chemotherapy in breast cancer. 2002 , 7, 254-64	10
1942	Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer. 2002 , 47, 172-5	45
1941	Therapie des metastasierten Mammakarzinoms. 2002 , 8, 874-879	4
1940	Primäre und adjuvante systemische Therapie beim operablen Mammakarzinom. 2002 , 8, 847-852	
1939	Mammakarzinom - prognostische und prädiktive Faktoren. 2002 , 8, 808-816	2
1938	Früherkennung. 2002 , 8, 1030-1039	3
1937	Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer. 2002 , 44 Suppl, S15-30	24
1936	Receptor tyrosine kinase mutations in myeloid neoplasms. 2002 , 117, 489-508	25

1935	Targeting molecular mechanisms in cancer. 2002 , 72, 760-3	1
1934	HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab. 2002 , 93, 1250-7	45
1933	p185(HER-2/neu) and p21(CIP1/WAF1) expression in primary tumors and lymph node metastases in non-small cell lung cancer. 2002 , 93, 1007-11	8
1932	Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. 2002 , 30, 149-55	8
1931	Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. 2002 , 9, 1287-93	269
1930	Tumour biology: herceptin acts as an anti-angiogenic cocktail. 2002 , 416, 279-80	562
1929	Therapeutic antibodies: magic bullets hit the target. 2002 , 417, 584-6	108
1928	Shedding growth factors in cardiac hypertrophy. 2002 , 8, 20-1	16
1927	Tumor-specific mutations in p53: the acid test. 2002 , 8, 21-3	23
1926	ErbB2 is essential in the prevention of dilated cardiomyopathy. 2002 , 8, 459-65	690
1925	Epithelial-mesenchymal transitions in tumour progression. 2002 , 2, 442-54	5249
1924	Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. 2002 , 86, 1449-56	179
1923	Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker. 2002 , 87, 414-22	83
1922	Reversible and irreversible cardiac dysfunction associated with trastuzumab in breast cancer. 2002 , 74, 131-4	7
1921	The status of breast cancer management: challenges and opportunities. 2002 , 75 Suppl 1, S61-5; discussion S57-9	9
1920	Biochemical modulation of 5-fluorouracil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer. 2002 , 20, 419-24	7
1919	Proteomics approaches to uncover the repertoire of circulating biomarkers for breast cancer. 2002 , 7, 407-13	33
1918	Expression of HER-2/neu receptor protein in adrenal tumors. 2002 , 198, 445-8	7

1917 Drug development in pancreatic cancer: finally, biology begets therapy. **2002**, 32, 91-106

1916 Recombinant antibodies for the diagnosis and treatment of cancer. **2003**, 25, 1-17

11

1915 The role of biological markers as predictors of response to preoperative chemotherapy in large primary breast cancer. **2003**, 20, 221-31

12

1914 HER-2/neu and topoisomerase IIalpha in breast cancer. **2003**, 78, 299-311

75

1913 Basic and translational advances in cancer metastasis: Nm23. **2003**, 35, 73-9

93

1912 Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets. **2003**, 22, 301-7

30

1911 Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy. **2003**, 79 Suppl 1, S11-8

56

1910 Upregulation of HER-2/neu by ovarian ablation: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patients. **2003**, 80, 245-55

8

1909 Role of Taxanes. **2003**, 81, 17-24

1

1908 Trastuzumab in Combination with Chemotherapy. **2003**, 81, 69-72

1

1907 Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin). **2003**, 82, 23-8

29

1906 Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. **2003**, 82, 155-64

77

1905 Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the 'self' tumor-associated antigen, neu in a rat mammary tumor model. **2003**, 82, 169-83

31

1904 Tissue microarrays. **2003**, 8, 347-58

25

1903 Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. **2003**, 10, 234-41

136

1902 General keynote: molecular therapeutics and pharmacogenomics. **2003**, 88, S84-7; discussion S93-6

2

1901 Specific keynote: immunological therapy for ovarian cancer. **2003**, 88, S105-9; discussion S110-3

9

1900 Short interfering RNA (siRNA)-mediated RNA interference (RNAi) in human cells. **2003**, 1002, 56-62

66

1899	Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancer. 2003 , 77, 185-8	13
1898	Anticancer Antibodies. 2003 , 119, 472-485	76
1897	Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. 2003 , 21, 283-90	499
1896	Cardiac safety of liposomal anthracyclines. 2003 , 8 Suppl 2, 17-24	126
1895	The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. 2003 , 8, 307-25	462
1894	Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?. 2003 , 4 Suppl 1, S26-33	61
1893	Severe infusion reaction induced by trastuzumab: a case report. 2003 , 10, 167-9	15
1892	Metastatic breast cancer of HER2 scored 2+ by IHC and HER2 gene amplification assayed by FISH has a good response to single agent therapy with trastuzumab: a case report. 2003 , 10, 170-4	5
1891	Enhanced gene delivery to HER-2-overexpressing breast cancer cells by modified immunolipoplexes conjugated with the anti-HER-2 antibody. 2003 , 10, 337-44	10
1890	Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: comparative study with myocardial perfusion, left ventricular function, and histopathological findings. 2003 , 17, 481-8	20
1889	Adjuvant systemic therapy of early stage breast cancer. 2003 , 4, 141-50	5
1888	Antibodies as molecular target-based therapy: trastuzumab. 2003 , 8, 224-9	20
1887	Progress in systemic adjuvant therapy of early-stage breast cancer. 2003 , 8, 239-47	5
1886	Experimentelle Therapie gynäkologischer Tumoren mit Peptidanaloga. 2003 , 1, 42-46	
1885	Inhibition der Signaltransduktion als therapeutisches Prinzip. 2003 , 9, 1088-1101	
1884	Anthrazyklintherapie beim Mammakarzinom. 2003 , 9, 1366-1374	1
1883	Evaluation of bone marrow in breast cancer patients: prediction of clinical outcome and response to therapy. 2003 , 12, 397-404	15
1882	ErbB2 pathways in heart and neural diseases. 2003 , 13, 80-6	77

1881	Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents. 2003 , 13, 441-53	8
1880	Detection of HER-2/neu gene amplification in breast cancer using a novel polymerase chain reaction/ligase detection reaction technique. 2003 , 197, 419-25	12
1879	Amplified genes as therapeutic targets in cancer. 2003 , 2, 147-153	1
1878	Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. 2003 , 3, 173-83	353
1877	Trastuzumab and cardiac dysfunction: update on preclinical studies. 2003 , 30, 49-53	34
1876	Ongoing adjuvant trials with trastuzumab in breast cancer. 2003 , 30, 54-64	37
1875	CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. 2003 , 30, 65-78	85
1874	Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma. 2003 , 30, 79-92	26
1873	Cardiac effects of adjuvant therapy for early breast cancer. 2003 , 30, 730-9	40
1872	The case for cancer immunotherapy. 2003 , 8, 530-1	
1871	Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. 2003 , 39, 724-7	183
1870	Novel systemic therapies for breast cancer. 2003 , 12, 277-87	7
1869	Diagnosis and treatment of breast cancer in the elderly. 2003 , 53, 227-44	79
1868	Integration of targeted therapies in gemcitabine chemotherapy regimens. 2003 , 4, 217-23	2
1867	Gefitinib in the treatment of advanced, refractory non-small-cell lung cancer: results in 124 patients. 2003 , 4, 347-55	10
1866	Targeted molecular therapy for cancer: The application of STI571 to gastrointestinal stromal tumor. 2003 , 40, 131-193	
1865	Vesicular stomatitis virus expressing a chimeric Sindbis glycoprotein containing an Fc antibody binding domain targets to Her2/neu overexpressing breast cancer cells. 2003 , 316, 337-47	32
1864	HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed?. 2003 , 88, 263-5	36

1863	Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy. 2003 , 89, 99-104	14
1862	Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. 2003 , 91, 231-40	24
1861	Immune responses in cancer. 2003 , 99, 113-32	92
1860	Detailed gene copy number and RNA expression analysis of the 17q12-23 region in primary breast cancers. 2003 , 36, 382-92	23
1859	Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial. 2003 , 97, 40-5	39
1858	The biology of breast carcinoma. 2003 , 97, 825-33	155
1857	Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. 2003 , 97, 1758-65	58
1856	Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. 2003 , 97, 2972-7	589
1855	HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. 2003 , 99, 310-5	35
1854	HER 2/neu expression and gene amplification in colon cancer. 2003 , 105, 796-802	76
1853	Gastrointestinal stromal tumors: from a surgical to a molecular approach. 2003 , 107, 171-6	111
1852	A single nucleotide polymorphism in the transmembrane domain coding region of HER-2 is associated with development and malignant phenotype of gastric cancer. 2003 , 107, 593-6	23
1851	Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. 2003 , 107, 976-83	40
1850	Absence of HER2 overexpression in metastatic malignant melanoma. 2003 , 84, 82-8	18
1849	Gastrointestinal stromal tumours. 2003 , 90, 1178-86	245
1848	Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. 2003 , 46 Suppl, S85-104	98
1847	Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. 2003 , 46 Suppl, S105-15	32
1846	New drugs and new approaches in metastatic bladder cancer. 2003 , 47, 195-206	25

1845	Follow-up care of breast cancer survivors. 2003 , 48, 89-99	15
1844	The pipeline of new anticancer agents for breast cancer treatment in 2003. 2003 , 48, 45-63	11
1843	Beyond Herceptin and Gleevec. 2003 , 7, 490-5	81
1842	HER2 oncogene amplification in extramammary Paget's disease. 2003 , 42, 575-9	41
1841	Overview of the clinical efficacy of investigational anticancer drugs. 2003 , 253, 46-75	67
1840	Clinical experience with trastuzumab (herceptin). 2003 , 9, 452-62	63
1839	The expanding role of pathologists in the diagnosis and management of breast cancer: Worldwide Excellence in Breast Pathology Program. 2003 , 9 Suppl 2, S94-7	17
1838	HER-2/neu expression in ovarian clear cell carcinomas. 2003 , 13, 28-31	17
1837	A surgeon's look at the treatment of cancer. 2003 , 7, B7-B17	
1836	Signal pathway profiling of prostate cancer using reverse phase protein arrays. 2003 , 3, 2142-6	185
1835	Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. 2003 , 199, 418-23	206
1834	Quantitative analysis of colorectal tissue microarrays by immunofluorescence and in situ hybridization. 2003 , 200, 577-88	40
1833	For the good of the patient: risks and benefits of medicines. 2003 , 12, 145-50	8
1832	Prognostic significance of c-erbB-2/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy. 2003 , 13, 849-55	28
1831	Targeted therapy for epithelial ovarian cancer: current status and future prospects. 2003 , 13, 701-34	39
1830	Application of differential display, with in situ hybridization verification, to microscopic samples of breast cancer tissue. 2003 , 84, 207-12	5
1829	Ready to partner. 2003 , 10, 158-9	33
1828	Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. 2003 , 89, 983-91	54

1827	DNA topoisomerase IIalpha expression and the response to primary chemotherapy in breast cancer. 2003 , 89, 666-71	77
1826	Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. 2003 , 421, 756-60	1138
1825	cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. 2003 , 22, 2680-8	131
1824	Biologic and therapeutic role of HER2 in cancer. 2003 , 22, 6570-8	304
1823	HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production. 2003 , 22, 6739-47	31
1822	Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. 2003 , 22, 6005-12	86
1821	Mechanisms of Taxol resistance related to microtubules. 2003 , 22, 7280-95	559
1820	Monoclonal antibody therapeutics and apoptosis. 2003 , 22, 9097-106	58
1819	Current perspectives on HER2 testing: a review of national testing guidelines. 2003 , 16, 173-82	207
1818	Immunotherapy: past, present and future. 2003 , 9, 269-77	455
1817	Rethinking clinical trials for cytostatic drugs. 2003 , 3, 540-5	55
1816	Targeting RAS signalling pathways in cancer therapy. 2003 , 3, 11-22	2424
1815	Tumour banks: well-guarded treasures in the interest of patients. 2003 , 3, 73-7	115
1814	Issues and progress with protein kinase inhibitors for cancer treatment. 2003 , 2, 296-313	410
1813	Met, metastasis, motility and more. 2003 , 4, 915-25	2175
1812	Determinants and prognoses of locoregional and distant progression in breast cancer. 2003 , 55, 1186-95	90
1811	Unique aspects of supportive care using monoclonal antibodies in cancer treatment. 2003 , 1, 38-48	34
1810	Primer on medical genomics. Part VI: Genomics and molecular genetics in clinical practice. 2003 , 78, 307-17	20

1809	Overview of novel anticancer drug targets. 2003 , 85, 3-28	
1808	Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors. 2003 , 46, 4657-68	51
1807	Allogeneic breast cancer cell vaccines. 2003 , 3 Suppl 4, S173-80	13
1806	Pharmacology of anticancer drugs in the elderly population. 2003 , 42, 1213-42	101
1805	Inhibiting Ras signaling in the therapy of breast cancer. 2003 , 3, 405-16; discussion 417-20	28
1804	Trastuzumab-based combinations in metastatic breast cancer: how to make a choice. 2003 , 4, 28-38	14
1803	Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. 2003 , 4, 114-9	89
1802	Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. 2003 , 4, 120-5	93
1801	A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2). 2003 , 4, 142-5	40
1800	Pegylated liposomal doxorubicin in the treatment of breast cancer. 2003 , 4, 318-28	86
1799	Trastuzumab regimens for HER2-overexpressing metastatic breast cancer. 2003 , 4, 329-37; discussion 338-9	16
1798	Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. 2003 , 4, 348-53	80
1797	Current status and future directions in breast cancer therapy. 2003 , 4 Suppl 2, S70-5	25
1796	Current status of liposomal anthracycline therapy in metastatic breast cancer. 2003 , 4 Suppl 2, S76-83	38
1795	Liposomal anthracyclines for breast cancer: overview. 2003 , 8 Suppl 2, 1-2	28
1794	Targeted therapies for the treatment of cancer. 2003 , 186, 264-8	59
1793	Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. 2003 , 35, 1473-9	191
1792	The Hsp90 chaperone complex as a novel target for cancer therapy. 2003 , 14, 1169-76	255

1791	The value of axillary lymphadenectomy. 2003 , 29, 701-2	3
1790	Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells. 2003 , 88, 1292-300	11
1789	Targeted therapy in non-small cell lung cancer: myth or reality. 2003 , 41 Suppl 1, S3-8	29
1788	Progress in systemic therapy for breast cancer: an overview and perspectives. 2003 , 1, 56-69	10
1787	Prognostic factors in ovarian cancer: current evidence and future prospects. 2003 , 1, 127-145	14
1786	Non-endocrine systemic therapies in advanced breast cancer. 2003 , 1, 287-298	2
1785	Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma. 2003 , 34, 639-45	50
1784	HER2/neu expression in cancer: the pathologist as diagnostician or prophet?. 2003 , 34, 635-8	14
1783	Targeting epidermal growth factor receptor--are we missing the mark?. 2003 , 362, 62-4	190
1782	HER2 and surgery: more questions to answer. 2003 , 362, 502-3	4
1781	Histidine kinases and histidine phosphorylated proteins in mammalian cell biology, signal transduction and cancer. 2003 , 190, 1-12	77
1780	Chemotherapy dose and schedule in adjuvant treatment of breast cancer: phoenix, turkey, or dodo?. 2003 , 362, 677-8	1
1779	An overview of targeted treatments in cancer. 2003 , 25, 2121-37	75
1778	Ligand-targeted liposomal anticancer drugs. 2003 , 42, 439-62	330
1777	Monoclonal antibody therapy for cancer. 2003 , 54, 343-69	158
1776	Levels of absolute survival benefit for systemic therapies of advanced cancer. a call for standards. 2003 , 39, 1194-8	10
1775	Exploiting the hallmarks of cancer: the future conquest of breast cancer. 2003 , 39, 1668-75	102
1774	Trends in cancer therapy: role of monoclonal antibodies. 2003 , 19, 169-79	12

1773	An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. 2003 , 12, 541-52	693
1772	Strategies to target HER2/neu overexpression for cancer therapy. 2003 , 6, 129-36	64
1771	Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. 2003 , 4, 397-406	243
1770	The Addition of Carboplatin to Trastuzumab/Paclitaxel Improves Efficacy in HER2-Overexpressing Metastatic Breast Cancer. 2003 , 3, 378-380	
1769	2003 Highlights From: 39th Annual Meeting of the American Society of Clinical Oncology Chicago, Illinois May 31 to June 3, 2003. 2003 , 4, 166-172	
1768	HER2-Overexpressing Metastatic Breast Cancer: The Role of Trastuzumab Regimens. 2003 , 4, 338-339	1
1767	Immunotherapy as part of combinations for the treatment of cancer. 2003 , 3, 1051-9	56
1766	Metastatic Bladder Cancer: Role of Chemotherapy and New Agents. 2003 , 1, 108-117	5
1765	[Laboratory's function in clinic practice of breast cancer]. 2003 , 120, 342-8	
1764	Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. 2004 , 6, 39-52	141
1763	Positron emitting 18F-2-deoxy-2-fluoro-D-glucose: potential hot new therapy. 2003 , 5, 329-31	4
1762	The future of cytotoxic therapy: selective cytotoxicity based on biology is the key. 2003 , 5, 154-9	32
1761	25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 10-14 December 2002 Update on clinical research. 2003 , 5, 113-6	0
1760	Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer. 2003 , 5, 96-100	40
1759	HER2-Positive Breast Cancer. 2003 , 2, 169-179	4
1758	Clinical Relevance of Micrometastatic Disease in Patients with Solid Tumors. 2003 , 2, 77-86	3
1757	Postmenopausal Metastatic Breast Cancer. 2003 , 2, 95-109	1
1756	Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. 2003 , 21, 2889-95	295

1755	Taking stock of targeted therapy in cancer: rational expectations or irrational exuberance?. 2003 , 3, 127-9	
1754	Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. 2003 , 21, 3965-71	260
1753	New chemotherapy treatments in advanced cancer patients: an easily applicable evaluation of clinical efficacy and cost-effectiveness. 2003 , 42, 895-902	10
1752	Higher dose and dose-rate in smaller tumors result in improved tumor control. 2003 , 21, 382-8	5
1751	Therapeutic potential of tyrosine kinase inhibitors in breast cancer. 2003 , 21, 782-91	10
1750	Novel chemotherapeutic and targeted agents in metastatic colorectal cancer: the time has arrived. 2003 , 12, 1939-1949	6
1749	Immunotherapy: new options in breast cancer treatment. 2003 , 3, 403-8	18
1748	Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. 2003 , 49, 1579-98	127
1747	Cancer target discovery using SAGE. 2003 , 7, 759-69	7
1746	Doxorubicin for metastatic breast cancer: time for a change?. 2003 , 21, 967-8	3
1745	Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer. 2003 , 8 Suppl 2, 10-6	19
1744	Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. 2003 , 532, 253-68	149
1743	New paradigms in adjuvant systemic therapy of breast cancer. 2003 , 10, 75-89	3
1742	Combination of trastuzumab and vinorelbine in metastatic breast cancer. 2003 , 33, 514-7	28
1741	Growth factor receptors in breast cancer: potential for therapeutic intervention. 2003 , 8, 5-17	81
1740	Developing inhibitors of the epidermal growth factor receptor for cancer treatment. 2003 , 95, 851-67	306
1739	Goals and objectives in the management of metastatic breast cancer. 2003 , 8, 514-20	102
1738	RESPONSE: Re: HER2 Testing in the Real World. 2003 , 95, 628-629	

1737	NSABP breast cancer clinical trials: recent results and future directions. 2003 , 1, 309-26	35
1736	Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer. 2003 , 8, 232-40	21
1735	Liposomal anthracyclines in metastatic breast cancer: clinical update. 2003 , 8 Suppl 2, 3-9	112
1734	Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. 2003 , 74, 593-601	15
1733	Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. 2003 , 21, 1022-8	90
1732	Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. 2003 , 278, 7607-16	414
1731	Re: HER2 testing in the real world. 2003 , 95, 628; author reply 628-9	14
1730	Rational approaches to human cancer immunotherapy. 2003 , 73, 3-29	93
1729	The Integration of Molecular Diagnostics With Therapeutics. 2003 , 119, 26-36	31
1728	Liposomal anthracyclines and new treatment approaches for breast cancer. 2003 , 8 Suppl 2, 25-30	19
1727	Novel pharmacological approaches in the treatment of breast cancer. 2003 , 12, 909-21	4
1726	The role of growth factors for disease and therapy in diseases of the head and neck. 2003 , 22, 593-606	5
1725	Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. 2003 , 14, 1346-63	78
1724	Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. 2003 , 88, 1587-91	92
1723	HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. 2003 , 89, 1305-9	55
1722	Cytotoxic T-cell precursor frequencies to HER-2 (369-377) in patients with HER-2/neu-positive epithelial tumours. 2003 , 89, 1055-61	27
1721	Farnesyl transferase inhibitors in the treatment of breast cancer. 2003 , 12, 413-21	26
1720	The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. 2003 , 278, 23441-50	117

1719	HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. 2003 , 21, 458-62	85
1718	Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. 2003 , 21, 46-53	250
1717	Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?. 2003 , 21, 2227-9	43
1716	Targeting of the VHL-hypoxia-inducible factor-hypoxia-induced gene pathway for renal cell carcinoma therapy. 2003 , 14, 2695-702	15
1715	Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?. 2003 , 21, 959-62	58
1714	Update on locally advanced breast cancer. 2003 , 8, 521-30	148
1713	Drugs acting on the immune system. 2003 , 26, 393-415	
1712	Signal transduction--directed cancer treatments. 2003 , 43, 199-231	76
1711	Receptor tyrosine kinase signaling in gliomagenesis: pathobiology and therapeutic approaches. 2003 , 2, 330-42	45
1710	What's new in...general surgery. 2003 , 149, 317-29	
1709	Combination chemotherapy for metastatic breast cancer: reaching for the cure. 2003 , 21, 580-2	11
1708	Is trastuzumab every three weeks ready for prime time?. 2003 , 21, 3900-1	11
1707	Combining trastuzumab (Herceptin) with hormonal therapy in breast cancer: what can be expected and why?. 2003 , 14, 1697-704	29
1706	Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?. 2003 , 95, 1813-5	7
1705	Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. 2003 , 10, 1-21	237
1704	The importance of paternal family history in hereditary breast cancer is underappreciated by health care professionals. 2003 , 64, 220-6	23
1703	Principles of Cancer Immunotherapy. 2003 , 79-93	
1702	Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. 2003 , 14, 1222-6	13

1701	Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells. 2003 , 26, 50-4	34
1700	Inhibiting Tyrosine Kinases: Successes and Limitations. 2003 , 2, 78-82	62
1699	. 2003 , 26, 95-97	7
1698	Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. 2003 , 22, 875	2
1697	Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation. 2003 , 22, 1225	5
1696	Relationship between HER2 status and proliferation rate in breast cancer assessed by immunohistochemistry, fluorescence in situ hybridisation and standardised AgNOR analysis. 2003 , 23, 1285	1
1695	Receptor tyrosine kinases: the main targets for new anticancer therapy. 2003 , 4, 113-21	75
1694	Emerging drugs for non-small cell lung cancer. 2003 , 8, 179-92	8
1693	Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. 2003 , 21, 2492-9	173
1692	Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study. 2003 , 26, 95-7	25
1691	Role of targeted therapy in non-small cell lung cancer: hype or hope?. 2003 , 3, 443-55	1
1690	The MYC oncogene as a cancer drug target. 2003 , 3, 163-75	104
1689	Inhibition of the biologic response to insulin-like growth factor I in MCF-7 breast cancer cells by a new monoclonal antibody to the insulin-like growth factor-I receptor. The importance of receptor down-regulation. 2003 , 35, 850-6	20
1688	Role of gemcitabine in the treatment of advanced and metastatic breast cancer. 2003 , 64, 191-206	76
1687	Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells. 2003 , 26, 163-70	30
1686	Abstract. 2003 , 21, 1-108	24
1685	Interlaboratory comparison in HercepTest assessment of HER2 protein status in invasive breast carcinoma fixed with various formalin-based fixatives. 2003 , 11, 339-44	13
1684	Current diagnostic methods of HER-2/neu detection in breast cancer with special regard to real-time PCR. 2003 , 27, 1565-70	31

1683	Chemosensitivity testing for gastrointestinal cancer: survival benefit potential and limitations. 2003 , 14, 715-23	6
1682	Molecular classification of breast carcinomas using tissue microarrays. 2003 , 12, 27-34	142
1681	Selection of higher molecular weight genomic DNA for molecular diagnosis from formalin-fixed material. 2003 , 12, 231-6	18
1680	The epidermal growth factor receptor HER2 is not a major therapeutic target in Ewing sarcoma. 2003 , 25, 459-66	16
1679	Pharmacopathology: a new spin on an old idea. 2003 , 27, 121-3	6
1678	Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. 2003 , 26, 139-48	91
1677	The drug development process: from target discovery to the clinic. 2003 , 3, 323-6	2
1676	Metastatic breast cancer: overview of treatment. 2003 , S132-7	39
1675	Algorithm for the diagnosis of HER-2/neu status in breast-infiltrating carcinomas. 2003 , 26, 465-70	8
1674	Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells. 2003 , 171, 5124-9	53
1673	Molecular cancer therapeutics: recent progress and targets in drug resistance. 2003 , 42, 237-43	36
1672	Development of HER2-specific humanized antibody Herceptin (trastuzumab). 2003 , 122, 504-14	2
1671	Cardiotoxicity of trastuzumab (herceptin) in chick embryos. 2003 , 26, 893-5	11
1670	HER-2/neu testing in breast cancer. 2003 , 120 Suppl, S53-71	19
1669	Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. 2003 , 101, 2507-13	184
1668	Functional Relationship and Gene Ontology Classification of Breast Cancer Biomarkers. 2003 , 18, 241-272	16
1667	Breast cancer. 2003 , 150-161	
1666	Markers of Prognosis and Response to Treatment: Ready for Clinical Use in Oncology? A Biostatistician's Viewpoint. 2003 , 18, 65-69	2

1665	Predictors of response and resistance to medical therapy: endocrine therapy. 2003 , 220-245	1
1664	Predictors of response and resistance to medical therapy: chemotherapy. 2003 , 246-263	
1663	The type I IGF receptor as a target for breast cancer therapy. 2003 , 17, 115-24	2
1662	Nuevas armas inmunol3gicas para la medicina del siglo XXI: Terapia biol3gica basada en el uso de anticuerpos monoclonales de ltima generaci3n. 2003 , 131, 1445	4
1661	The EGF receptor family as therapeutic targets in breast cancer. 2003 , 18, 33-43	15
1660	Breast Cancer. 429-464	
1659	[Oncology 2003: new therapeutic perspectives]. 2003 , 19, 131	0
1658	Molecular Genetics of Breast Cancer. 2003 , 3, 69-78	1
1657	Quantitative Assessment of HER-2/Neu Protein Concentration in Breast Cancer by Enzyme-Linked Immunosorbent Assay. 2003 , 18, 13-20	20
1656	Monoclonal antibodies in the treatment of cancer, Part 1. 2003 , 60, 1531-48	31
1655	Epidermal Growth Factor Receptor and c-erbB-2 Contents in Unresectable (UICC R1 or R2) Gastric Cancer. 2003 , 18, 200-206	7
1654	Assessment of thin-layer breast aspirates for immunocytochemical evaluation of HER2 status. 2003 , 47, 979-84	16
1653	[Current status and perspectives of chemotherapy for anthracycline-pretreated breast cancer]. 2003 , 26 Suppl 7, 11-6	
1652	Efficacy and Safety of Trastuzumab as a Single Agent in Heavily Pretreated Patients with Her-2/NEU-Overexpressing Metastatic Breast Cancer. 2004 , 90, 40-43	26
1651	Discordant Results Obtained for Different Methods of HER-2/Neu Testing in Breast Cancer IIA Question of Standardization, Automation and Timing. 2004 , 19, 1-13	12
1650	Breast Cancer. 85-99	
1649	HER-2/neu oncogene amplification by chromogenic in situ hybridization in 130 breast cancers using tissue microarray and clinical follow-up studies. 2004 , 19, 390-6	11
1648	[New antibodies in cancer treatment]. 2004 , 93, 1589-92	2

1647	Chemotherapy-Induced Cardiomyopathy. 2004 , 31, 185-187	
1646	Adjuvant therapy for breast cancer: practical lessons from the early breast cancer trialists' collaborative group. 2004 , 21, 3-13	2
1645	In Reply:. 2004 , 22, 3646-3648	1
1644	HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. 2004 , 4, 277-278	
1643	Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors. 2004 , 44, 52-8	21
1642	The role of growth factor signaling in malignancy. 2003 , 115, 19-72	13
1641	. 2004 ,	4
1640	. 2004 ,	4
1639	Membranous Levels of C-ErbB-2 Oncoprotein in Gastric Cancer: Their Relationship with Clinicopathological Parameters and Their Prognostic Significance. 2004 , 19, 268-274	4
1638	Cost-effectiveness analysis in cancer: toward an iterative framework for integration of evidence from trials and models. 2004 , 503-521	1
1637	Long-term complications of adjuvant chemotherapy for early stage breast cancer. 2004 , 21, 55-64	26
1636	Clinical Development Issues. 2004 , 287-306	1
1635	Therapeutic Strategies to Improve the Efficacy of Oxaliplatin in Gastrointestinal Tumors. 2004 , 19, 183-189	1
1634	A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. 2004 , 5, 1139-49	83
1633	Management of primary resistance to gemcitabine and cisplatin (G-C) chemotherapy in metastatic bladder cancer with HER2 over-expression. 2004 , 15, 538	7
1632	Molecular biological design of novel antineoplastic therapies. 2004 , 13, 577-607	4
1631	Current treatment options for endometrial cancer. 2004 , 4, 679-89	34
1630	Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer. 2004 , 5, 2147-57	3

- 1629 Leitlinienorientierte Therapie des Mammakarzinoms: Kontroversen in der individuellen Betreuung. **2004**, 36, 4-8
- 1628 Mammaglobin-based strategies for treatment of breast cancer. **2004**, 4, 531-42 24
- 1627 Principles of Molecular Oncology. **2004**, 6
- 1626 A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. **2004**, 15, 313-37 32
- 1625 Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells. **2004**, 10, 7747-56 45
- 1624 Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes. **2004**, 10, 2538-44 50
- 1623 The role of ErbB inhibitors in trastuzumab resistance. **2004**, 9 Suppl 3, 16-9 24
- 1622 Breast cancer with synchronous metastases: trends in survival during a 14-year period. **2004**, 22, 3302-8 339
- 1621 Bevacizumab in the treatment of breast cancer: rationale and current data. **2004**, 9 Suppl 1, 43-9 75
- 1620 Neuregulins regulate cardiac parasympathetic activity: muscarinic modulation of beta-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion. **2004**, 110, 713-7 55
- 1619 Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. **2004**, 22, 1621-9 95
- 1618 Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer. **2004**, 9 Suppl 3, 4-9 49
- 1617 Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors. **2004**, 64, 1087-93 59
- 1616 Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. **2004**, 22, 3886-92 88
- 1615 Enhanced Accuracy and Reliability of HER-2/neu Immunohistochemical Scoring Using Digital Microscopy. **2004**, 121, 620-630 92
- 1614 c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study. **2004**, 15, 594-7 41
- 1613 Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling. **2004**, 279, 51141-7 141
- 1612 Testing for epidermal growth factor receptor in lung cancer: have we learned anything from HER-2 testing?. **2004**, 22, 3646; author reply 3646-8 8

1611	Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. 2004 , 96, 759-69	245
1610	Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. 2004 , 22, 1180-7	171
1609	Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. 2004 , 10, 3927-33	50
1608	P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. 2004 , 64, 3981-6	256
1607	Facts and controversies in systemic treatment of metastatic breast cancer. 2004 , 9, 617-32	139
1606	Structure and function of the epidermal growth factor (EGF/ErbB) family of receptors. 2004 , 68, 1-27	61
1605	HER-2/neu Detection in Fine-Needle Aspirates of Breast Cancer. 2004 , 122, 246-255	68
1604	HERe-2 stay: the continuing importance of translational research in breast cancer. 2004 , 96, 725-7	17
1603	The Use of Cell Line Standards to Reduce HER-2/neu Assay Variation in Multiple European Cancer Centers and the Potential of Automated Image Analysis to Provide for More Accurate Cut Points for Predicting Clinical Response to Trastuzumab. 2004 , 122, 51-60	33
1602	HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. 2004 , 22, 854-63	194
1601	Evidence for the clinical use of tumour markers. 2004 , 41, 370-7	32
1600	Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. 2004 , 22, 1063-70	248
1599	Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. 2004 , 10, 8204-13	76
1598	HER-2 testing in breast cancer using parallel tissue-based methods. 2004 , 291, 1972-7	334
1597	Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?. 2004 , 11, 191-205	30
1596	Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia. 2004 , 64, 5825-9	57
1595	Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. 2004 , 10, 4062-7	59
1594	HMMC-1: a humanized monoclonal antibody with therapeutic potential against Mllerian duct-related carcinomas. 2004 , 10, 7071-8	18

1593	Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. 2004 , 22, 1646-54	232
1592	Toward customized trastuzumab in HER-2/neu-overexpressing non-small-cell lung cancers. 2004 , 22, 1171-3	32
1591	Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. 2004 , 10, 4489-97	75
1590	Selective tyrosine hyperphosphorylation of cytoskeletal and stress proteins in primary human breast cancers: implications for adjuvant use of kinase-inhibitory drugs. 2004 , 10, 3980-7	36
1589	Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. 2004 , 11, 793-814	245
1588	Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. 2004 , 15, 5268-82	383
1587	Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?. 2004 , 22, 759-61	63
1586	High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. 2004 , 10, 8195-203	458
1585	Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. 2004 , 22, 1071-7	101
1584	Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. 2004 , 10, 3273-81	74
1583	Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. 2004 , 10, 5650-5	400
1582	The prognostic value of BCAR1 in patients with primary breast cancer. 2004 , 10, 6194-202	47
1581	Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. 2004 , 10, 4793-8	157
1580	The use of TMA for interlaboratory validation of FISH testing for detection of HER2 gene amplification in breast cancer. 2004 , 52, 501-7	29
1579	Breast cancer highlights: key findings from the San Antonio Breast Cancer Symposium: a U.S. perspective. 2004 , 9, 471-8	6
1578	Identification and validation of cell surface antigens for antibody targeting in oncology. 2004 , 11, 659-87	91
1577	The role of BRCA1 in the cellular response to chemotherapy. 2004 , 96, 1659-68	346
1576	Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. 2004 , 279, 53907-14	91

1575	Evaluating the efficiency of targeted designs for randomized clinical trials. 2004 , 10, 6759-63	265
1574	Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease. 2004 , 109, 1196-205	114
1573	Handbook of Cancer Vaccines. 2004 ,	5
1572	HER-2 gene amplification can be acquired as breast cancer progresses. 2004 , 101, 9393-8	431
1571	A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. 2004 , 66, 38-45	45
1570	Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study. 2004 , 67, 250-6	25
1569	Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer. 2004 , 25, 1769	2
1568	c-kit expression in adenocarcinomas of the lung. 2004 , 25, 235-42	26
1567	Rationale for the use of gemcitabine in breast cancer (Review). 2004 , 24, 389-98	3
1566	Surrogate markers in oncology practice and anticancer drug development: lessons learned from antiretroviral therapy?. 2004 , 22, 164-8	
1565	Abstracts. 2004 , 22, 1-111	
1564	Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. 2004 , 22, 4737-45	58
1563	Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. 2004 , 173, 394-401	88
1562	Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. 2004 , 101, 10715-20	264
1561	Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. 2004 , 64, 3958-65	493
1560	Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments. 2004 , 10, 1100-11	105
1559	The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma. 2004 , 10, 7529-39	131
1558	Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. 2004 , 22, 785-94	1508

1557	Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. 2004 , 10, 3885-96	142
1556	Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. 2004 , 22, 4816-22	41
1555	Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. 2004 , 10, 8185-94	112
1554	HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ Hybridization. 2004 , 121, 631-636	130
1553	Her2-neu: a target in lung cancer?. 2004 , 15, 3-4	9
1552	Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. 2004 , 10, 3919-26	106
1551	Gefitinib induces apoptosis in the EGFR L858R non-small-cell lung cancer cell line H3255. 2004 , 64, 7241-4	316
1550	Synergistic interactions between tamoxifen and trastuzumab (Herceptin). 2004 , 10, 1409-20	68
1549	Activation of the MDR1 upstream promoter in breast carcinoma as a surrogate for metastatic invasion. 2004 , 10, 2776-83	40
1548	Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. 2004 , 10, 7136-43	17
1547	Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. 2004 , 64, 3780-9	117
1546	Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. 2004 , 22, 3700-4	108
1545	Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. 2004 , 96, 990-7	192
1544	Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. 2004 , 90, 449-54	127
1543	Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. 2004 , 90, 36-40	52
1542	New chondrocyte genes discovered by representational difference analysis of chondroinduced human fibroblasts. 2004 , 176, 41-53	21
1541	Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice. 2004 , 90, 2032-41	20
1540	Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients. 2004 , 90, 443-8	19

1539	Controlled-release and local delivery of therapeutic antibodies. 2004 , 4, 1029-44	41
1538	Trastuzumab-based combination therapy for breast cancer. 2004 , 5, 81-96	39
1537	Antisense Therapeutics. 2004 ,	1
1536	Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. 2004 , 43, 35-42	58
1535	Profiling Breast Cancer Using Real-Time Quantitative PCR. 2004 , 95-106	1
1534	Abstracts. 2004 , 22, 1-104	
1533	Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study. 2004 , 22, 670-7	43
1532	Primary intracranial myxopapillary ependymomas: report of two cases and review of the literature. 2004 , 45, 344-7	23
1531	HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis. 2004 , 22, 16-24	34
1530	A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. 2004 , 10, 5027-37	93
1529	Carboplatin in combination therapy for metastatic breast cancer. 2004 , 9, 518-27	56
1528	Nurse management of trastuzumab for patients with breast cancer. 2004 , 3, 35-39	1
1527	Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. 2004 , 64, 8022-8	79
1526	Targeting protein kinases in cancer therapy: a success?. 2004 , 4, 1113-24	41
1525	Targeting targeted therapy. <i>New England Journal of Medicine</i> , 2004 , 350, 2191-3	59.2 119
1524	Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. 2004 , 15, 19-27	289
1523	Management of endocrine resistant breast cancer. 2004 , 10, 16-23	1
1522	Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. 2004 , 22, 858-65	100

1521	Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. 2004 , 96, 1141-51	124
1520	Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. 2004 , 22, 4717-24	169
1519	COX-2 inhibitors as cancer treatment: will they be the new warfarin or trastuzumab?. 2004 , 22, 324-5	1
1518	Rituximab-CHOP or two-weekly CHOP + G-CSF in aggressive lymphoma of the elderly?. 2004 , 15, 538-9	2
1517	Tumor lysis syndrome in a multiple myeloma treated with thalidomide. 2004 , 15, 537	21
1516	Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK. 2004 , 58, 581-6	5
1515	Pathology of breast carcinoma. 2004 , 58, 29-34	5
1514	New concepts in breast cancer therapy. 2004 , 34, 266-9	5
1513	What are the reasons for negative phase III trials of molecular-target-based drugs?. 2004 , 95, 772-6	12
1512	Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. 2004 , 95, 608-13	59
1511	SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma. 2004 , 150, 252-8	26
1510	Chromogenic in situ hybridization analysis of HER-2/neu status in cytological samples of breast carcinoma. 2004 , 15, 315-20	13
1509	Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer. 2004 , 44, 332-8	51
1508	Increased cell size and Akt activation in HER-2/neu-overexpressing invasive ductal carcinoma of the breast. 2004 , 45, 142-7	10
1507	Kinase inhibitors in cancer therapy. 2004 , 2, 177-93	22
1506	Dramatic response of choroidal metastases from breast cancer to a combination of trastuzumab and vinorelbine. 2004 , 10, 54-6	19
1505	Cancer immunotherapy: breaking the barriers to harvest the crop. 2004 , 10, 887-92	110
1504	The anti-angiogenic basis of metronomic chemotherapy. 2004 , 4, 423-36	1156

1503	Pharmacogenomics: bench to bedside. 2004 , 3, 739-48	220
1502	Development of TGF-beta signalling inhibitors for cancer therapy. 2004 , 3, 1011-22	452
1501	HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support. 2004 , 34, 413-7	9
1500	Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer. 2004 , 11, 594-602	40
1499	Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. 2004 , 23, 1010-3	51
1498	A role for Janus kinases in crosstalk between ErbB3 and the interferon-alpha signaling complex in myeloma cells. 2004 , 23, 1197-205	10
1497	Overexpression of the amplified Pip4k2beta gene from 17q11-12 in breast cancer cells confers proliferation advantage. 2004 , 23, 1354-63	38
1496	Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. 2004 , 23, 2385-400	210
1495	HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. 2004 , 90, 2344-8	176
1494	Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. 2004 , 91, 639-43	316
1493	Preclinical characterisation of 111In-DTPA-trastuzumab. 2004 , 143, 99-106	125
1492	Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome. 2004 , 17, 227-87	50
1491	Oncogenic growth factor receptors: implications for signal transduction therapy. 2004 , 14, 262-70	110
1490	2004 Highlights from: Third Annual Future of Breast Cancer: An International Congress, Southampton, Bermuda, July 2004. 2004 , 5, 172-176	1
1489	2003 Highlights from: 26th Annual San Antonio Breast Cancer Symposium San Antonio, Texas, December 2003. 2004 , 5, 22-28	
1488	Continuation of Trastuzumab Beyond Disease Progression: More Questions Than Answers. 2004 , 5, 59-62	26
1487	Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies. 2004 , 5, 115-20	45
1486	Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. 2004 , 5, 317-28	837

1485	Opportunities and challenges in the development of targeted therapies. 2004 , 31, 21-7	27
1484	Targeting the HER-kinase axis in cancer. 2004 , 31, 9-20	53
1483	Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer. 2004 , 31, 3-8	33
1482	New targeted therapies in breast cancer. 2004 , 31, 20-5	34
1481	Introduction. 2004 , 31, 1-3	
1480	Optimizing treatment for patients with breast cancer. 2004 , 31, 4-5	111
1479	Molecular approach to breast cancer treatment. 2004 , 31, 6-13	59
1478	Improving patient care through molecular diagnostics. 2004 , 31, 14-20	21
1477	Optimizing treatment of HER2-positive metastatic breast cancer. 2004 , 31, 29-34	5
1476	Maximizing clinical benefit with trastuzumab. 2004 , 31, 35-44	68
1475	Future options with trastuzumab for primary systemic and adjuvant therapy. 2004 , 31, 51-7	42
1474	Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. 2004 , 31, 16-35	143
1473	Cardiac safety of liposomal anthracyclines. 2004 , 31, 161-81	131
1472	Future directions of liposome- and immunoliposome-based cancer therapeutics. 2004 , 31, 196-205	190
1471	Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. 2004 , 31, 53-90	109
1470	The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. 2004 , 31, 106-46	97
1469	Preferential targeting of vesicular stomatitis virus to breast cancer cells. 2004 , 330, 24-33	20
1468	ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. 2004 , 92, 31-9	84

1467	HMOCC-1, a human monoclonal antibody that inhibits adhesion of ovarian cancer cells to human mesothelial cells. 2004 , 95, 290-8	17
1466	The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study. 2004 , 95, 89-94	20
1465	HER-2/neu expression in Paget disease of the vulva and the female breast. 2004 , 95, 336-40	33
1464	Breast cancer—the role of the pathologist and targeted therapies/optimal pathology reporting. 2004 , 54, S10-S24	
1463	Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. 2004 , 5, 52-8; discussion 59-62	109
1462	Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. 2004 , 5, 293-8	30
1461	Single-agent gemcitabine in the treatment of advanced breast cancer. 2004 , 4 Suppl 3, S101-6	11
1460	Gemcitabine and trastuzumab combinations for patients with metastatic breast cancer overexpressing HER2/neu. 2004 , 4 Suppl 3, S117-20	7
1459	Cyclooxygenase-2 inhibitors in lung cancer. 2004 , 5, 245-53	5
1458	How does the immune system attack cancer?. 2004 , 41, 15-132	12
1457	Smart drugs in prostate cancer. 2004 , 45, 1-17	27
1456	Molecular mechanisms of prostate cancer. 2004 , 45, 683-91	56
1455	High incidence of HER-2 positivity in inflammatory breast cancer. 2004 , 13, 97-103	77
1454	Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. 2004 , 13, 173-83	137
1453	Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?. 2004 , 5, 525-31	82
1452	PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. 2004 , 6, 117-27	1462
1451	Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. 2004 , 6, 459-69	443
1450	An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. 2004 , 6, 497-506	279

1449	A new key in breast cancer metastasis. 2004 , 6, 429-30	38
1448	Somatic alterations in the human cancer genome. 2004 , 6, 433-8	128
1447	Targeting cell cycle and apoptosis for the treatment of human malignancies. 2004 , 16, 670-8	87
1446	Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents. 2004 , 34, 293-303	29
1445	Her-2/neu gene amplification and protein expression in primary male breast cancer. 2004 , 84, 215-23	96
1444	Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. 2004 , 86, 9-18	51
1443	Reproducible immunohistochemical criteria based on multiple raters' judgments for expression of thymidine phosphorylase in breast cancer tissue. 2004 , 86, 215-23	11
1442	Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer. 2004 , 86, 249-57	22
1441	Subcellular localization of immunohistochemical signals: knowledge of the ultrastructural or biologic features of the antigens helps predict the signal localization and proper interpretation of immunostains. 2004 , 12, 185-206	41
1440	Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. 2004 , 90, 1814-24	44
1439	Protein kinase inhibitors: insights into drug design from structure. 2004 , 303, 1800-5	1035
1438	Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib. 2004 , 444, 108-18	28
1437	A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. 2004 , 445, 255-62	50
1436	The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. 2004 , 130, 1-7	124
1435	Immunotherapy of cancer: from vision to standard clinical practice. 2004 , 130, 367-74	24
1434	The C-neu mammary carcinoma in Oncomice; characterization and monitoring response to treatment with herceptin by magnetic resonance methods. 2004 , 17, 260-70	9
1433	[Immunotherapy of malignant diseases--developments and prospects]. 2004 , 154, 235-41	1
1432	Breast cancer patients should not live without a HER-2/neu tissue result--but how safe can they live with it?. 2004 , 116, 3-5	2

1431	Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer. 2004 , 116, 26-31	33
1430	Kinase inhibitors translate lab discoveries into exciting new cures for cancers. 2004 , 71, 713-8	2
1429	Current status of antibody therapy for breast cancer. 2004 , 11, 10-4	17
1428	Neurotoxicity of taxanes: symptoms and quality of life assessment. 2004 , 11, 92-9	69
1427	Utility of immunohistochemistry in breast cancer practice. 2004 , 11, 334-8	14
1426	Sensitization of chemotherapy by anti-HER. 2004 , 11, 105-15	9
1425	The evolution of primary chemotherapy in breast cancer treatment. 2004 , 11, 148-55	6
1424	Successful combination therapy with trastuzumab and Paclitaxel for adriamycin- and docetaxel-resistant inflammatory breast cancer. 2004 , 11, 309-12	5
1423	Modelling and simulation in the development and use of anti-cancer agents: an underused tool?. 2004 , 31, 419-40	13
1422	The curability of breast cancer and the treatment of advanced disease. 2004 , 31 Suppl 1, S149-61	105
1421	Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. 2004 , 53, 110-7	64
1420	li-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. 2004 , 53, 490-6	37
1419	Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer. 2004 , 53, 777-85	30
1418	Phylogenetic origin of LI-cadherin revealed by protein and gene structure analysis. 2004 , 61, 1157-66	19
1417	Role of HER2/neu in tumor progression and therapy. 2004 , 61, 2965-78	110
1416	Wachstumsfödrernde Signalübertragungswege. 2004 , 37, 215-221	
1415	Management issues for elderly patients with breast cancer. 2004 , 5, 161-9	23
1414	A role for antiangiogenic therapy in breast cancer. 2004 , 6, 42-8	16

1413	Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. 2004 , 59, 234-42	91
1412	The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. 2004 , 60, 332-7	146
1411	A testing procedure for survival data with few responders. 2004 , 23, 1818-23	2
1410	Correction. 2004 , 23, 1823-1823	
1409	Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis. 2004 , 2, 26	26
1408	Is breast cancer survival improving?. 2004 , 100, 44-52	410
1407	Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?. 2004 , 100, 2052-63	102
1406	Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. 2004 , 100, 2125-31	103
1405	Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma. 2004 , 101, 258-63	26
1404	Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. 2004 , 101, 704-12	103
1403	The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. 2004 , 101, 810-6	132
1402	Utility of cytologic specimens in the evaluation of prognostic and predictive factors of breast cancer: current issues and future directions. 2004 , 30, 158-65	32
1401	Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. 2004 , 108, 334-41	170
1400	HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. 2004 , 108, 540-8	66
1399	Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling. 2004 , 110, 76-86	19
1398	Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study. 2004 , 112, 286-94	78
1397	Molecular pathology of head-and-neck cancer. 2004 , 112, 545-53	89
1396	Role of HER receptors family in development and differentiation. 2004 , 200, 343-50	168

1395	Epidermal growth factor receptor inhibitors in clinical development. 2004 , 58, 1003-7	28
1394	ATP-phosphopeptide conjugates as inhibitors of Src tyrosine kinases. 2004 , 12, 5753-66	20
1393	State of the science: molecular classifications of breast cancer for clinical diagnostics. 2004 , 37, 572-8	13
1392	Trastuzumab and docetaxel for metastatic breast cancer: an experience from a cancer centre in India. 2004 , 16, 115-8	1
1391	Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. 2004 , 9 Suppl 2, 24-32	199
1390	Guadagno di sopravvivenza dei nuovi farmaci. 2004 , 6, 95-104	5
1389	New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. 2004 , 6, 204-10	47
1388	Non-viral delivery of ribozymes for cancer gene therapy. 2004 , 4, 1749-55	8
1387	Characterization of engineered anti-p185HER-2 (scFv-CH3) ₂ antibody fragments (minibodies) for tumor targeting. 2004 , 17, 315-23	69
1386	Targeted Therapies for Cancer 2004. 2004 , 122, 598-609	220
1385	Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. 2004 , 56, 185-229	2619
1384	Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. 2004 , 22, 1103-9	670
1383	Determination of HER-2 Status and Chromosome 17 Polysomy in Breast Carcinomas Comparing HercepTest and PathVysion FISH Assay. 2004 , 121, 70-77	96
1382	Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. 2004 , 96, 739-49	433
1381	Oncogenic growth factor receptors: implications for signal transduction therapy. 2004 ,	
1380	Phase II de l'Étude de la doxorubicine pegylatè liposomale en association avec le paclitaxel comme premièr ligne de traitement du cancer du sein mètastatique. 2004 , 14, 287-293	
1379	Novel treatments in non-small cell lung cancer. 2004 , 18, 245-67	10
1378	Prognostic value of carbonic anhydrase IX and Ki67 as predictors of survival for renal clear cell carcinoma. 2004 , 171, 2461-6	156

1377	Clinical cardiac tolerability of trastuzumab. 2004 , 22, 322-9	224
1376	Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. 2004 ,	
1375	[Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting]. 2004 , 21, 881-5	0
1374	HER2 expression in salivary gland carcinomas: dependence on histological subtype. 2004 , 10, 944-6	164
1373	Biomarkers in cancer management: a crucial bridge toward personalized medicine. 2004 , 1, 305-311	1
1372	The combination of cytotoxic and molecularly targeted therapies [can it be done?]. 2004 , 1, 445-454	5
1371	Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. 2004 , 44, 2231-8	182
1370	Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. 2004 , 22, 663-9	92
1369	Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis. 2004 , 6, 42-51	80
1368	Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. 2004 , 13, 1-19	46
1367	Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. 2004 , 44, 99-110	100
1366	New targeted treatments in lung cancer--overview of clinical trials. 2004 , 45 Suppl 2, S199-208	11
1365	Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. 2004 , 4, 420-7	32
1364	Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. 2004 , 5, 105-16	58
1363	Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. 2004 , 5, 142-7	105
1362	A current perspective on local excision of rectal cancer. 2004 , 4, 26-35; discussion 36-7	18
1361	Molecular markers and prostate cancer prognosis. 2004 , 3, 157-64	16
1360	Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. 2004 , 5, 231-6	78

1359	In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles. 2004 , 5, 2269-74	166
1358	Targeted therapy in breast cancer: the HER-2/neu gene and protein. 2004 , 3, 379-98	226
1357	Targeted therapy for cancer. 2004 , 3, 205-214	1
1356	Rapid Cycle Real-Time PCR [Methods and Applications. 2004 ,	3
1355	CNS metastases in breast cancer. 2004 , 22, 3608-17	526
1354	ErbB receptors: directing key signaling networks throughout life. 2004 , 44, 195-217	486
1353	Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis. 2005 , 7, R145-55	26
1352	Report on the 4th European Breast Cancer Conference, Hamburg, Germany, 16-20 March 2004. 2004 , 6, 148-52	1
1351	Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. 2004 , 6, R275-83	72
1350	Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. <i>New England Journal of Medicine</i> , 2004 , 351, 337-45	59.2 4112
1349	From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. 2004 , 5, 571-9	101
1348	The immune response to breast cancer, and the case for DC immunotherapy. 2004 , 6, 154-63	12
1347	ONCOMINE: a cancer microarray database and integrated data-mining platform. 2004 , 6, 1-6	2548
1346	PI3K/Akt signalling pathway and cancer. 2004 , 30, 193-204	1519
1345	Taxanes in elderly breast cancer patients. 2004 , 30, 333-42	48
1344	Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines. 2004 , 30, 643-50	20
1343	Insulin-like growth factor-I and cancer risk. 2004 , 14, 261-9	77
1342	[Indications for Herceptin in breast cancer treatment]. 2004 , 32, 164-72	4

1341	Novel insights in clinical trials with preoperative systemic therapy for primary breast cancer. 2004 , 58, 531-5	1
1340	Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin alpha-conjugate. 2004 , 205, 161-71	22
1339	Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. 2004 , 212, 167-75	248
1338	Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. 2004 , 214, 215-24	59
1337	Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?. 2004 , 7, 325-31	15
1336	HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?. 2004 , 40, 56-63	99
1335	FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer. 2004 , 40, 707-21, discussion 722-4	54
1334	Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. 2004 , 40, 379-82	106
1333	Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. 2004 , 40, 988-97	60
1332	Targeted therapy--how successful has it been?. 2004 , 40, 2016-21	1
1331	The ErbB/HER receptor protein-tyrosine kinases and cancer. 2004 , 319, 1-11	309
1330	Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. 2004 , 321, 403-12	28
1329	Optimal construction of non-immune scFv phage display libraries from mouse bone marrow and spleen established to select specific scFvs efficiently binding to antigen. 2004 , 323, 583-91	29
1328	Chemotherapy targeted to cancers through tumoral hormone receptors. 2004 , 15, 300-10	165
1327	HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. 2004 , 63, 786-90	67
1326	The RET proto-oncogene: a potential target for molecular cancer therapy. 2004 , 10, 351-7	38
1325	Web-based tools for mining the NCI databases for anticancer drug discovery. 2004 , 44, 249-57	25
1324	Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment. 2004 , 40, 33-42	38

1323	Monoclonal antibodies as therapeutic agents for cancer. 2004 , 5, 292-302	265
1322	Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin. 2004 , 5, 575-7	20
1321	The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. 2004 , 64, 2343-6	465
1320	Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. 2004 , 9, 361-77	150
1319	EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. 2004 , 304, 1497-500	7937
1318	Platinum-based chemotherapy in metastatic breast cancer: current status. 2004 , 30, 53-81	159
1317	HER-2/neu evaluation in breast cancer are we there yet?. 2004 , 121 Suppl, S33-49	19
1316	Immune tolerance in breast cancer. 2004 , 20, 93-103	15
1315	Tumor response and survival end points in clinical trials: a clinician's perspective. 2004 , 27, 494-6	8
1314	Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma. 2004 , 13, 213-6	32
1313	Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. 2004 , 10, 1618-24	125
1312	Challenges in breast cancer clinical trial design in the postgenomic era. 2004 , 16, 536-41	13
1311	Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix. 2004 , 23, 13-7	16
1310	Chemotherapy for metastatic breast cancer. 2004 , 16, 37-41	18
1309	The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. 2004 , 29, e1-8	188
1308	Induction of remission in a patient with metastatic breast cancer refractory to trastuzumab and chemotherapy following treatment with gefitinib ('Iressa', ZD1839). 2004 , 15, 235-8	8
1307	A case of herceptin cardiotoxicity. 2004 , 11, 74-6	1
1306	IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL. 2004 , 103, 1891-900	40

1305	Biology of the epidermal growth factor receptor family. 2004 , 119, 1-13	28
1304	Gallbladder cancers rarely overexpress HER-2/neu, demonstrated by Hercep test. 2004 , 11, 815	2
1303	Her-2/neu as a paradigm of a tumor-specific target for therapy. 2004 , 20, 25-31	24
1302	Pegylated liposomal doxorubicin: Pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (Review). 2004 , 12, 549	1
1301	Novel insights in clinical trials with preoperative systemic therapy for primary breast cancer. 2004 , 58, 531-535	3
1300	Protein Kinase Inhibitors Drug Discovery. 2005 , 1191-1257	4
1299	3 Role of Immunohistochemical Expression of HER2/neu in High-Grade Ovarian Serous Papillary Cancer. 2005 , 4, 333-338	
1298	Medical paternalism and expensive unsubsidised drugs. 2005 , 331, 1075-7	18
1297	Targeting cytokine receptors and pathways in the treatment of breast cancer. 2005 , 126, 243-62	
1296	Somatic mutations in human cancer: insights from resequencing the protein kinase gene family. 2005 , 70, 43-9	21
1295	Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity. 2005 , 174, 5481-9	23
1294	The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk. 2005 , 15, 447-50	22
1293	Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. 2005 , 29, 1505-11	39
1292	Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. 2005 , 70, 139-48	145
1291	Cancer vaccine and immunotherapy. 2005 , 11, 3459-60	2
1290	Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments. 2005 , 26, 427-32	55
1289	Molecularly targeted therapies for breast cancer. 2005 , 12, 73-81	30
1288	Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): Phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor. 2005 , 14, 481	

1287	HER-2/neu evaluation by fluorescence in situ hybridization on destained cytologic smears from primary and metastatic breast cancer. 2005 , 49, 27-30	15
1286	HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization. 2005 , 13, 194-200	35
1285	Correlation of HER2 gene amplification with immunohistochemistry in breast cancer as determined by a novel monoplex polymerase chain reaction assay. 2005 , 13, 333-41	11
1284	Program for the Assessment of Clinical Cancer Tests (PACCT): assisting the development of tailored cancer therapy. 2005 , 2, 363-369	1
1283	Hypofractionated accelerated radiotherapy with cytoprotection combined with trastuzumab, liposomal doxorubicine, and docetaxel in c-erbB-2-positive breast cancer. 2005 , 28, 495-500	21
1282	Localization of mesothelin in epithelial ovarian cancer. 2005 , 13, 243-7	130
1281	Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer. 2005 , 28, 631-3	2
1280	The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. 2005 , 29, 1221-7	112
1279	Liposomal encapsulated anti-cancer drugs. 2005 , 16, 691-707	250
1278	Immunotherapy and cancer vaccines in the management of breast cancer. 2005 , 11, 3475-83	12
1277	Development of Precise Pharmacodiagnostic (PharmDx) Tests for Molecular Targeted Therapies. 2005 , 38, 209-216	1
1276	New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004. 2005 , 16, 211-21	26
1275	Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experience. 2005 , 16, 185-90	4
1274	Correlation of HER2 gene amplification with expression of the apoptosis-suppressing genes bcl-2 and bcl-x-L in ductal carcinoma in situ of the breast. 2005 , 13, 14-8	14
1273	Chemical Proteomics in Drug Development. 2005 , 109-122	2
1272	Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody. 2005 , 105, 1231-6	29
1271	Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution. 2005 , 105, 4583-9	37
1270	CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. 2005 , 105, 2941-8	243

1269	Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. 2005 , 106, 3127-33	80
1268	HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy. 2005 , 201, 141-4	6
1267	High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study. 2005 , 17, 630-5	23
1266	Protein kinases as targets for antimalarial intervention: Kinomics, structure-based design, transmission-blockade, and targeting host cell enzymes. 2005 , 1754, 132-50	70
1265	The dilemma of the strive for apoptosis in oncology: mind the heart. 2005 , 53, 101-13	9
1264	Overview of monoclonal antibodies in cancer therapy: present and promise. 2005 , 54, 11-29	181
1263	Drug-drug interactions in oncology: why are they important and can they be minimized?. 2005 , 55, 117-42	125
1262	Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors. 2005 , 23, 57-62	9
1261	A tat fusion protein-based tumor vaccine for breast cancer. 2005 , 12, 517-25	24
1260	Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. 2005 , 23, 1011-27	2248
1259	FLT3 antibody-based therapeutics for leukemia therapy. 2005 , 82, 108-14	5
1258	Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. 2005 , 192, 813-8	104
1257	Pathological complete response to trastuzumab and paclitaxel in a patient with inflammatory local recurrence following breast conserving surgery. 2005 , 12, 226-30	1
1256	HER-2/neu expression in locally advanced breast carcinomas: pre-and post-neoadjuvant chemotherapy. 2005 , 12, 294-8	29
1255	Translational research in breast cancer. 2005 , 12, 86-90	1
1254	Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification. 2005 , 16, 359-71	158
1253	Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective. 2005 , 19, 385-93	37
1252	Trial design for testing new therapies in ovarian cancer. 2005 , 15 Suppl 3, 258-65	4

1251	Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. 2005 , 95, 982-6	45
1250	Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. 2005 , 96, 440; author reply 440-1	4
1249	Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated-type breast carcinomas with 'stem-cell-like' features. 2005 , 96, 333-9	42
1248	Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. 2005 , 92, 1561-73	94
1247	Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. 2005 , 93, 107-15	123
1246	Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients. 2005 , 93, 23-8	45
1245	Monoclonal antibody therapy of cancer. 2005 , 23, 1147-57	916
1244	Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. 2005 , 7, 591-600	469
1243	Timeline: Chemotherapy and the war on cancer. 2005 , 5, 65-72	1259
1242	ERBB receptors and cancer: the complexity of targeted inhibitors. 2005 , 5, 341-54	2593
1241	Breast cancer metastasis: markers and models. 2005 , 5, 591-602	1591
1240	Exploiting the PI3K/AKT pathway for cancer drug discovery. 2005 , 4, 988-1004	1618
1239	Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. 2005 , 6, 112-26	709
1238	TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. 2005 , 24, 3002-10	101
1237	Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. 2005 , 24, 4531-9	203
1236	Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. 2005 , 24, 6213-21	222
1235	Recombinant approaches to IgG-like bispecific antibodies. 2005 , 26, 649-58	80
1234	Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. 2005 , 11, 433-9	48

1233	The transcriptional repressor Snail promotes mammary tumor recurrence. 2005 , 8, 197-209	585
1232	Trastuzumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: report on six patients. 2005 , 48, 771-5; discussion 775-8	24
1231	Breast cancer: what's HER-2/neu got to do with it?. 2005 , 62, 459-64	2
1230	Detection and molecular characterisation of disseminated tumour cells: implications for anti-cancer therapy. 2005 , 1756, 53-64	25
1229	Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines. 2005 , 14, 304-9	15
1228	Adjuvant chemotherapy for breast cancer--"one fits all"?. 2005 , 14, 564-9	7
1227	Antibodies and vaccines--hope or illusion?. 2005 , 14, 631-5	19
1226	Standards for follow-up care of patents with breast cancer. 2005 , 14, 500-8	8
1225	Recent advances in biomarkers for cancer diagnosis and treatment. 2005 , 10, 965-76	81
1224	2004 Highlights from: 27th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2004. 2005 , 5, 413-420	
1223	Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005. 2005 , 6, 380-4	1
1222	2004 Highlights From: The 27th Annual San Antonio Breast Cancer Symposium; San Antonio, TX December 2004. 2005 , 6, 15-22	4
1221	Advances in the Adjuvant Treatment of HER2-Overexpressing Breast Cancer with the Anti-HER2 Antibody Trastuzumab. 2005 , 6, 108-111	
1220	Analysis of Cardiac Toxicity in Phase III Adjuvant Trastuzumab Trials. 2005 , 6, 299-301	
1219	Adjuvant chemotherapy in early-stage non-small cell lung cancer. 2005 , 32, 279-83	10
1218	Gemcitabine plus paclitaxel in breast cancer. 2005 , 32, S14-21	16
1217	Other compounds and targets in non-small cell lung cancer. 2005 , 32, S30-6	5
1216	Recent developments in critical genes in the molecular biology of breast cancer. 2005 , 28, 71-5	8

1215	Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer. 2005 , 41, 97-8	17
1214	Cyclin E as a prognostic and predictive marker in breast cancer. 2005 , 15, 319-26	51
1213	Brain metastases in patients with breast cancer: new horizons. 2005 , 6, 115-24	29
1212	Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. 2005 , 6, 150-7	31
1211	Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. 2005 , 6, 240-6	296
1210	Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. 2005 , 6, 325-9	42
1209	Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therapeutic approach. 2005 , 55, 757-65	28
1208	Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial. 2005 , 5, 21	9
1207	COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?. 2005 , 96, 159-67	48
1206	Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. 2005 , 98, 24-30	80
1205	A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. 2005 , 99, 50-7	61
1204	HER-2: a biomarker at the crossroads of breast cancer immunotherapy and molecular medicine. 2005 , 205, 10-8	27
1203	In vivo identification of the interaction site of ErbB2 extracellular domain with its autoinhibitor. 2005 , 205, 335-43	14
1202	C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. 2005 , 113, 678-82	203
1201	Expression patterns of potential therapeutic targets in prostate cancer. 2005 , 113, 619-28	130
1200	High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. 2005 , 116, 340-50	443
1199	Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases. 2005 , 103, 1881-90	61
1198	Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. 2005 , 103, 1763-9	134

1197	Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells. 2005 , 103, 2199-207	26
1196	Women age 2005, 103, 2466-72	63
1195	Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. 2005 , 104, 1391-7	121
1194	Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma. 2005 , 104, 2149-55	64
1193	Protein Interaction Targeted Drug Discovery. 2005 , 323-345	
1192	A new ligand for immunoglobulin g subdomains by screening of a synthetic peptide library. 2005 , 6, 1242-53	38
1191	Cellular uptake of radioiodine delivered by trastuzumab can be modified by the addition of epidermal growth factor. 2005 , 32, 771-7	9
1190	Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft. 2005 , 54, 315-27	43
1189	Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production. 2005 , 54, 468-76	24
1188	Resistance to endocrine therapy in breast cancer. 2005 , 56 Suppl 1, 39-46	48
1187	Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. 2005 , 56, 361-9	202
1186	[Molecular target structures in oncology]. 2005 , 46, 847-8, 850-4, 856-60	2
1185	Neue molekulare Therapiekonzepte beim Mammakarzinom. 2005 , 38, 432-438	
1184	Therapie des metastasierten Mammakarzinoms. 2005 , 38, 425-431	
1183	Blockade of epidermal growth factor receptor (EGFR) activity. 2005 , 53, 179-92	17
1182	Current status of monoclonal antibodies as therapeutic agents for solid cancer. 2005 , 40, 1009-11	1
1181	Stability of the HER2 gene after primary chemotherapy in advanced breast cancer. 2005 , 446, 136-41	38
1180	HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. 2005 , 446, 489-96	61

1179	Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA). 2005 , 131, 701-14	4
1178	The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status. 2005 , 131, 420-8	7
1177	The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein. 2005 , 8, 249-52	42
1176	Unknown primary carcinoma, diagnosed as inflammatory breast cancer, and successfully treated with trastuzumab and vinorelbine. 2005 , 10, 285-8	8
1175	«Cancers du sein». 2005 , 7, 342-379	12
1174	Infectious inflammation of the CNS involves activation of mitogen-activated protein kinase and AKT proteins in CSF in humans. 2005 , 26, 324-9	6
1173	Immuntherapie gyn&ologischer Malignome. 2005 , 11, 530-535	
1172	Systemische Therapie des Mammakarzinoms. 2005 , 11, 693-704	
1171	Entwicklung der Krebsimmuntherapie. 2005 , 11, 582-584	
1170	Molekulare Diagnostik bei nicht-h&atologischen malignen Erkrankungen. 2005 , 11, 873-888	
1169	Integrating trastuzumab in the treatment of breast cancer. Current status and future trends. 2005 , 7, 99-100	6
1168	[Molecular protocol for HER2/neu analysis in breast carcinoma]. 2005 , 7, 504-11	3
1167	Engineered antibodies act as targeted therapies in cancer treatment. 2005 , 72, 943-7	2
1166	Targeted therapies for gynecologic malignancies. 2005 , 6, 121-32	2
1165	Strategies and methodologies for identifying molecular targets in sarcomas and other tumors. 2005 , 6, 487-97	5
1164	The influence of aging on the early detection, diagnosis, and treatment of breast cancer. 2005 , 7, 23-30	10
1163	Adjuvant chemotherapy for transitional cell carcinoma of the bladder: paradigms for the design of clinical trials. 2005 , 7, 207-14	2
1162	Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. 2005 , 23, 391-409	78

1161	Locally advanced breast cancer in octogenarian women. 2005 , 89, 81-90	7
1160	Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. 2005 , 93, 3-11	152
1159	Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. 2005 , 91, 187-201	73
1158	Optimizing the treatment of metastatic breast cancer. 2005 , 89 Suppl 1, S9-S15	55
1157	The future of breast cancer: the role of prognostic factors. 2005 , 89 Suppl 1, S17-26	25
1156	Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. 2005 , 92, 1-9	29
1155	Antibody-based therapeutics: focus on prostate cancer. 2005 , 24, 521-37	36
1154	Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels. 2005 , 22, 915-22	3
1153	EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients. 2005 , 22, 1757-61	17
1152	Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. 2005 , 205, 388-96	128
1151	Targeted therapy: for kids, too. 2005 , 45, 623-34	2
1150	[Humanized antibodies as therapeutics]. 2005 , 21, 1054-62	0
1149	Monoclonal Antibody Strategies for Targeting HER2. 2005 , 627-645	
1148	Glioma-Genesis. 2005 , 18, 521-556	
1147	Therapeutic Monoclonal Antibodies in Oncology. 2005 , 98, 146-152	20
1146	Trastuzumab cardiac side effects: only time will tell. 2005 , 23, 7775-6	15
1145	Signal Transduction Pathway Targeting. 2005 ,	
1144	Antibodies and Recombinant Cytokines. 2005 ,	

1143	Protein Kinases as Targets in Cancer Therapy: Validated and Emerging Approaches. 2005 , 291-315	
1142	Development of Inhibitors of HER2 With Taxanes. 2005 , 175-195	
1141	The era of ErbB-receptor-targeted therapies: advances toward personalized medicine. 2005 , 2, 301-315	3
1140	Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens. 2005 , 49, 471-6	32
1139	Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene quantification and ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast cancer patients. 2005 , 51, 1093-101	78
1138	Targeted therapies for esophageal cancer. 2005 , 10, 590-601	114
1137	Prognostic and predictive factors for breast cancer: translating technology to oncology. 2005 , 23, 1596-7	21
1136	An integrated approach for tailored treatment in breast cancer. 2005 , 16 Suppl 2, ii203-8	4
1135	Gene profile and response to treatment. 2005 , 16 Suppl 2, ii195-202	11
1134	Effect of gamma-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogene. 2005 , 97, 1611-5	30
1133	Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure. 2005 , 289, H660-6	87
1132	A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. 2005 , 16, 909-14	46
1131	Toxicity of the topoisomerase II inhibitors. 2005 , 4, 219-34	79
1130	Development of oncology drug response markers using transcription profiling. 2005 , 5, 103-10	6
1129	From traditional biomarkers to transcriptome analysis in drug development. 2005 , 5, 29-38	34
1128	Prostate cancer cell lines lack amplification: overexpression of HER2. 2005 , 44, 490-5	11
1127	Pharmacogenomics steps toward personalized medicine. 2005 , 2, 325-337	60
1126	Receptor tyrosine kinases and anticancer therapy. 2005 , 11, 1139-49	36

1125	New developments in the treatment of metastatic breast cancer: from chemotherapy to biological therapy. 2005 , 16 Suppl 2, ii191-4	21
1124	Comparison of Immunohistochemical and Fluorescence In Situ Hybridization Assessment of HER-2 Status in Routine Practice. 2005 , 123, 766-770	36
1123	Extending survival with chemotherapy in metastatic breast cancer. 2005 , 10 Suppl 3, 20-9	454
1122	Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. 2005 , 11, 5539-48	234
1121	Genomics and proteomics--the way forward. 2005 , 16 Suppl 2, ii30-44	19
1120	Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities. 2005 , 280, 54-63	49
1119	Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. 2005 , 11, 6634-40	109
1118	Testing chemotherapy for breast cancer: timing is everything. 2005 , 23, 5434-6	8
1117	The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. 2005 , 5, 233-43	40
1116	Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma. 2005 , 35, 324-31	17
1115	Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. 2005 , 65, 1384-93	153
1114	Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies. 2005 , 65, 2815-24	43
1113	Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistance. 2005 , 12 Suppl 1, S145-57	28
1112	Copy number aberrations in mouse breast tumors reveal loci and genes important in tumorigenic receptor tyrosine kinase signaling. 2005 , 65, 9695-704	46
1111	Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. 2005 , 289, H1153-60	98
1110	Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. 2005 , 11, 3315-9	149
1109	Correlation of HER-2 Status With Estrogen and Progesterone Receptors and Histologic Features in 3,655 Invasive Breast Carcinomas. 2005 , 123, 541-546	139
1108	Type I insulin-like growth factor receptor as a therapeutic target in cancer. 2005 , 65, 10123-7	92

1107	Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. 2005 , 11, 5300-9	87
1106	Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. 2005 , 65, 5561-70	285
1105	Neuregulin receptor ErbB2 localization at T-tubule in cardiac and skeletal muscle. 2005 , 53, 87-91	25
1104	Trastuzumab plus chemotherapy: convincing survival benefit or not?. 2005 , 23, 4247-50	19
1103	IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma. 2005 , 58, 1086-90	21
1102	Selective identification of secreted and transmembrane breast cancer markers using <i>Escherichia coli</i> ampicillin secretion trap. 2005 , 65, 8209-17	17
1101	HER-2/neu and Topoisomerase II α Gene Amplification and Protein Expression in Invasive Breast Carcinomas. 2005 , 123, 889-895	42
1100	Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. 2005 , 16, 1772-7	110
1099	Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?. 2005 , 23, 5856-8	67
1098	The effect of low molecular weight heparin on survival in patients with advanced malignancy. 2005 , 23, 2130-5	503
1097	Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. 2005 , 23, 5323-33	286
1096	[Therapy of hormone refractory prostate cancer: new standards, new trends]. 2005 , 36, 342-8	1
1095	Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma. 2005 , 16, 1889-97	37
1094	Trastuzumab and breast cancer. Are we just beyond the prologue of a fascinating story?. 2005 , 28, 547-9	5
1093	Trastuzumab. 2005 , 1, 161-9	
1092	Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity. 2005 , 5, 727-35	2
1091	Pharmacogenomics and drug development. 2005 , 6, 857-64	20
1090	Targeting EGFR in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2005 , 353, 200-2	59.2 30

1089	BRCA1 gene expression in breast cancer in Kuwait: correlation with prognostic parameters. 2005 , 14, 67-72	9
1088	Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. 2005 , 69 Suppl 3, 17-24	51
1087	[Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy]. 2005 , 36, 423-9	7
1086	[Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives]. 2005 , 130, 1438-42	0
1085	Role of chemotherapy in breast cancer. 2005 , 5, 1095-110	7
1084	Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients. 2005 , 2, 337-48	40
1083	Immunocytochemistry. 2005 , 555-571	
1082	Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. 2005 , 23, 3676-85	916
1081	Gefitinib in non-small cell lung cancer. 2005 , 6, 985-93	41
1080	Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response. 2005 , 5, 1069-83	44
1079	Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly. 2005 , 10, 602-12	48
1078	Digital karyotyping technology: exploring the cancer genome. 2005 , 5, 917-25	6
1077	The role of taxanes in the treatment of breast cancer. 2005 , 6, 1073-94	34
1076	Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. 2005 , 23, 254-66	328
1075	Application of Apoptosis to Cancer Treatment. 2005 ,	
1074	ERBB2 in pediatric cancer: innocent until proven guilty. 2005 , 10, 508-17	25
1073	Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. 2005 , 92, 1253-60	92
1072	Allele quantification using molecular inversion probes (MIP). 2005 , 33, e183	70

1071	Epidermal growth factor receptor inhibitors: a moving target?. 2005 , 11, 7203-5	16
1070	Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. 2005 , 23, 1152-60	206
1069	Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. 2005 , 23, 2460-8	203
1068	Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. 2005 , 23, 7811-9	626
1067	Chemotherapy: what progress in the last 5 years?. 2005 , 23, 1760-75	87
1066	Detection of micrometastatic disease in bone marrow: is it ready for prime time?. 2005 , 10, 480-92	18
1065	Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. 2005 , 12, 983-98	40
1064	Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma. 2005 , 58, 864-71	14
1063	Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. 2005 , 174, 817-26	437
1062	Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. 2005 , 174, 4228-36	77
1061	Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. 2005 , 4, 1837-49	77
1060	Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. 2005 , 23, 6838-45	513
1059	Molecularly-targeted therapies for non-small cell lung cancer. 2005 , 6, 2667-79	5
1058	Abstracts. 2005 , 23, 1-117	
1057	Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. 2005 , 65, 1642-6	569
1056	Chromogenic In Situ Hybridization for the Detection of HER-2/neuGene Amplification in Breast Cancer With an Emphasis on Tumors With Borderline and Low-Level Amplification. 2005 , 123, 237-243	54
1055	Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. 2005 , 97, 880-7	402
1054	Tumor Immunology and Cancer Vaccines. 2005 ,	2

1053	Integration/Interaction of Oncologic Growth. 2005,	3
1052	Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. 2005, 23, 5542-51	421
1051	Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. 2005, 23, 3614-21	158
1050	Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. 2005, 58, 611-6	119
1049	Therapeutic targeting of receptor tyrosine kinases in lung cancer. 2005, 9, 533-59	20
1048	Molecular basis of therapeutic strategies for breast cancer. 2005, 5, 379-96	21
1047	Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. 2005, 65, 9751-61	133
1046	Membrane Receptor and Antiangiogenic Targeted Therapies in the Treatment of Cancer. 2005, 1, 51-61	1
1045	Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. 2005, 11, 4898-904	78
1044	Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. 2005, 16 Suppl 4, iv7-13	36
1043	Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. 2005, 280, 2092-104	49
1042	Therapy of breast cancer with molecular targeting agents. 2005, 16 Suppl 4, iv28-36	35
1041	EGFR gene mutations: a call for global x global views of cancer. 2005, 97, 326-8	23
1040	Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. 2005, 23, 2162-71	343
1039	Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization. 2005, 11, 8348-57	86
1038	HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. 2005, 4, 87-95	113
1037	Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy. 2005, 27, 1125	1
1036	Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series. 2005, 28, 558-64	5

1035	Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab. 2005 , 28, 95-7	1
1034	Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). 2005 , 28, 582-6	42
1033	Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. 2005 , 11, 6382-9	170
1032	Adjuvant trastuzumab for breast cancer. 2005 , 331, 1035-6	16
1031	Therapeutic monoclonal antibodies in oncology. 2005 , 98, 146-52	18
1030	Gemcitabine in metastatic breast cancer. 2005 , 5, 429-43	32
1029	Circadian clock genes as modulators of sensitivity to genotoxic stress. 2005 , 4, 901-7	60
1028	Biomarkers to predict response to epidermal growth factor receptor inhibitors. 2005 , 4, 1369-72	63
1027	C�ncer de mama (y II). Estrategias terap�uticas. 2005 , 9, 1692-1703	
1026	C�ncer de mama: evoluci�n de una paciente durante 17 a�os. 2005 , 9, 1737-1740	
1025	Blood pharmacokinetics of various monoclonal antibodies labeled with a new trifunctional chelating reagent for simultaneous conjugation with 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid and biotin before radiolabeling. 2005 , 11, 7171s-7177s	10
1024	[Metastatic involvement of the central nervous system in breast cancer: role of herceptin]. 2005 , 205, 553-5	
1023	Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. 2005 , 304, 604-19	136
1022	PKB mediates c-erbB2-induced epithelial beta1 integrin conformational inactivation through Rho-independent F-actin rearrangements. 2005 , 307, 259-75	6
1021	Neuregulin-1alpha and beta isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro. 2005 , 311, 135-46	90
1020	Current and future pathological examination in breast cancer. 2005 , 3, 121-130	
1019	Adjuvant treatment of early breast cancer. 2005 , 3, 149-166	1
1018	Combination versus sequential single-agent therapy for the treatment of metastatic breast cancer. 2005 , 3, 3-8	4

1017	A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer. 2005 , 92, 1261-7	23
1016	Recent advances in the discovery of Src kinase inhibitors. 2005 , 15, 1183-1207	20
1015	Beyond lymph node staging: molecular predictors of outcome in breast cancer. 2005 , 14, 69-84, vi	1
1014	Clinical applications for targeted therapy in bladder cancer. 2005 , 32, 239-46, vii	6
1013	Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells. 2005 , 24, 582-94	32
1012	Medical Biomethods Handbook. 2005 ,	2
1011	Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004. 2005 , 6, 1257-67	
1010	Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. 2005 , 23, 7768-71	80
1009	A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab. 2005 , 5, 853-66	18
1008	A bifunctional targeted peptide that blocks HER-2 tyrosine kinase and disables mitochondrial function in HER-2-positive carcinoma cells. 2005 , 65, 6891-900	42
1007	Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. 2005 , 9, 1217-33	118
1006	Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania. 2005 , 23, 296-302	16
1005	Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. 2005 , 23, 4265-74	1244
1004	Predictive markers in breast and other cancers: a review. 2005 , 51, 494-503	128
1003	Genomics and the second golden era of cancer drug development. 2005 , 1, 17-26	43
1002	Controversies in breast cancer: adjuvant and neoadjuvant therapy. 2005 , 6, 1055-72	5
1001	Treatment of elderly cancer patients with chemotherapy. 2005 , 23, 537-47	9
1000	Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. 2005 , 23, 2445-59	613

999	Adjuvant therapy of breast cancer. 2005 , 23, 548-60	8
998	Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. 2005 , 23, 483-7	32
997	Docetaxel/trastuzumab combination therapy for the treatment of breast cancer. 2005 , 6, 1555-64	13
996	Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. 2005 , 11, 4393-9	87
995	Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin. 2005 , 10, 780-91	51
994	Receptor-targeted cancer therapy. 2005 , 24, 271-82	27
993	Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol. 2005 , 16, 1117-25	29
992	Pharmacogenetics/genomics and personalized medicine. 2005 , 14 Spec No. 2, R207-14	140
991	Tyrosine kinases as targets for cancer therapy. <i>New England Journal of Medicine</i> , 2005 , 353, 172-87	59.2 1084
990	Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu--a new method of epitope definition. 2005 , 42, 1121-4	31
989	Targeted therapy for colorectal cancer: mapping the way. 2005 , 11, 327-35	16
988	Cerb-B2 ou Her-2 : marqueur d'intff dans la prise en charge du cancer du sein ?. 2005 , 20, 92-95	2
987	Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. 2005 , 36, 250-61	136
986	The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. 2005 , 36, 348-56	57
985	Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. 2005 , 36, 1127-34	48
984	Extramammary Paget's disease: analysis of growth signal pathway from the human epidermal growth factor receptor 2 protein. 2005 , 36, 1273-80	33
983	The molecular pathology of new anti-cancer agents. 2005 , 11, 329-339	8
982	Liver metastases from breast cancer: management of patients with significant liver dysfunction. 2005 , 31, 35-48	17

981	Central nervous system metastases in breast cancer patients administered trastuzumab. 2005 , 31, 312-8	43
980	Novel cytotoxic and biological agents for prostate cancer: where will the money be in 2005?. 2005 , 41, 954-64	11
979	Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. 2005 , 41, 1349-61	109
978	Growth factors and their relationship to neoplastic and paraneoplastic disease. 2005 , 16, 83-94	3
977	Antitumor activity of HER-2 inhibitors. 2005 , 227, 9-23	77
976	HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-induced apoptosis. 2005 , 579, 4149-58	31
975	Breast cancer metastasis to the central nervous system. 2005 , 167, 913-20	327
974	Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer. 2005 , 166, 1229-38	128
973	[Therapeutic monoclonal antibodies: a little history, a lot of engineering, and... some clinical successes]. 2005 , 12, 114-22	4
972	Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein. 2005 , 23, 4793-803	20
971	[Molecular alterations in breast cancer: clinical implications and new analytical tools]. 2005 , 26, 470-8	3
970	Inhibition of the cell cycle with chemical inhibitors: a targeted approach. 2005 , 16, 369-81	12
969	Systemic Treatment for Stage I and Stage II Breast Cancer. 2005 , 537-555	
968	Brain metastases of breast cancer. 2005 , 5, 253-68	8
967	Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. 2005 , 23, 5314-22	402
966	Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer. 2005 , 6, 77-80	17
965	Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. 2005 , 6, 247-52	43
964	Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. 2005 , 6, 354-6	107

963	Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. 2005 , 6, 425-32		118
962	Monoclonal antibodies and fusion proteins in medicine. 2005 , 116, 721-9; quiz 730		31
961	Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features. 2005 , 47, 315-23		29
960	Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. 2005 , 69 Suppl 3, 46-56		75
959	Mechanisms of drug resistance in cancer chemotherapy. 2005 , 14 Suppl 1, 35-48		411
958	[Optimizing current drugs]. 2005 , 63, 17-24		0
957	Immunologic approaches to breast cancer treatment. 2005 , 14, 1-31, v		6
956	Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. <i>New England Journal of Medicine</i> , 2005 , 353, 1673-84	59.2	4284
955	ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer (MBC). 2005 , 16 Suppl 1, i10-2		19
954	Liposomal Doxorubicin. 2005 , 4, 193-206		6
953	Trastuzumab in the treatment of breast cancer. <i>New England Journal of Medicine</i> , 2005 , 353, 1734-6	59.2	227
952	Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. 2005 , 11, 6816-22		125
951	Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials. 2005 , 6, 1477-91		30
950	Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. 2005 , 45, 357-84		107
949	Intracellular signal transduction pathway proteins as targets for cancer therapy. 2005 , 23, 5386-403		155
948	Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. <i>New England Journal of Medicine</i> , 2005 , 353, 1659-72	59.2	3921
947	Docetaxel in the treatment of breast cancer: current experience and future prospects. 2005 , 5, 613-33		8
946	Treatment of solid tumors with immunotoxins. 2005 , 7, 184-6		5

945	Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. 2005, 7, R617-26	75
944	Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. 2005, 7, R598-604	46
943	Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. 2005, 7, R796-807	78
942	Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. 2005, 7, R436-43	115
941	Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. 2005, 7, R256-66	24
940	Role of translational studies in optimizing palliative chemotherapy. 2005, 7, 1	1
939	Classical versus new prognostic factors for adjuvant treatment selection based on line software to estimate risk and benefit. 2005, 7, 1	78
938	The role of Xeloda in metastatic breast cancer. 2005, 7, 1	78
937	SOLTI (Solid Tumor Intensification) Group experience with high-dose chemotherapy treatment for early breast carcinoma. 2005, 7, 1	78
936	New agents for bone metastasis. 2005, 7, 1	78
935	Predictors of positive axillary lymph nodes in breast cancer patients with metastatic sentinel lymph node. 2005, 7, 1	78
934	Clinical profile and management of bilateral breast cancer. 2005, 7, 1	2
933	Nanoparticulate paclitaxel loaded into sterically stabilized mixed phospholipid micelles to improve chemotherapy of breast cancer. 2005, 7, 1	1
932	Breast cancer-screening programme amongst unprivileged women in Charleroi (Hainaut), Belgium. 2005, 7, 1	78
931	The role of gene expression profiling by microarray analysis for prognostic classification of breast cancer. 2005, 7, 1	2
930	A phase II randomized trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer (MBC). 2005, 7, 1	78
929	Methods for gene expression profiling in clinical trials for breast cancer. 2005, 7, 1	78
928	Expression of c-met gene in invasive ductal carcinomas. 2005, 7, 1	78

927	Simultaneous breast reconstruction. 2005, 7, 1	78
926	Chemoprevention: beyond tamoxifen. 2005, 7, 1	78
925	Tamoxifen resistance and adjuvant hormone therapy. 2005, 7, 1	78
924	Adjuvant chemotherapy for operable breast cancer: old vs new schema. 2005, 7, 1	78
923	Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer. 2005, 7, 1	78
922	Cyclo-oxygenase-2 expression is associated with poor clinical outcome after doxorubicin-based chemotherapy in node-positive breast cancer: integration of tissue microarray. 2005, 7, 1	78
921	Fibroadenoma of breast in Iranian women between 1994 and 2004. 2005, 7, 1	78
920	Adjuvant radiotherapy after surgery in breast cancer: evaluation of acute toxicity. 2005, 7, 1	78
919	6-(1-oxobutyl)-5,8-dimethoxy-1,4-naphthoquinone inhibits the growth of MCF-7 cells via inhibition of angiogenesis and hypoxia inducible factor alpha. 2005, 7, 1	1
918	A performance study of different soft-computing procedures for automatic detection of breast cancer malignancy. 2005, 7, 1	78
917	Gene expression profiles and molecular classification to predict distant metastasis and tamoxifen-resistant breast cancer. 2005, 7, 1	2
916	The role of magnetic resonance imaging as an imaging tool to assess disease status and residual disease in locally advanced breast cancer. 2005, 7, 1	78
915	The axillary study with ultrasound and cytological puncture with fine needle in invasive breast cancer.. 2005, 7, 1	78
914	Gene expression profile-based predictors of response to chemotherapy. 2005, 7, 1	78
913	Minimal residual disease (MRD) in the bone marrow in ER-positive primary breast cancer patients. 2005, 7, 1	78
912	[ASCRIT] Antisense chemoradioimmunotherapy consisting of anti-POEM (Arg-Gly-Asp) scFv linked onto high-energy radioisotopes, vinorelbine-tartrate and 21-nucleotide double-stranded siRNA targeted to DNMT1 induce apoptosis in metastatic breast cancer (MBC) characterized by hypermethylated p53, p16, RASSF1A, RAR- β 2, BRCA2, H1C1, ESR1, CDH1, T1beta1, GSTP1, CCND2 and overexpression of hsk2, cd27c, D-f-1 and P116. 2005, 7, 1	78
911	Simultaneous reconstructive surgery for radical mastectomy. 2005, 7, 1	78
910	Preoperative hormonal therapy: results and implications. 2005, 7, 1	1

909	Radiotherapy in early stage invasive breast cancer: current tendencies. 2005 , 7, 1	1
908	Neoadjuvant treatment: the MD Anderson experience. 2005 , 7, 1	78
907	Prognostic studies in patients with high-risk primary breast cancer (HRPBC) receiving high-dose chemotherapy (HDC). 2005 , 7, 1	78
906	The roles of PET and CT/PET as preoperative studies. 2005 , 7, 1	78
905	Present situation and future of genetic profiling for prognosis and treatment. 2005 , 7, 1	78
904	Circulating tumor cells and novel biomarkers for prognostic and biological of breast cancer. 2005 , 7, 1	1
903	Sentinel node biopsy versus conventional axillary dissection in clinically node-negative breast cancer patients. 2005 , 7, 1	78
902	Primary chemotherapy for operable breast cancer: the NSABP experience. 2005 , 7, 1	4
901	Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial. 2005 , 7, 1	78
900	Targeting the right chemotherapy for the right patient. 2005 , 7, 1	1
899	Oral vinorelbine in metastatic breast cancer. 2005 , 7, 1	2
898	Partial breast irradiation: why and how. 2005 , 7, 1	6
897	HER2 therapy: molecular mechanisms of trastuzumab resistance. 2006 , 8, 215	311
896	Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status. 2006 , 8, R36	28
895	A SURVEY OF NOVEL MOLECULAR TARGETS FOR ANTICANCER DRUG DISCOVERY. 2006 , 1-35	
894	Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. 2006 , 3, 448-57	552
893	Forthcoming receptor tyrosine kinase inhibitors. 2006 , 10, 793-7	4
892	Cancer du sein. 2006 ,	

891	First-Line Treatment of Metastatic Breast Cancer. 2006 , 5, 99-110	11
890	Cost Considerations for Monoclonal Antibody-Targeted Therapy in Cancer. 2006 , 5, 19-26	3
889	Breast Cancer and Molecular Medicine. 2006 ,	2
888	Breast Cancer. 2006 ,	2
887	Biomarkers in Breast Cancer. 2006 ,	3
886	Comparison of HER-2 Overexpression in Primary Breast Cancer and Metastatic Sites and Its Effect on Biological Targeting Therapy of Metastatic Disease. 2006 , 17, 188-189	
885	Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. 2006 , 3, 269-80	756
884	Lessons from phase III clinical trials on anti-VEGF therapy for cancer. 2006 , 3, 24-40	865
883	Principles of Targeted and Biological Therapies. 2006 , 73-90	
882	Evaluation of Tumor Markers: An Evidence-Based Guide for Determination of Clinical Utility. 2006 , 106-111	
881	Cancer Drug Resistance. 2006 ,	17
880	Pharmacodynamic biomarkers for molecular cancer therapeutics. 2007 , 96, 213-68	124
879	Anthracyclines and related compounds. 2006 , 245-255	
878	Dendritic cell immunotherapy for breast cancer. 2006 , 6, 591-604	17
877	Anthracycline cardiotoxicity. 2006 , 5, 791-809	97
876	Spotlight on Trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer. 2006 , 20, 259-62	9
875	Effect of dominant-negative epidermal growth factor receptors on cardiomyocyte hypertrophy. 2006 , 26, 659-77	13
874	Potential use of humanized antibodies in the treatment of breast cancer. 2006 , 6, 1065-74	14

873	Cancer Genome Anatomy Project. 2006,	3
872	Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer. 2006, 24, 187-91	34
871	Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. 2006, 6, 1249-69	61
870	Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials. 2006, 6, 951-62	6
869	Emerging use of nanoparticles in diagnosis and treatment of breast cancer. 2006, 7, 657-67	416
868	Recent advances in the treatment of metastatic breast cancer by adding trastuzumab. 2006, 4, 9-13	
867	Docetaxel and trastuzumab in the adjuvant setting: Translating SABCS into clinical practice. 2006, 4, 5-9	
866	Metastatic breast cancer: why are we here and where are we going?. 2006, 4, 2-5	2
865	Interpreting metastatic breast cancer data in the latter half of this decade. 2006, 4, 6-11	
864	Potential of biologically targeted therapies for breast cancer. 2006, 4, 23-26	1
863	Pharmacogenetics and pharmacogenomics: development, science, and translation. 2006, 7, 223-45	149
862	DNA vaccines against cancer. 2006, 20, 613-36	16
861	IIIA.2 Molecular-targeted therapies for elderly patients with breast cancer. 2006, 60, S5-S6	
860	Trastuzumab (Herceptin) for Ductal Carcinoma in Situ of the Breast. 2006, 17, 122-125	
859	Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer. 2007, 60, 1067-8	34
858	Recent advances in the treatment of malignant astrocytoma. 2006, 24, 1253-65	258
857	Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. 2006, 66, 29-33	153
856	Clinical trials in a molecular world. 2006, 16, 681-94, ix	3

855	La place des th�apeutiques cibl�es dans la prise en charge des CBNPC. 2006 , 23, 148-157	
854	Cardiac Evaluation, Toxicity and Monitoring in the Treatment of Breast Cancer. 2006 , 9, 160-167	1
853	Adjuvant Trastuzumab: Lessons Learned from Large Trials and Preliminary Results. 2006 , 17, 120-121	
852	Trastuzumab in the Treatment of Early-Stage Breast Cancer. 2006 , 17, 19-22	
851	Adjuvant therapy for patients who have node-positive breast cancer. 2006 , 40, 77-98	3
850	Th�apies cibl�es et immunomodulation dans les tumeurs solides. 2006 , 15, 297-302	
849	IIIA.1 The role of new targeted agents in metastatic colorectal cancer. 2006 , 60, S4-S5	
848	Heart failure induced by non-cardiac drugs. 2006 , 29, 567-86	82
847	Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. 2006 , 66, 449-75	85
846	Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions. 2006 , 66, 1577-91	51
845	Highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2006. 2006 , 7, 306-14	0
844	[Determination of Her2/neu status in breast tumours: PCR versus FISH]. 2006 , 127, 35-6	
843	Expression of tyrosine kinase receptors in lung carcinoids. 2006 , 27, 153-7	13
842	Liposomes as targeted drug delivery systems in the treatment of breast cancer. 2006 , 14, 301-10	62
841	Proteomics and Drug Discovery. 2006 , 233-271	3
840	Novel--and "neu"--therapeutic possibilities for heart failure. 2006 , 48, 1448-50	9
839	Targeting angiogenesis with integrative cancer therapies. 2006 , 5, 9-29	80
838	Role of exon-16-deleted HER2 in breast carcinomas. 2006 , 13, 221-32	91

837	Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. 2006 , 66, 1526-35	275
836	Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. 2006 , 126, 489-502	372
835	Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. 2006 , 340, 469-75	52
834	her-2 upstream open reading frame effects on the use of downstream initiation codons. 2006 , 350, 834-41	19
833	Metastatic breast cancer: an updating. 2006 , 60, 548-56	91
832	Herceptin: mechanisms of action and resistance. 2006 , 232, 123-38	353
831	Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and epidermal growth factor receptor (EGFR) family expression. 2006 , 244, 34-41	14
830	Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy. 2006 , 32, 106-18	61
829	Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. 2006 , 32, 180-90	106
828	Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence. 2006 , 32, 144-8	5
827	Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. 2006 , 42, 186-92	24
826	A genomic explanation connecting "Mediterranean diet", olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, 2006 , 42, 2125-33	88
825	Multinational clinical trials in oncology and post-trial benefits for host countries: where do we stand?. 2006 , 42, 2675-7	22
824	Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis. 2006 , 42, 1501-6	33
823	Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn. 2006 , 42, 1715-9	26
822	Evidence-based treatment of metastatic breast cancer - 2006 recommendations by the AGO Breast Commission. 2006 , 42, 2897-908	19
821	PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. 2006 , 7, 572-9	534
820	TRAIL receptor-targeted therapy. 2006 , 2, 493-508	39

819	Deconstructing the molecular portrait of basal-like breast cancer. 2006 , 12, 537-44	119
818	Compensatory increases in Her-2/neu activation in response to EGFR tyrosine kinase inhibition in colon cancer cell lines. 2006 , 136, 227-31	10
817	Thérapeutiques anticancéreuses ciblées. 2006 , 27, S285-S288	2
816	Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. 2006 , 41, 228-35	112
815	"To erb-B or not to erb-B..." Neuregulin-1/ErbB signaling in heart development and function. 2006 , 41, 215-8	22
814	Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. 2006 , 41, 845-54	141
813	Breast cancer. 2006 , 1, 187-210	2
812	Cancer therapy with engineered monoclonal antibodies. 2006 , 1, 147-157	11
811	Epidermal growth factor receptor pathway inhibitors. 2006 , 1, 299-310	5
810	Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. 2006 , 68, 110-5	29
809	Significance of erb-B2 immunoreactivity in cervical cancer. 2006 , 11, 2071-6	3
808	Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor negative fulvestrant-resistant MCF-7 cells. 2006 , 29, 1237	4
807	HER2 Testing in Breast Cancer: Opportunities and Challenges. 2006 , 1, 69-76	3
806	Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer. 2006 , 16, 393	1
805	Antibody Therapy for Solid Tumors. 2006 , 433-444	
804	ErbB and HB-EGF signaling in heart development and function. 2006 , 31, 1-14	97
803	Clinicopathologic factor and Lymphovascular Invasion in Breast cancer. 2006 , 9, 317	1
802	Monoclonal antibody therapy. 2006 , 11, 1620-35	33

801	Trastuzumab as Intellectual, Medical and Economical Challenge. 2006 , 1, 64-65	
800	Early-Stage Breast Cancer [Highlights at ASCO 2006. 2006 , 1, 265-269	1
799	Trastuzumab (Herceptin®): Monoclonal Antibody in the Treatment of HER2/neu-Overexpressing Breast Cancer in the Metastatic and (Neo)adjuvant Situation. 2006 , 1, 78-84	1
798	[Therapeutic advances in breast cancer]. 2006 , 63, 255-61	1
797	Viral vectors for cancer immunotherapy. 2006 , 11, 804-17	24
796	Targeted therapies in solid tumors: Monoclonal antibodies and small molecules. 2006 , 15, 103-111	12
795	Circulating HER2/neu. 2006 , 235-265	
794	The war on cancer: a report from the front lines. 2006 , 19, 323-34	1
793	What has been Learned from the Studies of Oxidative Stress-induced Carcinogenesis: Proposal of the Concept of Oxygenomics. 2006 , 39, 3-10	27
792	Clinical Utility of Determination of HER-2/neu and EGFR Fragments in Serum of Patients with Metastatic Breast Cancer. 2006 , 21, 131-140	10
791	Different Expression of HER2/neu Oncogene in Breast Carcinoma and in Liver Metastasis. Description of a Case. 2006 , 92, 536-539	1
790	Cancer Chemotherapy, Theoretical Foundations of. 2006 ,	
789	. 2006 ,	6
788	erb-B2 as a Therapeutic Target. 2006 , 159-175	1
787	Precision weapons. 2006 , 6, S22-S23	
786	Trastuzumab. 2006 , 3480-3481	
785	Monoclonal Antibody Therapy of Cancer. 2006 , 487-502	
784	Genomic and Chromosomal Instability. 2006 ,	

783	The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. 2006 , 107, 4039-46	127
782	Overview of pharmacogenetics. 2006 , Chapter 9, Unit 9.19	1
781	Assays for Gene Amplification. 2006 , 65-77	
780	The Epidermal Growth Factor Receptor Pathway as a Selective Molecular-Targeted Treatment in Human Breast Cancer. 2006 , 177-191	
779	Current Status of Financing and Reimbursement of Trastuzumab (Herceptin®) for Adjuvant and Advanced Therapy of Breast Cancer in Germany. 2006 , 1, 86-94	6
778	Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy. 2006 , 33, 265-72	7
777	Update on Epidermal Growth Factor Receptor Inhibitor Development in Lung Cancer. 2006 , 1, 740-743	2
776	c-Myc and downstream targets in the pathogenesis and treatment of cancer. 2006 , 1, 305-26	29
775	Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis. 2006 , 1, 147-167	8
774	Personalized medicine for breast cancer: moving forward and going back. 2006 , 3, 363-370	1
773	Taxane therapy for early stage breast cancer. 2006 , 2, 99-114	2
772	HER-2 gene amplification in Paget disease of the nipple and extramammary site: a chromogenic in situ hybridization study. 2006 , 15, 131-5	25
771	The role of platinum-based therapy for HER-2-positive breast cancer. 2006 , 9, 1-7	1
770	Herceptin (Trastuzumab) in the Adjuvant Setting: The Need for Accurate HER-2 Testing in Breast Cancer. 2006 , 13, 200-201	
769	What race and ethnicity measure in pharmacologic research. 2006 , 46, 401-4	12
768	Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. 2006 , 15, 1373-7	73
767	Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry. 2006 , 38, 120-4	34
766	Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France. 2006 , 22, 396-401	13

765	Update on Epidermal Growth Factor Receptor Inhibitor Development in Lung Cancer. 2006 , 1, 740-743	4
764	Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. 2006 , 15, 65	22
763	Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). 2006 , 1, 1-13	38
762	Matching patients with drugs: triumphs and challenges. 2006 , 3, 335-344	2
761	Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance. 2006 , 29, 90-5	28
760	Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer. 2006 , 29, 267-75	12
759	Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients. 2006 , 18, 24-8	133
758	HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system. 2006 , 14, 132-7	34
757	HER-2/neu and bcl-2 in ovarian carcinoma: clinicopathologic, immunohistochemical, and molecular study in patients with shorter and longer survival. 2006 , 14, 181-6	15
756	Designer drugs: the biologic therapies. 2006 , 6, 337-43	1
755	Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy. 2006 , 29, 53-60	20
754	HER-2/neu in breast cancer: a comparative study between histology, immunohistochemistry, and molecular technique (FISH). 2006 , 14, 127-31	10
753	Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. 2006 , 30, 1097-104	206
752	Her-2/neu in barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization. 2006 , 15, 125-30	23
751	Systemic treatments for inflammatory breast cancer. 2005 , 22, 55-65	13
750	Oncology, Molecular. 2006 ,	
749	Predictive Value of c-erb-B2 for Endocrine Therapy and Chemotherapy in Breast Cancer. 2006 , 129-157	
748	Molecular determinants in targeted therapy for esophageal adenocarcinoma. 2006 , 141, 476-81; discussion 481-2	22

747	Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer. 2006 , 6, 2	29
746	Putting the colours into chromogenic in situ hybridization (CISH). 2006 , 210, 1-2	6
745	The challenging estrogen receptor-negative/ progesterone receptor-negative/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy?. 2006 , 12, 360-2	40
744	The impact of HER-2 status on local recurrence in women with stage I-II breast cancer treated with breast-conserving therapy. 2006 , 12, 431-6	22
743	Monoclonal antibodies as targeting and therapeutic agents: prospects for liver transplantation, hepatitis and hepatocellular carcinoma. 2006 , 33, 482-8	17
742	Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. 2002 , 963, 104-15	55
741	Targeted molecular therapy of GBM. 2003 , 13, 52-61	174
740	Onkologika. 2020 , 671-732	1
739	Histological Changes of Feline Mammary Carcinoma Treated by NPe6 HVJ-E PDT. 2020 , 40, 403-407	
738	Computer Optimization of Stealth Biodegradable Polymeric Dual-loaded Nanoparticles for Cancer Therapy Using Central Composite Face-centered Design. 2020 , 8, 108-132	0
737	Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer.	
736	Heart Slice Culture System Reliably Demonstrates Clinical Drug-Related Cardiotoxicity.	
735	CTDPathSim: Cell line-tumor deconvoluted pathway-based similarity in the context of precision medicine in cancer *.	
734	Assessment of Cardiac Function by Advanced Echocardiography in Breast Cancer Patients (HER2 Positive vs HER2 Negative). 2020 , 11,	
733	Predicting clinical drug response from model systems by non-linear subspace-based transfer learning.	2
732	Precision combination therapies based on recurrent oncogenic co-alterations.	
731	Current regimens for use of vinorelbine in metastatic breast cancer: role and place of oral dosage form, metronome therapy, combinations with anti-HER 2 drugs. 2020 , 6-11	
730	Cancer Therapeutics-Related Cardiac Dysfunction - Insights From Bench and Bedside of Onco-Cardiology. 2020 , 84, 1446-1453	4

729	N-Glycoproteomics Study of Putative N-Glycoprotein Biomarkers of Drug Resistance in MCF-7/ADR Cells. 2021 , 1, 269	1
728	Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics. 2021 , 1	1
727	Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis. 2021 , 11, 731148	1
726	A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer. 2021 ,	0
725	Auf dem Weg zur Präzisionsonkologie: Biomarker, molekulargenetische Tumorprofile und Big Data. 2020 , 193-207	
724	Mammakarzinomrezidiv und metastasiertes Mammakarzinom. 2020 , 421-437	
723	Updated Bayesian Network Meta-Analysis of Adjuvant Targeted Treatment Regimens for Early Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer. 2020 , 23, 410-429	
722	Engineering large chromosomal deletions by CRISPR-Cas9.	
721	The current status of cancer survivorship care and a consideration of appropriate care model in Korea. 2020 , 16, 110-118	
720	Applications of Antibodies in Therapy, Diagnosis, and Science. 2021 , 129-159	
719	Major Classes of Biotherapeutics. 2020 , 47-69	1
718	HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials. 2020 , 8, 1634	1
717	Clinical Profile of Carcinoma Breast Patients Treated with Trastuzumab: A Single Centre Study. 2020 , 09, 110-118	
716	Cancer Treatment Infusion Reactions. 2020 , 107-112	
715	Chapter 17: Oncology: Somatic Disease and Pharmacogenomics. 2020 ,	
714	Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies. 2019 , 15, 250-257	3
713	ERBB2 Targeting Increases Cardiomyocyte β -Adrenergic Receptor Density.	
712	Renal Cancer Including Molecular Characterization. 2020 , 551-559	

- 711 Trastuzumab: A Milestone in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. **2020**, 41, 54-56
- 710 Treatment options for HER2-positive metastatic breast cancer. **2020**, 2, 28
- 709 Targeted Therapies. **2020**, 1-13
- 708 Prioritization of Factors of Breast Cancer Treatment Using Fuzzy AHP. **2020**, 336-344
- 707 Heart Muscle Tissue Engineering. **2020**, 99-121
- 706 Applications of Salivary Bioscience to Precision Medicine. **2020**, 711-721 1
- 705 Adjuvante Therapie des Mammakarzinoms. **2020**, 403-419
- 704 The Quiet Revolution in Breast Cancer Care: From Laboratory to Survival. **2020**, 2, 37
- 703 Cardiovascular and Central Nervous System Toxicity by Anticancer Drugs in Breast Cancer Patients. **2020**, 765-789
- 702 Cardio-Oncology: Preventing Broken Hearts in Women with Breast Cancer. **2020**, 217-236
- 701 CHAPTER 15:Precision Oncology. **2020**, 345-362 0
- 700 Intellectual Structure and Evolutionary Trends of Precision Medicine Research: Coword Analysis. **2020**, 8, e11287 2
- 699 Ado-Trastuzumab Emtansine The Monoclonal Drug Conjugate in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. **2020**, 41, 218-220
- 698 Drug-Induced Heart Failure (Part 1: The Urgency of the Problem, the Prevalence, the Effect of Certain Groups of Drugs on the Risk of Development/Progression Heart Failure). **2020**, 8, 23-35 1
- 697 Attenuating treatment-related toxicity in women recently diagnosed with breast cancer via a tailored physical exercise program using a mobile app ATOPE+ Protocol of the ATOPE trial. (Preprint).
- 696 Efficacy and Safety of Tradipitant in Diabetic and Idiopathic Gastroparesis: A Randomized, Placebo-Controlled Study. 0
- 695 Development and validation of a nomogram for predicting survival of breast cancer patients with ipsilateral supraclavicular lymph node metastasis. **2021**, 134, 2692-2699 0
- 694 Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2. **2021**, 0

- 693 HER2 targeting near-infrared photoimmunotherapy for a CDDP-resistant small-cell lung cancer. **2021**, 10, 8808 4
- 692 Study on Prognostic Implications of HER2/Neu Expression in Colorectal Cancer in Eastern India. **2020**, 7, 1414-1419
- 691 Personomics [An innovative tool of precision medicine and its role in the individualized treatment of patients with breast cancer. **2020**, 1-8
- 690 An Overview of HER-targeted therapy with lapatinib in breast cancer.
- 689 Maligne Tumoren der Mamma. **2014**, 1-30 0
- 688 Detection and Characterisation of Occult Metastatic Cells in Bone Marrow of Breast Cancer Patients: Implications for Adjuvant Therapy. **2003**, 47-56
- 687 Medical, Psychosocial, and Health-Related Quality of Life Issues in Breast Cancer Survivors. **2006**, 1846-1868
- 686 Evidence-Based Management of Breast Cancer. **2006**, 960-991 1
- 685 Targeting Oncogenes Which Regulate Apoptosis. **2005**, 117-144
- 684 Les th rapeutiques cibl es ou le traitement des m canismes mol culaires de la progression tumorale. **2006**, 515-527
- 683 Breast cancer with HER 2 overexpressed. From laboratory to clinical practice. **2006**, 205-220
- 682 Cancers du sein avec HER2 surexprim : quoi de neuf dans la prise en charge clinique ?. **2006**, 221-231
- 681 Endokrinium und Tumorwachstum. **2005**, 527-557 1
- 680 Molekularbiologie und Targeted therapy[beim Pleuramesotheliom. **2005**, 103-115
- 679 Para- und autokrine Aspekte der Pathogenese des duktales Pankreaskarzinoms: Einfluss von Zytokinen und Wachstumsfaktoren. **2006**, 309-321
- 678 Antineoplastische Therapie. 561-638
- 677 Maligne Tumoren der Mamma. **2005**, 1-30
- 676 Signal transduction inhibitors. **2006**, 185-199

675 Detection and Characterisation of Occult Metastatic Cells in Bone Marrow of Breast Cancer Patients: Implications for Adjuvant Therapy. **2003**, 47-65

674 Monoclonal Antibody Therapy of Cancer. **2007**, 321-342

1

673 DNA Vaccines Against Cancer. **2007**, 193-215

672 Systemic Therapy for Breast Cancer: Using Toxicity Data to Inform Decisions. **2008**, 373-394

671 Chemosensitization. **2005**, 335-348

670 Principles of Medical Management. **2006**, 93-100

669 Metastatic Breast Carcinoma. **2006**, 117-121

668 Signaling Modules in Glial Tumors and Implications for Molecular Therapy. **2006**, 389-417

667 Herceptin Resistance. **2006**, 459-467

666 Somatic Alterations in Prostate Cancer Progression. **2007**, 269-283

665 Intercellular Targets of Prostate Cancer. **2007**, 475-486

664 Molecular Targets in Ovarian Cancer and Endometrial Cancer. **2008**, 291-308

663 Targeted Therapy For Breast Cancer. **2008**, 309-342

662 Antibody Therapy of Cancer. **2008**, 371-412

661 Patient Selection for Rational Development of Novel Anticancer Agents. **2008**, 641-648

660 Neurologic Complications of Breast Cancer. **2008**, 423-448

659 Combining Targeted Therapies. **2008**, 361-381

658 Targeted Therapy in Breast Cancer. **2008**, 43-59

- 657 Targeted Therapy in Melanoma. **2008**, 183-211
- 656 Traitement adjuvant et cancer du sein surexprimant HER2. **2007**, 197-208
- 655 Traitement du cancer du sein m̄astatique. **2007**, 209-225
- 654 Prise en charge des cancers du sein m̄astatique HER2 surexprim̄. **2007**, 239-252
- 653 Cancer du sein m̄astatique HER2 n̄gatif n̄cessitant un traitement par chimioth̄rapie. **2007**, 253-265
- 652 Traitements n̄-adjuvants des cancers du sein HER2 positif. **2007**, 425-443
- 651 Anticancer antibodies. **2003**, 119, 472-85 18
- 650 Applications of Proteomics to Clinical Questions in Breast Cancer. **2006**, 623-639
- 649 Targeting the HER Family of Receptors in the Treatment of Advanced Breast Cancer. **2006**, 643-670
- 648 Adjuvante Therapie des Mammakarzinoms. **2007**, 325-333
- 647 Therapie des Mammakarzinomrezidivs. **2007**, 335-345
- 646 Progress in the Treatment of Early and Advanced Breast Cancer. **2008**, 239-256
- 645 Chemotherapy in the Management of Malignant Tumors of Salivary Gland Origin. **2007**, 477-494
- 644 Tiermodelle in der biomedizinischen Forschung. **2008**, 207-241
- 643 Maligne Tumoren der Mamma. **2009**, 1-32
- 642 Effectiveness of Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in a Real-Life Setting: One Decade of Experience Under National Treatment Coverage Regulations. **2020**, 6, 217-223 1
- 641 Immunotherapy for Pediatric Sarcomas. **2021**, 165-180
- 640 Somatic chromosomal number alterations affecting driver genes inform in-vitro and clinical drug response in high-grade serous ovarian cancer. 0

639	Role of Anti-HER2/Neu Molecules in the Management of HER2-Positive Early Breast Cancer. 2021 , 157-163	
638	Monoclonal Antibodies for Cancer Immunotherapy. 2021 , 273-312	1
637	Cardiac overexpression of microRNA-7 is associated with adverse cardiac remodeling.	
636	Options of precision medicine in clinical oncological practice. 2020 , 14, 178-181	
635	CTDPathSim. 2020 ,	0
634	Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy. 2020 , 15, e0241775	2
633	Brain metastatic breast cancer: Epidemiology, survival and prognosis: Single center experience. 2020 , 34, 156-156	
632	Triple-Positive Breast Carcinoma: Histopathologic Features and Response to Neoadjuvant Chemotherapy. 2021 , 145, 728-735	0
631	Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).	
630	The breast. 571-687	1
629	Clinical proteomics: present and future prospects. 2006 , 27, 99-116	50
628	Renal cell carcinoma and the use of sorafenib. 2006 , 2, 87-98	11
627	The Jeremiah Metzger Lecture: intelligent design of cancer therapy: trials and tribulations. 2007 , 118, 253-61	4
626	Biological response modifiers in cancer. 2006 , 8, 33	4
625	Adjuvant trastuzumab: progress, controversies, and the steps ahead. 2006 , 13, 8-13	6
624	Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 2. 2006 , 13, 99-107	40
623	From the editor's desk: the emergence of "personalized medicine" in medical care. 2007 , 10, 1-2	
622	A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer. 2007 , 3, 665-73	14

621	Gemcitabine and taxanes in metastatic breast cancer: a systematic review. 2008 , 4, 1157-64	9
620	Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. 2007 , 2, 567-83	128
619	Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer. 2007 , 1, 229-39	5
618	First line targeted therapies in breast cancer: focus on bevacizumab. 2007 , 1, 3-10	2
617	Trastuzumab in the management of early and advanced stage breast cancer. 2007 , 1, 19-31	31
616	HER2 breast cancer therapies: a review. 2009 , 3, 289-301	43
615	The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure. 2009 , 14, e62-7	8
614	From bench to bedside: the growing use of translational research in cancer medicine. 2010 , 2, 1-18	48
613	Breast cancer (metastatic). 2007 , 2007,	1
612	Emerging tactical strategies for fighting the war on cancer based on the genetic landscape. 2011 , 3, 251-8	1
611	Cardiac dysfunction after cancer treatment. 2011 , 38, 248-52	11
610	Nanotechnology of emerging targeting systems. 2008 , 20, 127-131	
609	Pharmacoeconomic considerations in the treatment of breast cancer. 2010 , 2, 47-61	7
608	Breast cancer (metastatic). 2010 , 2010,	4
607	Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear. 2011 , 84, 371-80	44
606	Introduction to monoclonal antibodies. 2012 , 12, 11	3
605	Recent advances in adjuvant systemic treatment for breast cancer: all systems go!. 2006 , 13, 147-59	
604	Trastuzumab for a patient with heavily pretreated gastric cancer plus massive ascites and ovarian metastasis. 2012 , 5, 97-9	

603	Change of HER2 status in metastatic esophageal adenocarcinoma: heterogeneity of the disease? Case report and review of literature. 2012 , 3, 358-61	6
602	Demonstrating the value of biologics: a call to action. 2007 , 4, 33-42	
601	A RTK-based functional RNAi screen reveals determinants of PTX-3 expression. 2013 , 6, 660-8	3
600	Targeting breast cancer stem cells with HER2-specific antibodies and natural killer cells. 2013 , 3, 211-20	12
599	RNA aptamers and their therapeutic and diagnostic applications. 2013 , 4, 27-40	56
598	HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer. 2006 , 26, 4235-43	47
597	Chemotherapy and cardiotoxicity. 2008 , 9, 75-83	42
596	Clinicopathological factors associated to HER-2 status in a hospital-based sample of breast cancer patients in Puerto Rico. 2010 , 29, 265-71	2
595	New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin. 2009 , 1, 1-18	1
594	Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer. 2014 , 39, 206-12	5
593	Human epidermal growth factor receptor 2 expression in urothelial carcinoma of the renal pelvis: correlation with clinicopathologic parameters. 2014 , 7, 2544-50	9
592	Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?. 2014 , 4, 353-68	47
591	Gastric cancer: toward a cisplatin-free disease?. 2014 , 5, 318-22	2
590	Dual HER2-targeting without chemotherapy and estrogen deprivation in the neoadjuvant setting. 2014 , 3, 81-4	2
589	Development of a peptide by phage display for SPECT imaging of resistance-susceptible breast cancer. 2014 , 4, 435-47	10
588	Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas. 2014 , 7, 6254-61	7
587	The role of HER-2 in Breast Cancer. 2014 , 2, 4-9	5
586	Downregulation of ER- β expression sensitizes HER2 overexpressing breast cancer cells to tamoxifen. 2015 , 5, 530-44	4

585	A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK. 2015 , 7, 733-50	40
584	Gemcitabine-(C)-[anti-HER2/] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma. 2013 , 2,	8
583	The Prognostic Significance of Her2-Neu Over expression in Gastric Carcinomas. 2011 , 4, 170-6	4
582	Synchronous primary breast cancer and hepatocellular carcinoma in a male patient: a case report. 2015 , 8, 11722-8	1
581	Glutamine synthetase predicts adjuvant TACE response in hepatocellular carcinoma. 2015 , 8, 20722-31	3
580	Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword. 2013 , 29, 295-303	7
579	Antibody Therapeutics in Oncology. 2016 , 2,	9
578	Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients. 2016 , 6, 120-7	26
577	Good manufacturing practice production of [(68)Ga]Ga-ABY-025 for HER2 specific breast cancer imaging. 2016 , 6, 135-53	14
576	Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers. 2016 , 6, 714-46	19
575	Extracellular MicroRNA in liquid biopsy: applicability in cancer diagnosis and prevention. 2016 , 6, 1461-93	38
574	Cardiovascular Risk and Level of Statin Use Among Women With Breast Cancer in a Cardio-Oncology Clinic. 2016 , 16, 217-24	5
573	Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management. 2016 , 16, 250-6	17
572	Cardiotoxicity Following Cancer Treatment. 2017 , 86, 3-9	4
571	Breast Cancer Immunotherapy. 2015 , 10, 185-191	5
570	Systemic Therapy for Early-Stage Breast Cancer: What the Plastic Surgeon Should Know. 2017 , 17, e7	5
569	AMP-activated protein kinase and energy balance in breast cancer. 2017 , 9, 197-213	13
568	Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer. 2017 , 146, 563-571	3

567	CATCH-KB: Establishing a Pharmacogenomics Variant Repository for Chemotherapy-Induced Cardiotoxicity. 2018 , 2017, 168-177	2
566	A Review of Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Breast Cancer. 2018 , 12, 111-116	
565	Implications of Autophagy and Oxidative Stress in Trastuzumab-Mediated Cardiac Toxicities. 2017 , 2,	8
564	Differential Expression of RAGE, EGFR and Ki-67 in Primary Tumors and Lymph Node Deposits of Breast Carcinoma. 2018 , 19, 2269-2277	0
563	Therapeutic Considerations for Ron Receptor Expression in Prostate Cancer. 2018 , 1,	1
562	Diagnostic HER2-binding radiopharmaceutical, [Ga]Ga-ABY-025, for routine clinical use in breast cancer patients. 2019 , 9, 12-23	13
561	Application of Multiplex Ligation-Dependent Probe Amplification in Determining the Copy Number Alterations of Gene Family Members in Invasive Ductal Breast Carcinoma. 2019 , 8, 91-101	1
560	Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+ breast cancer. 2019 , 11, 6110-6116	5
559	The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. 2020 , 10, 1045-1067	22
558	Data-driven Sublanguage Analysis for Cancer Genomics Knowledge Modeling: Applications in Mining Oncological Genetics Information from Patients' Genetic Reports. 2020 , 2020, 720-729	1
557	Trastuzumab increases pulmonary vein arrhythmogenesis through modulating pulmonary vein electrical and conduction properties via phosphatidylinositol 3-kinase signaling. 2020 , 23, 865-870	
556	[Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice]. 2020 , 52, 254-260	2
555	[Pharmacological effects of site specific conjugated anti-human epidermal growth factor receptor 2-antibody drug conjugate using unnatural amino acid technology]. 2019 , 51, 797-804	1
554	Anticancer therapeutics: a brief account on wide refinements. 2020 , 10, 3599-3621	1
553	[Research Progress of Targeted Therapy for HER2 Gene ?in Advanced Non-small Cell Lung Cancer]. 2020 , 23, 1108-1112	
552	Studies on polyethylene glycol-monoclonal antibody conjugates for fabrication of nanoparticles for biomedical applications. 2020 , 4, 1-9	
551	Cytotoxicity effect of trastuzumab on canine peripheral blood mononuclear cells. 2020 , 21, 263-268	
550	Precision Medicine: A New Paradigm in Therapeutics. 2021 , 12, 12	0

549	A tipping-point for apoptosis following dual inhibition of HER2 signaling network by T-DM1 plus GDC-0980 maximizes anti-tumor efficacy. 2021 , 11, 2867-2892	1
548	Mechanism and prevention strategy of a bidirectional relationship between heart failure and cancer (Review). 2021 , 22, 1463	1
547	Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. 2021 ,	10
546	HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer. 2021 , 12, 1109	1
545	The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy. 2021 , 13,	2
544	Toward Understanding the Binding Synergy of Trastuzumab and Pertuzumab to Human Epidermal Growth Factor Receptor 2. 2021 , 18, 4553-4563	0
543	Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer. 2021 , 13,	1
542	Endocrine Treatment for Breast Cancer Patients Revisited-History, Standard of Care, and Possibilities of Improvement. 2021 , 13,	3
541	Oncology drug-companion diagnostic combinations. 2021 , 29, 100492	1
540	Cancer-A Major Cardiac Comorbidity With Implications on Cardiovascular Metabolism.. 2021 , 12, 729713	4
539	Assessing the Overall Validity of Randomised Controlled Trials. 1-24	
538	Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer. 2021 , 1-11	1
537	Immunotherapy in Breast Cancer: When, How, and What Challenges?. 2021 , 9,	7
536	Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach. 2021 , 26, 300574	2
535	Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments. 2021 , 13,	1
534	Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-based Regimens. 2021 ,	
533	Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Metastatic Breast Cancer with Hormone Receptor-positive and HER2-positive (SYSUCC-002). 2021 ,	5
532	Comparison of the Efficacy, Safety, Pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) With the Kadcylla (Trastuzumab Emtansine) in the Treatment of HER2-Positive Metastatic Breast Cancer: A Randomized, Open-Label, Multicenter Study in India.. 2021 ,	0

531	Cardiac expression of microRNA-7 is associated with adverse cardiac remodeling. 2021 , 11, 22018	1
530	Genomic landscape and clinical utility of Korean advanced pan-cancer patients from prospective clinical sequencing: K-MASTER program. 2021 ,	4
529	Research Progress on Clinical Features and Related Treatment of Senile Breast Cancer. 2021 , 11, 5613-5619	
528	A Retrospective analysis of biosimilar and reference trastuzumab in human epidermal growth factor receptor-2 positive early and/or locally advanced breast cancer patients treated with neoadjuvant-adjuvant setting: Safety and event-free survival outcomes. 2021 , 5, 97	
527	Study of human epidermal growth factor receptor (HER2/neu) expression in primary colorectal carcinoma in a tertiary care hospital. 2021 , 8, 325	
526	Expresi3n de receptores hormonales como factor predictivo de respuesta al tratamiento en pacientes con c3ncer de mama temprano y localmente avanzado con sobreexpresi3n de HER2 en un hospital privado. 2021 , 66, 258-262	
525	Encyclopedia of Gerontology and Population Aging. 2021 , 4895-4908	
524	Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine.. 2022 , 6, e2000508	1
523	Alpha-crystallin B chains in trastuzumab-resistant breast cancer cells promote endothelial cell tube formation through activating mTOR.. 2021 , 588, 175-181	1
522	A comprehensive review on immuno-nanomedicine for breast cancer therapy: Technical challenges and troubleshooting measures.. 2021 , 103, 108433	0
521	Vaccination against Her-2/neu, with focus on peptide-based vaccines.. 2022 , 7, 100361	1
520	ErbB tyrosine kinase receptor inhibitors in breast cancer treatment. 2004 , 6, 12-21	1
519	Mammakarzinom: Krebsregister deckt Metastasierungsprozess auf.	
518	Mechanistic science in cardiovascular-oncology: the way forward to maximise anti-cancer drug effects and minimise cardiovascular toxicity. 2021 , 135, 2661-2663	1
517	Blocking the Increase of Intracellular Deuterium Concentration Prevents the Expression of Cancer-Related Genes, Tumor Development, and Tumor Recurrence in Cancer Patients.. 2022 , 29, 10732748211068963	
516	Updated Austrian treatment algorithm in HER2+ metastatic breast cancer.. 2022 , 134, 63	0
515	Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer: A Review.. 2022 ,	1
514	Immunotherapeutic Strategies in Cancer and Atherosclerosis-Two Sides of the Same Coin.. 2021 , 8, 812702	

513	Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer.. 2022,	0
512	From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression.. 2021, 12, 757994	0
511	Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer.. 2022, 12,	0
510	Methods of screening, monitoring and management of cardiac toxicity induced by chemotherapeutics?. 2022,	1
509	Visualizing surface marker expression and intratumoral heterogeneity with SERRS-NPs imaging.. 2022, 6, 256-269	2
508	Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study.. 2022, 12, 1068	0
507	Cardiac Function Checkup During Trastuzumab Therapy Among Patients With Breast Cancer.. 2022,	
506	Role of Fcγ receptors in HER2-targeted breast cancer therapy.. 2022, 10,	6
505	Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial.. 2022,	1
504	Molecular Imaging of HER2 in Patient Tissues with Touch Prep-Quantitative Single Molecule Localization Microscopy.. 2022, 2394, 231-248	
503	Human Epidermal Growth Factor Receptor 2-Mutant Non-Small-Cell Lung Cancer: Continued Progress But Challenges Remain.. 2022, JCO2102550	
502	FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer.. 2022, 12, 241	2
501	Precision medicine for metastatic colorectal cancer in clinical practice.. 2022, 14, 17588359211072703	2
500	Artificial Intelligence in Clinical Trials. 2022, 453-501	
499	Non-Surgical Management of Metastatic Breast Cancer and Palliative Care. 2022, 497-517	
498	Extracellular Vesicles as Mediators of Therapy Resistance in the Breast Cancer Microenvironment.. 2022, 12,	1
497	The initial hormone receptor/HER2 subtype is the main determinant of subtype discordance in advanced breast cancer: a study of the SONABRE registry.. 2022, 192, 331	
496	Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience.. 2022,	1

495	Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines.. 2022 , 14, 17588359211066677	5
494	Physicochemical stability of PF-05280014 (trastuzumab-qyyp; Trazimera), a trastuzumab biosimilar, under extended in-use conditions.. 2022 , 10781552221074649	
493	The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment.. 2021 , 8, 821663	4
492	Terapia personalizada en cáncer de mama precoz. Implicancias prácticas. 2022 , 33, 17-24	
491	Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer.. 2022 , 14,	0
490	Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial.. 2022 , 11, 216-225	1
489	Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience.. 2022 , 12,	0
488	Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti-Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma.. 2022 , 6, e2100330	0
487	Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A. 2021 , JCO2101375	7
486	Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial.. 2022 ,	8
485	Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers.. 2022 , 13, 273-280	0
484	Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data.. 2022 , 62, 1-9	0
483	Neoadjuvant pertuzumab in non-metastatic HER2-positive breast tumors: Multicentric study in Peru (NeoHer).. 2022 , 16, 70	
482	HEROHE Challenge: Assessing HER2 Status in Breast Cancer Without Immunohistochemistry or In Situ Hybridization.	1
481	Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer: A Systematic Review and Meta-analysis.. 2022 ,	0
480	HER2 Positivity Is Affected by the Papillary Structure and Has a Bidirectional Prognostic Value for Gallbladder Carcinoma.. 2021 , 12, 831318	
479	Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study.. 2022 , 36, 55-69	0
478	The spectrum of HER2 expression in breast cancer: linking immunohistochemistry quantification with in situ hybridization assay.. 2022 , 1	0

- 477 Anti-HER2 therapy in metastatic breast cancer: many choices and future directions.. **2022**, 41, 193 1
- 476 Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial.. **2022**, 192, 593 0
- 475 Una propuesta práctica para seleccionar tratamientos quimioterápicos en pacientes oncológicos avanzados según su coste-efectividad. **2003**, 5, 33-36
- 474 Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action.. **2021**, 4, e2138793 12
- 473 Sensitization of breast cancer to Herceptin by redox active nanoparticles. **2021**, 11, 4884-4899
- 472 A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin. **2021**, 9, 390-396
- 471 Biomarker-Driven Adaptive Phase III Clinical Trials. **2021**, 1-12
- 470 Introduction to the Imaginary of Precision Oncology. **2022**, 17-28
- 469 First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCG.. **2022**, 16, 11782234221086992
- 468 Filled with Desire, Perceive Molecules. **2022**, 251-267
- 467 Publication Bias in Precision Oncology and Cancer Biomarker Research; Challenges and Possible Implications. **2022**, 155-174
- 466 Nuclear medicine therapy of lung cancer, breast cancer and colorectal cancer. **2022**,
- 465 Patient-Derived In Vitro and In Vivo Models of Cancer.. **2022**, 1361, 215-233 0
- 464 Signal Detection of Adverse Events Associated with Trastuzumab in a Cohort of Elderly Patients with Breast Cancer.. **2022**,
- 463 Overview of MicroRNA Expression in Predicting Response to Neoadjuvant Therapies in Human Epidermal Growth Receptor-2 Enriched Breast Cancer - A Systematic Review.. **2022**, 16, 11782234221086684 0
- 462 HER2 Revisited: Reflections on the Future of Cancer Biomarker Research. **2022**, 97-119
- 461 Greenspace, Inflammation, Cardiovascular Health, and Cancer: A Review and Conceptual Framework for Greenspace in Cardio-Oncology Research.. **2022**, 19, 2
- 460 Herceptin-Mediated Cardiotoxicity: Assessment by Cardiovascular Magnetic Resonance.. **2022**, 2022, 1910841 0

459	Research progress on RNA-binding proteins in breast cancer.. 2022 , 23, 121	1
458	Evaluation of an I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers.. 2022 , 12, 3020	1
457	Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis.. 2022 , 3, 100526	0
456	Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib.. 2022 , 8, 22	0
455	Clinical Applications and Anticancer Effects of Antimicrobial Peptides: From Bench to Bedside.. 2022 , 12, 819563	1
454	Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer.. 2022 , 5, e2145460	2
453	Template-based assembly of proteomic short reads for de novo antibody sequencing and repertoire profiling.	
452	Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients.. 2022 , 22, 242	
451	Emerging Roles for G Protein-Coupled Estrogen Receptor 1 in Cardio-Renal Health: Implications for Aging.. 2022 , 12,	0
450	Cardiovascular toxicity associated with the multitargeted tyrosine kinase inhibitor anlotinib.. 2022 , 3008916221084362	
449	Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society.. 2022 , 24, 22	7
448	A Proposed TUSC7/miR-211/Nurr1 ceRNET Might Potentially be Disturbed by a cer-SNP rs2615499 in Breast Cancer.. 2022 , 1	
447	Cancer proteogenomics: current impact and future prospects.. 2022 ,	7
446	The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005).. 2022 , 22, 271	
445	Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis-The Adjuvant Role of Lifestyle Changes.. 2022 , 29, 1890-1901	1
444	Management of early stage HER2 positive breast cancer and increased implementation of axillary imaging to improve identification of nodal metastasis.. 2022 ,	0
443	INHBA is a mediator of aggressive tumor behavior in HER2+ basal breast cancer.. 2022 , 24, 18	0
442	Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome.	0

441	Intracranial Metastatic Disease: Present Challenges, Future Opportunities.. 2022 , 12, 855182	0
440	In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation.. 2022 , 1	1
439	Targeted Therapies for Perihilar Cholangiocarcinoma.. 2022 , 14,	0
438	mTOR inhibition and trastuzumab-emtansine (T-DM1) in HER2-positive breast cancer.. 2022 ,	0
437	Margetuximab Versus Trastuzumab in Patients With Advanced Breast Cancer: A Cost-effectiveness Analysis.. 2022 ,	0
436	HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer.. 2022 , 9, 834651	7
435	Personalisierte Therapie bei fortgeschrittenen/metastasierten Mammakarzinomen: Biomarker ffü ein lüngerer Überleben. 2022 , 20, 28-30	
434	IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment.. 2022 , 12, 866014	4
433	Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association.. 2022 , CIR0000000000001056	4
432	Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer.. 2022 ,	0
431	HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.. 2022 , 20, 105	2
430	Personalized Risk-Based Screening Design for Comparative Two-Arm Group Sequential Clinical Trials.. 2022 , 12,	1
429	Familial breast cancer, pregnancy and cardiotoxicity associated with the use of doxorubicin and reaction with trastuzumab.. 2022 , 10781552221080081	1
428	Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival.. 2022 , 7, 100409	0
427	Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review.. 2022 , 29, 2539-2549	1
426	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2022 , 101161CIR0000000000001063	35
425	Value of CT-Based Radiomics in Predicating the Efficacy of Anti-HER2 Therapy for Patients With Liver Metastases From Breast Cancer.. 2022 , 12, 852809	0
424	Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer - a review of current evidence for and against the use of anti-HER2 treatment regimens.. 2022 ,	1

423	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2022,	49
422	Potential molecular mechanisms and clinical progress in liver metastasis of breast cancer.. 2022, 149, 112824	0
421	Genetics of cancer therapy-associated cardiotoxicity.. 2022,	2
420	Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer. 2021, 100, e27632	0
419	Stomach cancer gets a triple punch of therapy.. 2021, 600, 608-609	0
418	Predicting patient response with models trained on cell lines and patient-derived xenografts by nonlinear transfer learning. 2021, 118,	1
417	. 2021, 108, 11S8-11S18	0
416	Updates on targeting human epidermal growth factor receptor 2-positive breast cancer: what's to know in 2021.. 2022, 34, 41-45	0
415	The efficacy and safety of pyrotinib in treating HER2-positive breast cancer patients with brain metastasis: A multicenter study.. 2021,	3
414	Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study. 2021, 36-46	
413	Neoadjuvant chemotherapy for HER2-positive breast cancer using dose-consolidated regimens and dual anti-HER2 blockade with pertuzumab and trastuzumab (preliminary results). 2021, 1, 38-43	
412	The influence of a supervised group exercise intervention combined with active lifestyle recommendations on breast cancer survivors' health, physical functioning, and quality of life indices: study protocol for a randomized and controlled trial.. 2021, 22, 934	0
411	Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer.. 2021, 14,	1
410	Neoadjuvant Systemic Therapy for Breast Cancer Based on Underlying Tumor Biology. 2022, 125-150	1
409	HDAC Inhibition to Prime Immune Checkpoint Inhibitors.. 2021, 14,	4
408	Adapted Physical Activity for Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Trastuzumab Against HER2 (APACAN2): A Protocol for a Feasibility Study.. 2021, 11, 744609	0
407	The Visualization of Protein-Protein Interactions in Breast Cancer: Deployment Study in Pathological Examination.. 2021, 54, 177-183	1
406	Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer.. 2022, 119,	1

405	Starring role of Biomarkers and Anticancer Agents as a Major Driver in Precision Medicine of Cancer Therapy.. 2021 ,	
404	Oncology: Biochemists' Perspective. 2022 , 211-237	
403	Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies.. 2022 , OF1-OF11	1
402	HER2 protein expression level is positively associated with the efficacy of neoadjuvant systemic therapy in HER2-positive breast cancer.. 2022 , 234, 153900	0
401	SEC14L3 plays a tumor-suppressive role in breast cancer through a Wnt/ β -catenin-related way.. 2022 , 113161	
400	Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection.. 2022 , 9, 847012	0
399	The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.. 2022 ,	
398	Precision combination therapies based on recurrent oncogenic co-alterations.. 2022 ,	1
397	Development of software enabling Chinese medicine-based precision treatment for osteoporosis at the gene and pathway levels.. 2022 , 17, 47	1
396	Temporal trends in disease-specific causes of cardiovascular mortality amongst patients with cancer in the USA between 1999 to 2019.. 2022 ,	1
395	Kinome Inhibition States and Multiomics Data Enable Prediction of Cell Viability in Diverse Cancer Types.	0
394	Prognosis of cancer. 473-498	
393	Novel Molecular and Genetic Prognostic Biomarkers in Prostate Cancer. 2005 , 377-391	
392	Data_Sheet_1.docx. 2019 ,	
391	Table_2.XLSX. 2019 ,	
390	Data_Sheet_1.docx. 2020 ,	
389	Image_1.TIFF. 2019 ,	
388	Image_2.TIFF. 2019 ,	

387 Image_3.TIFF. 2019,

386 Table_1.XLSX. 2019,

385 Image_1.JPEG. 2020,

384 Image_2.JPEG. 2020,

383 Table_1.XLSX. 2019,

382 Image_1.TIF. 2019,

381 Image_2.TIF. 2019,

380 Image_3.TIF. 2019,

379 Image_4.TIF. 2019,

378 Image_5.TIF. 2019,

377 Table_1.XLS. 2019,

376 Data_Sheet_1.docx. 2020,

375 Natural history and characteristics of ERBB2-mutated hormone receptor-positive advanced breast cancer: a retrospective case-control study from AACR Project GENIE.. 2022, 0

374 Expression of glucose-regulated protein 78 as prognostic biomarkers for triple-negative breast cancer. 2020, 35, 559-568 2

373 Evaluating Trastuzumab in the treatment of HER2 positive breast cancer. 2020, 35, 1059-1075 1

372 Long-Term Prognostic Significance of HER2-Low and HER2-Zero in Node-Negative Breast Cancer.

371 Imaging the Cardiovascular System in the Cancer Patient. 2022, 1-24

370 Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.. 2022, 29, 10732748221099230 0

- 369 Diagnostic Applications of Nuclear Medicine: Breast Cancer. **2022**, 1-27
- 368 Cardiotoxicity monitoring of pyrotinib in combination with nab-paclitaxel, doxorubicin, and cyclophosphamide in HER2-positive breast cancer: a single-armed clinical trial.. **2022**, 11, 742-750
- 367 Human Epidermal Growth Factor Receptor 2 Overexpression and Amplification in Patients With Colorectal Cancer: A Large-Scale Retrospective Study in Chinese Population.. **2022**, 12, 842787
- 366 Patient-Derived Organoids of Colorectal Cancer: A Useful Tool for Personalized Medicine. **2022**, 12, 695 ○
- 365 N-((1-(4-Fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-2-methylene-3-oxo-olean-12-en-28-amide Induces Apoptosis in Human Breast Cancer Cells by Stimulating Oxidative Stress and Inhibiting the Notch-Akt Signaling Pathway.. **2022**, 2022, 8123120 ○
- 364 Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC.. **2022**, 14, 1
- 363 Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals.. **2022**, 14, ○
- 362 Cardiovascular toxicities of chemotherapies: challenging the paradigm for left ventricular ejection fraction monitoring during and after treatment. **2022**, 16, 100140
- 361 Prognostic Significance of Low HER2 Expression in Patients With Early Hormone Receptor Positive Breast Cancer.. **2022**, 2, 316-323 2
- 360 Disentangling ERBB Signaling in Breast Cancer Subtypes: A Model-Based Analysis. **2022**, 14, 2379 ○
- 359 Monoclonal-induced cardiotoxicity in patients with non-Hodgkin's lymphoma and breast cancer: A retrospective study in an oncology clinic.. **2022**, 10781552221098426
- 358 Functional mechanism and clinical implications of miR-141 in human cancers.. **2022**, 110354 ○
- 357 Molecular Progression of Breast Cancer and Personalized Medicine in Terms of Clinical Trials. **2022**, 367-401
- 356 N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer.. **2022**, 13, 2672 6
- 355 Breast Cancer. **2022**, 151-192
- 354 HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment. **2022**, 14, 2424 ○
- 353 Systemic Diseases. **2016**, 739-804
- 352 Targeting ErbB receptor signaling: A pan-ErbB approach to cancer. **2004**, 3, 1335-1342 17

- 351 Cancer therapeutics-related cardiovascular dysfunction: Basic mechanisms and clinical manifestation.. **2022**,
- 350 Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. **2022**, 14, 2470 ○
- 349 In vivo stealthified molecularly imprinted polymer nanogels incorporated with gold nanoparticles for radiation therapy. 2
- 348 Technologies for Identification and Validation of Cancer Biomarkers. **2022**, 27-64
- 347 Nanotechnology for Cancer Biomarkers. **2022**, 345-365
- 346 Cardiac Monitoring and Heart Failure in Advanced Breast Cancer Patients Treated With Trastuzumab in Ontario, Canada. **2022**, 9, ○
- 345 Management of HER2-Positive Early Breast Cancer in Italy: A Maze Presenting Opportunities and Challenges. **2022**, 12,
- 344 The AKT1E17K Allele Promotes Breast Cancer in Mice. **2022**, 14, 2645
- 343 A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. 1
- 342 Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy. **2022**, 23, 5686 2
- 341 Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers. **2022**, 29, 107327482211062
- 340 Label-Free Detection and Translocation Dynamics Study of Single-Molecule Herceptin Using Solid-State Nanopores. 2200018
- 339 New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies. **2022**, 10, 27 ○
- 338 Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials*. 1-19
- 337 Use of Radionuclide-Based Imaging Methods in Breast Cancer. **2022**, ○
- 336 BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. **2022**, 14, 2596 1
- 335 Contemporary breast cancer treatment-associated thrombosis. **2022**, 213, S8-S15
- 334 Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer. **2022**, 14, 2795 ○

- 333 Cardiovascular risks of chemotherapy. **2023**, 20-35
- 332 Cancer therapeutic drug guide. **2023**, 451-506
- 331 Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer. **2022**, 14, 175883592211066
- 330 Translational Epidemiology in Cancer Research: The Less Travelled Path. **2022**, 349-366
- 329 Prädiktive Testung von Tumorgewebe und ihre klinischen Konsequenzen. **2022**, 1-15
- 328 Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era. **2022**, 1-11 ○
- 327 Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071. **2022**, 14, 1092
- 326 Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue. 12, 1
- 325 Potential value of tumor stiffness and sE-cadherin in predicting the response to neoadjuvant therapy in HER2-positive breast cancers.
- 324 Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: real-world data from a multicentric European cohort. 1
- 323 A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab. **2022**, 29, 4224-4234
- 322 The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Publish Ahead of Print, ○
- 321 Breast Cancer Genomics: Primary and Most Common Metastases. **2022**, 14, 3046
- 320 The importance of cardiovascular disease in breast cancer survivors. mini review. **2022**, 6, 106-108
- 319 Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer. ○
- 318 Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer. **2022**, 3, 100668
- 317 Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy. 9, ○
- 316 Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma. 9, 1

315	Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer. 12,	0
314	Inactivating amplified HER2: challenges, dilemmas, and future directions.	0
313	Advances in the Prevention and Treatment of Obesity-Driven Effects in Breast Cancers. 12,	4
312	The Effect of HER2 Status on Metaplastic Breast Cancer A Propensity Score-Matched Analysis. 13,	0
311	Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity. 2022 , 23, 6547	0
310	Nano-Based Drug Delivery of Anticancer Chemotherapeutic Drugs Targeting Breast Cancer. 2022 , 17,	
309	Myocardial Dysfunction in Patients with Cancer. 2022 , 18, 361-374	1
308	Cardioprotection of High-Risk Individuals. 2022 , 18, 385-402	1
307	Spontaneous Feline Mammary Carcinoma Is a Model of HER2 Overexpressing Poor Prognosis Human Breast Cancer. 2005 , 65, 907-912	31
306	Glycolipid-peptide conjugate vaccines elicit CD8 + T-cell responses and prevent breast cancer metastasis. 2022 , 11,	1
305	cAMP Signaling in Cancer: A PKA-CREB and EPAC-Centric Approach. 2022 , 11, 2020	0
304	Structural variations in cancer and the 3D genome.	0
303	Determining the Optimal (Neo)Adjuvant Regimen for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Regarding Survival Outcome: A Network Meta-Analysis. 13,	
302	Baseline cardiac function checkup in patients with gastric or breast cancer receiving trastuzumab or anthracyclines.	
301	Template-Based Assembly of Proteomic Short Reads For De Novo Antibody Sequencing and Repertoire Profiling.	0
300	Extrapolating evidence for molecularly targeted therapies from common to rare cancers: a scoping review of methodological guidance. 2022 , 12, e058350	1
299	Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer.	0
298	Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. 2022 , 14, 3305	2

297	Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study. 12,	1
296	Defucosylated mouse-dog chimeric anti-HER2 monoclonal antibody exerts antitumor activities in mouse xenograft models of canine tumors. 2022, 48,	1
295	Is there a window of opportunity to optimize trastuzumab cardiac monitoring?. 2022, 14, 403-410	0
294	Real-world outcomes in patients with brain metastases secondary to HER2-positive breast cancer: An Australian multi-centre registry-based study. 2022,	
293	Efficacy and safety of HER2-targeted inhibitors for metastatic colorectal cancer with HER2-amplified: A meta-analysis. 2022, 182, 106330	
292	Bheddinglight on HER4 signaling in normal and malignant breast tissues. 2022, 97, 110401	0
291	Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer. 2022, 173, 10-19	2
290	Decreased Accessibility and Lack of Activation of ErbB2 in JIMT-1, a Herceptin-Resistant, MUC4-Expressing Breast Cancer Cell Line. 2005, 65, 473-482	119
289	Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. 2004, 3, 1585-1592	94
288	Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. 2004, 3, 459-463	20
287	Perioperative Care of the Cancer Patient: Breast Procedures. 2023, 262-281	
286	Novel peptide ligands for integrin $\alpha 5 \beta 1$ overexpressed in cancer cells. 2004, 3, 1329-1334	7
285	Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis.	0
284	Use of peroral form of vinorelbine in metastatic breast cancer: Choice in favor of quality of life. 2022, 7-13	
283	Hitting the target in HER2 mutant cancers. 2022, 3, 785-786	1
282	KSTAR: An algorithm to predict patient-specific kinase activities from phosphoproteomic data. 2022, 13,	
281	Trastuzumab-induced cardiotoxicity in early breast cancer over a 10-year period in Uruguay. 2022, 101, e29927	1
280	Optimize the combination regimen of Trastuzumab and Nab-paclitaxel in HER2-positive tumors via modulating Caveolin-1 expression by lovastatin. 2022,	

279	Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer. 2022,	
278	Comparative Assessment of Quantification Methods for Tumor Tissue Phosphoproteomics. 2022, 94, 10893-10906	0
277	HEROHE Challenge: Predicting HER2 Status in Breast Cancer from HematoxylinEosin Whole-Slide Imaging. 2022, 8, 213	0
276	BIOMARKERS, TYPES AND ROLE IN PERSONALIZED MEDICINE. 2022, 2, 6-16	0
275	Impact of cancer diagnosis on distribution and trends of cardiovascular hospitalizations in the USA between 2004 to 2017.	0
274	Imaging Features of Breast Cancer Subtypes on Mammography and Ultrasonography: an Analysis of 479 Patients.	
273	Overcoming Resistance to HER2-Directed Therapies in Breast Cancer. 2022, 14, 3996	2
272	Hepatic circadian and differentiation factors control liver susceptibility for fatty liver disease and tumorigenesis. 2022, 36,	1
271	Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer. 2022, 14, 3973	
270	High expression of cuproptosis-related SLC31A1 gene in relation to unfavorable outcome and deregulated immune cell infiltration in breast cancer: an analysis based on public databases. 2022, 23,	0
269	Long-term follow-up of early stage HER2-positive breast cancer patients treated with trastuzumab: A population-based real world multicenter cohort study. 12,	0
268	Tailoring antiHer2 treatment strategies in breast cancer and beyond. 2022, 100892	
267	The Roles of Immune Cells in Gastric Cancer: Anti-Cancer or Pro-Cancer?. 2022, 14, 3922	2
266	Optimizing combination therapy in a murine model of HER2+ breast cancer. 2022, 115484	
265	A Causal Framework for Making Individualized Treatment Decisions in Oncology. 2022, 14, 3923	0
264	Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin. 12,	0
263	Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups. 12,	
262	Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers. 2022, 15, 1041	0

- 261 Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer. **2022**, 10, 2045 0
- 260 Trastuzumab biosimilar HLX02 versus reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a model-based economic evaluation for China. 1-10
- 259 Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma. **2022**, 0
- 258 Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers. **2022**, 0
- 257 A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting. 1
- 256 Cardiotoxicity of adjuvant chemotherapy with trastuzumab: a Japanese claim-based data analysis. **2022**, 9, e002053
- 255 Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer. 1
- 254 Trastuzumab therapies in human epidermal growth factor receptor 2 cancer. 8, 32-40
- 253 Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study. **2022**, 7, 100183
- 252 Targeted therapy for breast cancer: An overview of drug classes and outcomes. **2022**, 204, 115209 2
- 251 Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma[®]) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 1814/KM10B). **2022**, 65, 172-178
- 250 The Evolution of Antibodies into Versatile Tumor-Targeting Agents. **2005**, 11, 129-138 7
- 249 Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions. 0
- 248 Hyaluronidase responsive second near-infrared fluorescent nanocomplex for combined HER2 blockade and chemotherapy of HER2+ breast cancer. **2022**, 141, 213115 0
- 247 Annexin A2 (AnxA2) association with the clinicopathological data in different breast cancer subtypes: A possible role for AnxA2 in tumor heterogeneity and cancer progression. **2022**, 308, 120967 0
- 246 Therapeutic peptides targeting protein kinase: progress, challenges, and future directions, featuring cancer and cardiovascular disease. **2022**, 333-356 0
- 245 Next-generation sequencing, should I use anti-HER2 therapy for HER2-amplified tumors off-label? Illustrating an extrapolation framework. **2022**, 14, 175883592211128 0
- 244 Targeted nanomedicine delivery to human epidermal growth receptor. **2022**, 111-130 0

- 243 Imaging the Cardiovascular System in the Cancer Patient. **2022**, 1729-1752 ○
- 242 Biomarker-Driven Adaptive Phase III Clinical Trials. **2022**, 2367-2378 ○
- 241 Diagnostic Applications of Nuclear Medicine: Breast Cancer. **2022**, 715-741 ○
- 240 Chapter 21: Oncology: Rasburicase/G6PD Case. **2022**, ○
- 239 Abbreviations. **2022**, ○
- 238 Chapter 29: Pharmacogenomics in Ethical and Social Contexts. **2022**, ○
- 237 Appendix 2: Glossary. **2022**, ○
- 236 Chapter 27: Rheumatology/Musculoskeletal Pain: Codeine/CYP2D6 Case. **2022**, ○
- 235 Chapter 8: Cardiology: Simvastatin/SLCO1B1 Case. **2022**, ○
- 234 Chapter 28: Information Resources for Pharmacogenomics. **2022**, ○
- 233 Chapter 18: Oncology: Somatic Disease and Pharmacogenomics. **2022**, ○
- 232 Chapter 17: Neurology: Fosphenytoin/Phenytoin/CYP2C9, HLA-B Case. **2022**, ○
- 231 Chapter 9: Cardiology: Warfarin/CYP2C9, VKORC1, CYP4F2 Case. **2022**, ○
- 230 Chapter 25: Rheumatology/Musculoskeletal Pain: Allopurinol/HLA-B Case. **2022**, ○
- 229 Chapter 12: Infectious Diseases: Abacavir/HLA-B Case. **2022**, ○
- 228 Chapter 15: Infectious Diseases: Gentamicin/MT-RNR1 Case. **2022**, ○
- 227 Pharmacogenomics: Foundations, Competencies, and the Pharmacists' Patient Care Process, 2nd Edition. **2022**, ○
- 226 Chapter 13: Infectious Diseases: Atazanavir/UGT1A1 Case. **2022**, ○

- 225 Chapter 30: Pharmacogenomics and Secondary/Incidental Findings. **2022,** ○
- 224 Chapter 16: Neurology: Carbamazepine/HLA-A, HLA-B Case. **2022,** ○
- 223 Dedication. **2022,** ○
- 222 Chapter 3: Pharmacogenomics Testing. **2022,** ○
- 221 Chapter 24: Metabolic/Respiratory: Ivacaftor/CFTR Case. **2022,** ○
- 220 Chapter 23: Psychiatry: Paroxetine/CYP2D6 Case. **2022,** ○
- 219 Copyright. **2022,** ○
- 218 Chapter 2: Pharmacogenomics: Drug Exposure and Response. **2022,** ○
- 217 Chapter 22: Psychiatry: Amitriptyline/CYP2C19, CYP2D6 Case. **2022,** ○
- 216 Chapter 6: The Pharmacists' Patient Care Process (PPCP). **2022,** ○
- 215 Trastuzumab-deruxtecan: New treatment, familiar complications. 1-2 ○
- 214 Chapter 10: Endocrinology: Glipizide/G6PD Case. **2022,** ○
- 213 Chapter 1: Foundations of Pharmacogenomics. **2022,** ○
- 212 Chapter 20: Oncology: Capecitabine/DPYD Case. **2022,** ○
- 211 Preface. **2022,** ○
- 210 Chapter 14: Infectious Diseases: Voriconazole/CYP2C19 Case. **2022,** ○
- 209 Chapter 19: Oncology: Mercaptopurine/TPMT, NUDT15 Case. **2022,** ○
- 208 Chapter 7: Cardiology: Clopidogrel/CYP2C19 Case. **2022,** ○

207	Chapter 4: Pharmacists' Competencies in Genomics. 2022,	0
206	Appendix 1: Competency Connections. 2022,	0
205	Chapter 5: Implementation of Pharmacogenomics across Practice Settings. 2022,	0
204	Chapter 26: Rheumatology/Musculoskeletal Pain: Azathioprine/TPMT, NUDT15; Celecoxib/CYP2C9 Case. 2022,	0
203	Chapter 11: Immunology: Tacrolimus/CYP3A5 Case. 2022,	0
202	Permissive Cardiotoxicity. 2022, 4, 302-312	2
201	Immuno-PET Imaging and Radioimmunotherapy of Lymphomas. 2022, 19, 3484-3491	0
200	Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study.	0
199	An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low).	1
198	Rethinking cancer targeting strategies in the era of smart cell therapeutics.	1
197	Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab. 9,	0
196	TP53-positive clones are responsible for drug-tolerant persister and recurrence of HER2-positive breast cancer.	0
195	Molecular Classification of Breast Carcinoma in a Tertiary Hospital of India: the Recent Trends.	0
194	From organoids to bedside: advances in modeling, decoding and targeting of colorectal cancer.	0
193	Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board. 2022, 14, 4430	0
192	IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target. 2022, 39,	0
191	Evaluation of lung adverse events with trastuzumab using the Japanese pharmacovigilance database. 2022, 39,	1
190	Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features. 2022, 22,	1

189	Integrated multi-omics analysis of adverse cardiac remodeling and metabolic inflexibility upon ErbB2 and ERR α deficiency. 2022 , 5,	0
188	Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors. 2022 , 10, 2211	1
187	Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy.	0
186	Cardio-oncology: Implications for Clinical Practice for Women.	0
185	HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment. 10,	0
184	Cardiac computed tomographic imaging in cardio-oncology: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). Endorsed by the International Cardio-Oncology Society (ICOS). 2022 ,	1
183	From tumor mutational burden to characteristic targets analysis: Identifying the predictive biomarkers and natural product interventions in cancer management. 9,	0
182	Editorial: Translating clinical genomics and health informatics into precision oncology. 13,	0
181	Evaluation of Nanoparticle Stability under Blood Flow Shear.	0
180	Functional genomics of complex cancer genomes. 2022 , 13,	0
179	Why Academic Health Systems Must Lead the Third Wave of Digital Health Innovation (Preprint).	0
178	Pain and Nausea Intensity, Social Function, and Psychological Well-Being among Women with Metastatic Breast Cancer. 2022 , 9, 237437352211347	0
177	Cancer de mama metastático. 2022 , 58, 1-9	0
176	Sabizabulin, a Potent Orally Bioavailable Colchicine Binding Site Agent, Suppresses HER2+ Breast Cancer and Metastasis. 2022 , 14, 5336	0
175	Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer. 2022 , 13,	1
174	A Soft Label Deep Learning to Assist Breast Cancer Target Therapy and Thyroid Cancer Diagnosis. 2022 , 14, 5312	1
173	Early and isolated breast cancer metastasis to the pituitary: A case report and systematic review. 13, 462	0
172	An allosteric switch between the activation loop and a c-terminal palindromic phospho-motif controls c-Src function.	0

171	Trastuzumab-based regimens beyond progression: A crucial treatment option for HER2+ advanced/metastatic breast cancer. 2022,	0
170	New treatment strategies for human epidermal growth factor receptor 2-positive breast cancer in 2023. Publish Ahead of Print,	0
169	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. 2022, 15,	1
168	Resistance to Trastuzumab. 2022, 14, 5115	1
167	Therapeutic landscape of advanced HER2-positive breast cancer in 2022. 2022, 39,	3
166	EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy. 2022, 188827	0
165	Modern breast cancer therapy: from tamoxifen to T-cell engineering. 2022, 21, 109-122	1
164	Aberrant Signaling Pathways in Cancer. 1-10	0
163	Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy. 2022, 10, 2511	0
162	Precision medicine: the precision gap in rheumatic disease.	2
161	Clinical Characteristics and Survival Outcomes of Patients with De Novo Metastatic Breast Cancer. Volume 14, 363-373	0
160	Additivity predicts the efficacy of most approved combination therapies for advanced cancer.	0
159	Regional efficacy evaluation in multi-regional clinical trials using a discounting factor weighted Z test.	0
158	Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?. 2022, 14, 2326	0
157	MYC and therapy resistance in cancer: risks and opportunities. 2022, 16, 3828-3854	0
156	Deciphering the Impact of HER2 Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches. 2022, 12, 1651	0
155	Monoclonal Antibody and Targeted Toxin Therapy. 1-31	0
154	Neoplasms of the Breast. 1-62	0

153	Principles of Medical Oncology. 1-13	0
152	A Case of Sustained Tumor Regression With MP0274, a Novel DARPIn Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab. 2022 ,	0
151	Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer. 2022 , 66, 217-226	0
150	Her2 Expression in Thyroid Tumors. 2003 , 69, 1100-1103	1
149	Cardioprotective Approaches to the Management of Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Do We Need Increased Surveillance in Elderly Women on Trastuzumab?. 83-91	0
148	Antitumor Activities in Mouse Xenograft Models of Canine Fibroblastic Tumor by Defucosylated Mouse-Dog Chimeric Anti-HER2 Monoclonal Antibody (H77Bf).	0
147	Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma. 13,	0
146	Integrating pharmacogenomics into clinical trials of hearing disorders. 2022 , 152, 2828-2839	2
145	Targeting HER2-positive breast cancer: advances and future directions.	3
144	Local Therapy for Oligometastatic Disease—Art Before the Horse?. 2022 , 114, 836-839	0
143	Defucosylated Mouse-Dog Chimeric Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody (H77Bf) Exerts Antitumor Activities in Mouse Xenograft Models of Canine Osteosarcoma.	0
142	Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose ²¹¹ At-Labeled Anti-HER2 Single-Domain Antibody Fragment. 2023 , 64, 124-130	0
141	Current Standard Clinical Predictive Markers. 2022 , 873-894	0
140	Chemotherapeutic drugs. 2023 , 425-437	0
139	RNA biomarker discovery and validation. 2023 , 723-742	0
138	Acute skin radiation toxicity seen with concurrent T-DM1: A single institutional report of 35 patients. 2023 , 67, 26-29	0
137	Systemic Therapy for Early- and Late-Stage, Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer. 2023 , 37, 103-115	0
136	An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs. 2023 , 554, 216024	0

- 135 Immunoliposomes as an emerging nanocarrier for breast cancer therapy. **2023**, 184, 111781 ○
- 134 Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Results in Alterations in Preoperative Tumor Marker Status. **2004**, 70, 1103-1106 3
- 133 Principalele abordări de profilare moleculară în oncologie: tehnologie, avantaje și limitări. **2022**, 4, 34 ○
- 132 Cardiotoxicity in breast cancer patients receiving trastuzumab with or without prior anthracycline-based chemotherapy: A prospective study from a tertiary cancer institute at Guwahati, India. **2022**, 6, 66 ○
- 131 Formulation of Lipid-Based Nanoparticles for Simultaneous Delivery of Lapatinib and Anti-Survivin siRNA for HER2+ Breast Cancer Treatment. **2022**, 15, 1452 ○
- 130 Antibody-Drug Conjugates in Breast Cancer: Searching for Magic Bullets. ○
- 129 Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis. **2022**, 14, 2519 ○
- 128 Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects. **2022**, 21, 1341-1355 ○
- 127 Targeted Therapies in the Treatment of Uterine Serous Carcinoma. **2022**, 23, 1804-1817 ○
- 126 Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer. **2022**, 14, 5678 ○
- 125 Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm?. **2022**, 11, 7239 2
- 124 Nanotechnology-based electrochemical biosensors for monitoring breast cancer biomarkers. ○
- 123 Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome. **2022**, ○
- 122 Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer – An Analysis of a Large University Breast Cancer Centre. ○
- 121 Autophagy activation in breast cancer cells in vitro after the treatment with PI3K/AKT/mTOR inhibitors. **2022**, 9, 61-70 ○
- 120 Expanding the reach of HER2-targeted therapies: transformation of an historical paradigm. **2022**, 132, ○
- 119 Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer. ○
- 118 Oncoproteomics: insight into current proteomic technologies in cancer biomarker discovery and treatment. ○

- 117 UK recommendations for HER2 assessment in breast cancer: an update. *jcp-2022-208632* ○
- 116 Store-operated calcium entry via ORAI1 regulates doxorubicin-induced apoptosis and prevents cardiotoxicity in cardiac fibroblasts. **2022**, 17, e0278613 ○
- 115 18F-FDG and 18F-FLT Uptake Profiles for Breast Cancer Cell Lines Treated with Targeted PI3K/Akt/mTOR Therapies. ○
- 114 Overrepresentation of human epidermal growth factor receptor 2 positive- and Luminal B breast cancer metastases in the eyes and orbit. ○
- 113 99mTc-labeled single-domain antibody for SPECT/CT assessment of HER2 expression in diverse cancer types. ○
- 112 The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: A piggy-back systematic review and meta-analysis. **2022**, 17, e0275321 1
- 111 Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. **2022**, 29, 9891-9895 ○
- 110 Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer: a retrospective study. 12, ○
- 109 Targeted thorium-227 conjugates as treatment options in oncology. 9, ○
- 108 Tumour Genetics and Genomics to Personalise Cancer Treatment. **2011**, 40, 362-368 ○
- 107 Trastuzumab subcutáneo en el tratamiento del cáncer de mama HER2 positivo. **2023**, 21, ○
- 106 Precision Oncology with Electronic Medical Records. 64-72 ○
- 105 Physical Activity in Patients with Breast Cancer. **2022**, 293-311 ○
- 104 Biosimilar Competition and Payments in Medicare: The Case of Trastuzumab. ○
- 103 PI3K/AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds. **2023**, 13, 93 1
- 102 Cardiotoxicity with human epidermal growth factor receptor-2 inhibitors in breast cancer: Disproportionality analysis of the FDA adverse event reporting system. **2023**, ○
- 101 Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives. **2023**, 1
- 100 Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer. **2023**, ○

- 99 Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry. ○
- 98 Immuno-PET as a Tool for Cancer Detection and Monitoring Response to Treatments. **2023**, 1-18 ○
- 97 Single-cell gene regulatory network prediction by explainable AI. ○
- 96 Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer. **2023**, 15, 175883592211461 ○
- 95 PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications. ○
- 94 Usefulness of on-site cytology of liver tumor biopsy in specimen sampling for cancer genomic profiling test. ○
- 93 Synergistic therapeutic potential of alpelisib in cancers (excluding breast cancer): Preclinical and clinical evidences. **2023**, 159, 114183 ○
- 92 Tumor Targeting of ²¹¹At-Labeled Antibody under Sodium Ascorbate Protection against Radiolysis. 1
- 91 ERK1 confers oncogenesis and cisplatin resistance via transcriptionally activating CCNE2 in breast cancer. ○
- 90 SRC kinase-mediated signaling pathways and targeted therapies in breast cancer. **2022**, 24, ○
- 89 Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer. **2022**, 8, ○
- 88 Câncer de mama metastático HER2 positivo. **2015**, 20, ○
- 87 Overcoming the On-Target Toxicity in Antibody-Mediated Therapies via an Indirect Active Targeting Strategy. 2206912 ○
- 86 Risk factor structure of heart failure in patients with cancer after treatment with anticancer agents: assessment by big data from a Japanese electronic health record. ○
- 85 miRNAs as Epigenetic Cancer Biomarker. **2023**, 241-271 ○
- 84 A nomogram based on combining clinical features and contrast enhanced ultrasound is not able to identify Her-2 over-expressing cancer from other breast cancers. 13, ○
- 83 Chimeric antigen receptor-modified cells for the treatment of solid tumors: First steps in a thousand-mile march. **2023**, 97-131 ○
- 82 Zebrafish Cancer Avatars: A Translational Platform for Analyzing Tumor Heterogeneity and Predicting Patient Outcomes. **2023**, 24, 2288 ○

- 81 HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC. ○
- 80 Pertuzumab, primer inhibidor de la dimerizaci3n HER. **2013**, 18, ○
- 79 Breast Cancer Disease Exploitation to Recure a Healthy Lifestyle. **2022**, 2617-2635 ○
- 78 Nucleic Acid-Based Micellar Therapy for the Treatment of Different Diseases. **2023**, 155-174 ○
- 77 Anthracycline Therapy Modifies Immune Checkpoint Signaling in the Heart. **2023**, 24, 6052 ○
- 76 Chromosomal Instability as Enabling Feature and Central Hallmark of Breast Cancer. Volume 15, 189-211 ○
- 75 Predicting individual-specific cardiotoxicity responses induced by tyrosine kinase inhibitors. 14, ○
- 74 Cardiotoxicity, Cardioprotection, and Prognosis in Survivors of Anticancer Treatment Undergoing Cardiac Surgery: Unmet Needs. **2023**, 15, 2224 ○
- 73 Deciphering breast cancer: from biology to the clinic. **2023**, 186, 1708-1728 ○
- 72 Immunogenic cell death inducer peptides: A new approach for cancer therapy, current status and future perspectives. **2023**, 161, 114503 1
- 71 Current Updates in Management of HER2-Positive and HER2-Low Breast Cancer. ○
- 70 Using quantitative single molecule localization microscopy to optimize multivalent HER2-targeting ligands. 10, ○
- 69 A co-culture model system to quantify antibody-dependent cellular cytotoxicity in human breast cancer cells using an engineered natural killer cell line. **2023**, 4, 102224 ○
- 68 Incidence, Clinicopathologic Features, HER2 Fluorescence in Situ Hybridization Profile, and Oncotype DX Results of Human Epidermal Growth Factor Receptor 2-Low Breast Cancers: Experience From a Single Academic Center. **2023**, 36, 100164 ○
- 67 Digital ECMT Cancer Trial Matching Tool: an Open Source Research Application to Support Oncologists in the Identification of Precision Medicine Clinical Trials. **2023**, ○
- 66 MULTIMODALITY TESTING OF HER2/NEU MARKER IN BREAST CANCER: A CORRELATIVE STUDY. 1413-1443 ○
- 65 Monoclonal antibodies in breast cancer: A critical appraisal. **2023**, 183, 103915 ○
- 64 Molecular Testing for Diagnostics, Prognostication, and Treatment Stratification in Cancers. **2023**, 29, 3-8 ○

63	Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges. 2023 , 114, 102520	1
62	Preventive effect of dexamethasone premedication on the development of infusion-related reaction in breast cancer patients receiving trastuzumab.	0
61	Her2low breast cancer. New opportunities and challenges. 2022 , 30, 62-74	0
60	Human Epidermal Growth Factor Receptor 2 (HER2) Expression by Immunohistochemistry and Its Clinical Significance in Hepatocellular Carcinoma: A Single-Center Analysis. 2023 ,	0
59	Predicting heart failure symptoms in breast cancer patients receiving Trastuzumab using cardiovascular magnetic resonance strain assessment.	0
58	Integrating single-cell RNA-seq and bulk RNA-seq to construct prognostic signatures to explore the role of glutamine metabolism in breast cancer. 14,	0
57	Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer.	0
56	Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy. 2023 , 12, 457	0
55	CAR Based Immunotherapy of Solid TumoursA Clinically Based Review of Target Antigens. 2023 , 12, 287	2
54	HER2 Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review. 2023 , 24, 3590	0
53	Validation of Linear Range HER2/Estrogen Receptor/Progesterone Receptor IHC Controls for Daily Quality Assurance. 2023 , 159, 274-282	0
52	Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer. 2023 , 75,	0
51	Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.	0
50	Lessons from other fields of medicine, Part 1: Breast cancer. 2023 , 101-118	0
49	Trans-activating mutations of the pseudokinase ERBB3.	0
48	Sonic Hedgehog stimulates migration of MCF-7 breast cancer cells through Rac1. 2019 , 33, 297	0
47	Urachal carcinoma: The journey so far and the road ahead. 2023 , 243, 154379	0
46	Simultaneous Detection and Classification of Partially and Weakly Supervised Cells. 2023 , 313-329	0

- 45 Convection-enhanced delivery of nanoencapsulated gene locoregionally yielding ErbB2/Her2-specific CAR-macrophages for brainstem glioma immunotherapy. **2023**, 21, ○
- 44 HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks. Volume 16, 115-132 ○
- 43 Kinome inhibition states and multiomics data enable prediction of cell viability in diverse cancer types. **2023**, 19, e1010888 ○
- 42 Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery. 10, ○
- 41 Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution. **2023**, 15, 1385 ○
- 40 Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer. **2023**, 15, 1413 ○
- 39 Suppression of Platelet-Derived Growth Factor Receptor-Alpha Overcomes Resistance to Trastuzumab through STAT3-Dependent IL-6 Reduction in HER2-Positive Breast Cancer Cells. **2023**, 11, 675 ○
- 38 Canada's First Joint Oncology-Allergy Clinic: Successful Desensitization to Trastuzumab Following Severe Anaphylactic Reaction in Which Epinephrine Was Inappropriately Withheld. **2023**, 30, 2862-2868 ○
- 37 Comparing the pharmacokinetics, safety, and immunogenicity of HLX02 to US- and EU-approved trastuzumab in healthy Chinese male subjects: A Phase I, randomized, double-blind, parallel-group study. 1-9 ○
- 36 Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine. 10, ○
- 35 Response of Therapy in Cell-Cycle Regulatory Genes in Breast Cancer. **2023**, 335-353 ○
- 34 Planning for return to work during the first year after breast cancer metastasis: A Swedish cohort study. ○
- 33 Chemotherapy-Induced Cardiotoxicity in Cancer Treatment: Mechanisms and Its Prevention. **2023**, 1-31 ○
- 32 Blocking soluble TNF α sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression. **2023**, 11, e005325 1
- 31 Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group. **2023**, 15, 1667 ○
- 30 HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments. **2023**, 15, 1738 ○
- 29 Integrating antibody drug conjugates in the management of gynecologic cancers. **2023**, 33, 420-429 ○
- 28 Ginger-Derived 3HDT Exerts Antiproliferative Effects on Breast Cancer Cells by Apoptosis and DNA Damage. **2023**, 24, 5741 ○

- 27 Clinical Trials for Personalized Medicine: Design and Data Analysis. **2022**, 43, 97-119 ○
- 26 Computational Methods Summarizing Mutational Patterns in Cancer: Promise and Limitations for Clinical Applications. **2023**, 15, 1958 ○
- 25 The therapeutic potential of immunotherapy in the treatment of breast cancer: Rational strategies and recent progress. **2023**, 124, 477-494 ○
- 24 Emerging Targeted Therapies for HER2-Positive Breast Cancer. **2023**, 15, 1987 ○
- 23 Targeting Tn-positive tumors with an afucosylated recombinant anti-Tn IgG. **2023**, 13, ○
- 22 Clinical management of drug-induced cardiotoxicity in patients with HER-2+ breast cancer: current recommendations and future outlook. **2023**, 19, 109-119 ○
- 21 Mecanismos de resistencia al trastuzumab. **2023**, 17, ○
- 20 Tumor-specific activity of precision medicines in the NCI-MATCH trial. ○
- 19 The targeted next-generation sequence revealed SMAD4, AKT1, and TP53 mutations from circulating cell-free DNA of breast cancer and its effect on protein structure \square A computational approach. 1-14 ○
- 18 Target Hyperactive ERK Signaling for Cancer Therapy. **2023**, 1-39 ○
- 17 Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis. **2023**, ○
- 16 Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type. **2023**, 15, 2204 ○
- 15 Insights into the metastatic cascade through research autopsies. **2023**, ○
- 14 Personalizing therapy selection in inflammatory bowel disease. **2023**, 19, 431-438 ○
- 13 Interaction between Radiation Therapy and Targeted Therapies in HER2-Positive Breast Cancer: Literature Review, Levels of Evidence for Safety and Recommendations for Optimal Treatment Sequence. **2023**, 15, 2278 ○
- 12 Health-related quality of life in Her2-positive early breast cancer woman using trastuzumab: A systematic review and meta-analysis. 14, ○
- 11 Detailed curriculum vitae of HER2-targeted therapy. **2023**, 245, 108417 ○
- 10 Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047. OF1-OF16 ○

- 9 Deep learning radiomics model based on breast ultrasound video to predict HER2 expression status. 14,
- 8 Early and late onset cardiotoxicity following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors. **2023**,
- 7 Generation of Rat Monoclonal Antibodies Against Human Epidermal Growth Factor Receptor 2.
- 6 Incident cardiovascular events and imaging phenotypes in UK Biobank participants with past cancer. heartjnl-2022-321888
- 5 Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis. **2023**, 8, 101216
- 4 Amphiphilic Polypeptides Obtained by Post-Polymerization Modification of Poly-L-Lysine as Systems for Combined Delivery of Paclitaxel and siRNA. **2023**, 15, 1308
- 3 Triple-Negative Breast Cancer: Basic Biology and Immuno-Oncolytic Viruses. **2023**, 15, 2393
- 2 mRNA vaccination in breast cancer: current progress and future direction.
- 1 Characteristics and research status among clinical trials in cardio-oncology by bibliometric and visualized analysis.